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ABSTRACT 
The potent immune regulatory capacity of mesenchymal stromal cells (MSC) has 
been extensively characterised in terms of T cells, natural killer cells and dendritic cells 
suppression; however the ability of MSC to modulate B cell biology is not fully 
understood.  This immune suppressive ability has led to the development of MSC therapy 
for the treatment of inflammatory and auto-immune disease, and has already 
demonstrated beneficial effects during GvHD and Crohn’s disease.  However, the 
mechanisms employed by MSC therapy to modulate disease progression have not been 
identified.  The key goals for this thesis were (1) to determine how MSC effect B cell 
function and to identify the mechanisms by which this effect is mediated, and (2) the 
development of novel mouse models of chronic and acute GvHD to elucidate the 
mechanism of action by which MSC attenuate disease progression. 
This study demonstrated than MSC support the activation, proliferation and 
survival of human CD19+ peripheral B cells in vitro.  MSC support of B cell survival was 
mediated through the cell contact dependent up-regulation of VEGF production by the 
MSC.  Soluble VEGF bound by B cells induced AKT phosphorylation, inhibited caspase 
3 cleavage and reduced apoptosis.  
The second part of this thesis focused on developing murine models of chronic 
and acute GvHD and to investigate the efficacy of xenogeneic MSC therapy in these 
models.  In addition, a robust humanised model of aGvHD was developed to investigate 
mechanism of MSC protection. MSC therapy significantly increased survival of aGvHD 
mice and this protection correlated with significantly reduced TNF-α production and 
significantly increased numbers of regulatory T cells in aGvHD target organs. 
These findings further the understanding of the immune regulation capacity of 
MSC in vitro and provide a robust and clinically relevant model of aGvHD from which 
the mechanisms behind MSC modulation can be investigated. 
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1.1 MESENCHYMAL STROMAL CELLS 
The field of mesenchymal stromal cell (MSC) research traces its origin to 1966 
when Alexander Friedenstein first described a rare, non-haematopoietic, osteogenic 
precursor cell population (0.01-0.001%) from the bone marrow which formed plastic 
adherent colonies in vitro (Friedenstein et al. 1966; Friedenstein et al. 1968; Friedenstein 
et al. 1974). The multi-lineage differentiation capacity of these cells was first suggested 
by Owen and colleagues after observing bone and cartilage formation following 
implantation of cells into rats (Ashton et al. 1980).  In 1991, Arnold Caplan identified 
their potential in regenerative medicine and coined the phrase “mesenchymal stem cells” 
(Caplan 1991).  However, it was not until 1999 that Pittenger et al. demonstrated the 
ability of MSC to differentiate into osteocytes, chondrocytes and adipocytes (Pittenger et 
al. 1999).   
In the last decade, in vitro and in vivo data has highlighted the potential of MSC 
therapy in regenerative medicine.  Initial studies focused on the differentiation ability of 
MSC and examined the capacity of MSC therapy to repair bone damage or regenerate 
cartilage in arthritis patients.  However, the conceptual focus of using MSC in 
regenerative medicine has shifted with an appreciation of the wide range of  MSC secreted 
trophic factors capable of promoting tissue repair and potent immune-modulation (Barry 
et al. 2005). In 2005, the International Society for Cellular Therapy (ISCT) suggested that 
the nomenclature of these cells be changed to “mesenchymal stromal cell” to provide a 
more accurate reflection of their functional capacity (Horwitz et al. 2005).  However, the 
in vivo identification and subsequent isolation of human MSC remained a controversial 
issue, complicated by the lack of a specific set of surface markers capable of identifying 
human MSC populations.  Therefore, the ISCT proposed the minimal criteria for defining 
human MSC in vitro (Dominici et al. 2006), suggesting that human MSC must be plastic 
adherent, should express CD73, CD90 and CD105 but not CD10, CD11b, CD14, CD34, 
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CD45, CD79α or HLA-DR and furthermore, MSC must be capable of differentiating to 
osteocytes, chondrocytes and adipocytes in vitro (Dominici et al. 2006). 
 
1.2 MSC AND IMMUNE REGULATION 
The capacity of allogeneic MSC to influence immune responses was first 
described by Bartholomew et al. (2002).  The authors demonstrated that baboon derived 
MSC potently suppressed allogeneic lymphocyte proliferation in vitro and furthermore 
showed that allogeneic baboon MSC were capable of prolonging skin graft survival in 
vivo (Bartholomew et al. 2002).  The following year, an in vitro allogeneic immune 
suppressive capacity was reported for human MSC (Tse et al. 2003) and in 2004, 
allogeneic MSC therapy was successfully used to treat a paediatric patient suffering from 
grade IV steroid resistant GvHD (Le Blanc et al. 2004).  The last decade has seen 
advances in understanding the mechanism by which MSC modulate specific immune cell 
populations.  The ability of allogeneic MSC to suppress T cell proliferation (English et 
al. 2007; Tobin et al. 2013), dendritic cell (DC) maturation, antigen presentation (Wang 
et al. 2008; English et al. 2008; Spaggiari et al. 2009) and natural killer (NK) cell function 
(Spaggiari et al. 2008; Noone et al. 2013) has now been extensively characterised.  It has 
also become apparent that the activation of MSC following exposure to pro-inflammatory 
cytokines promotes the immune suppressive ability of these cells (Ryan et al. 2007; 
Polchert et al. 2008).  However, the extent to which allogeneic MSC therapy enjoy 
immune privilege remains a matter of debate.  The original hypothesis suggesting that 
MSC are invisible to allogeneic immune cells has been challenged by studies which 
suggest that MSC evade allogeneic immune responses (Ankrum et al. 2014). Studies 
investigating the engraftment of MSC in murine systems have shown that transplanted 
MSC were undetectable after 48 hours of infusion (Lee et al. 2009; Toma et al. 2009).  In 
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a direct comparison with autologous MSC, the infusion of allogeneic murine MSC to 
healthy mice resulted in significantly lower engraftment (Zangi et al. 2009); however 
allogeneic MSC were rejected at a significantly slower rate than allogenic fibroblasts 
(Zangi et al. 2009).  This study also demonstrated that mice which had received allogeneic 
MSC, rapidly rejected a subsequent infusion of fibroblasts from the same donor 
suggesting an acquired immunological memory following allogeneic MSC recognition 
(Zangi et al. 2009).  These results suggest that allogeneic MSC are not immune privileged 
but should be more accurately referred to as immune evasive and that local immune 
suppression by the allogeneic MSC may be key to their prolonged survival.  Therefore an 
understanding of the in vivo action of MSC in cell therapy requires an appreciation and 
exploration of MSC-immune system interaction. 
 
1.3 MSC AND THE INNATE IMMUNE SYSTEM   
 1.3.1. MSC AND NATURAL KILLER CELLS 
 The innate immune system is the primary barrier and defence against infection 
and is also the first set of confounding processes encountered by an allogeneic cell 
therapy.  Therefore developing an understanding of exactly how MSC interact with cells 
of the innate immune system is essential for progressing MSC therapy.  MSC have been 
shown to interact with cells of both the innate and adaptive immune system through a 
repertoire of soluble factors and cell contact signals.  Natural killer (NK) cells are major 
lymphoid effector cells of the innate immune system which play a key role in the 
recognition and destruction of virally infected, allogeneic or abnormal host cells (Biron 
1997; Moretta et al. 2002).  NK cell activation also helps to trigger the adaptive immune 
response through the production of pro-inflammatory cytokines including IFN-γ (Fauriat 
et al. 2010).  The innate immune system represents one of the primary obstacles 
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encountered by an allogeneic stem cell therapy and understanding how MSC interact with 
NK cell in vivo is essential to generate a successful cell therapy (Gill 2010).  Over the last 
8 years there have been a number of breakthroughs in identifying how allogeneic MSC 
therapies evade clearance by NK cells.  Some of the initial studies showed that MSC 
reduced NK cell proliferation in vitro (Sotiropoulou et al. 2006; Boissel et al. 2008; 
Spaggiari et al. 2008).  However, subsequent studies reported the capacity for IL-2 or IL-
15 activated NK cells to kill autologous or allogeneic MSC (Spaggiari et al. 2008; 
Götherström et al. 2011).  Interestingly, MSC derived from adipose tissue were shown to 
be less susceptible to NK cell mediated killing than bone marrow derived MSC (DelaRosa 
et al. 2012).  Noone et al. demonstrated that resting NK cells do not kill MSC, however, 
following NK activation, cytotoxicity is restored.  NK cytotoxicity of MSC is mediated 
through the NKG2D-perforin granzyme pathway (Noone et al. 2013).  The mechanism 
by which MSC evade NK cell killing was also investigated by Noone et al.  They showed 
that MSC suppress NK cell activation through the secretion of prostaglandin and IDO 
without a requirement for cell contact.  The pre-stimulation of MSC with IFN-γ protected 
MSC from NK mediated apoptosis through the elevated expression of the inhibitory MHC 
Class I molecules (HLA-ABC) and IDO production.  More recently, TLR stimulation has 
also been shown to protect MSC from NK cell mediated apoptosis (Giuliani et al. 2014).  
Many studies have demonstrated that IDO is significantly increased upon IFN-γ 
stimulation (English et al. 2007; Ryan et al. 2007). Importantly, Noone et al. further 
identified that increased HLA-ABC expression (following IFN- γ stimulation) inversely 
correlated with NK cell cytotoxicity (Noone et al. 2013). 
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 1.3.2. MSC AND DENDRITIC CELLS 
 Dendritic cells (DC) are specialised antigen presenting cells capable of inducing 
a T cell mediated response against a specific antigen.  In recent years there has been a 
range of studies that have strived to identify how MSC interfere with DC function, 
resulting in the identification of 3 key processes by which MSC modulate DC.  Firstly, 
MSC limit the normal up-regulation of co-stimulatory molecules CD40, CD80, CD86 and 
MHC Class II by DC in response to LPS stimulation (Jung et al. 2007; English et al. 
2008).  Secondly, MSC impair the antigen presentation ability of DC (English et al. 2008) 
and thirdly, MSC abrogate the capacity of DC to migrate to the lymph node  derived 
chemokines by down-regulating CCR7 and maintaining the expression of e-cadherin on 
DC (English et al. 2008).  The ability of MSC to impair DC maturation is mediated 
through a combination of soluble factors and cell contact signals.  The two main soluble 
factors are IL-6 and PGE2 (Djouad et al. 2007; Chen et al. 2007).  IL-6 secretion by the 
MSC induces a semi-mature phenotype in DC and subsequently reduces the 
differentiation of progenitor cells to DC (Djouad et al. 2007).  Chen et al., also 
demonstrated that the chemical inhibition of PGE2 synthesis within MSC restored DC 
differentiation and function (Chen et al. 2007).  The cell contact signal contributing to the 
MSC ability to modulate DC maturation remains unclear but recent studies have indicated 
that there may be a role for the notch signalling pathway (Tobin et al, In re-submission).  
Aldinucci et al. demonstrated that cell contact was required for complete inhibition of DC 
function (Aldinucci et al. 2010).  In the presence of MSC, DC remained in an immature 
state and were unable to form functional immune synapses, retained endocytic activity 
and podosome-like structures. MSC suppression of DC function in vitro is also 
maintained in vivo.  Chiesa et al demonstrated that MSC therapy significantly impaired 
the migration of LPS activated DC to draining lymph nodes and subsequently inhibited 
T cell priming (Chiesa et al. 2011). 
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1.4. MSC AND THE ADAPTIVE IMMUNE SYSTEM 
1.4.1 MSC AND T CELLS 
MSC inhibition of T cell activation and proliferation has been extensively 
characterised over the last decade and has been the foundation behind the progression of 
MSC therapy to clinical application.  In vitro, MSC suppress T cell function through a  
combination of chemokines (Ren et al. 2008), direct cell contact and release of soluble 
factors (Di Nicola 2002).  MSC first attract T cells through the production of CXCR3 
(Ren et al. 2008) and MCP-1 (Akiyama et al. 2012) before binding the T cell via the 
ICAM-1 and VCAM-1 (Ren et al. 2010).  MSC secrete a wide range of soluble factors, 
including HGF, TGF-β (Di Nicola 2002), IDO (Meisel et al. 2004), PGE2 (Németh et al. 
2009), IL-10 (Yang et al. 2009), IL-6 (Najar et al. 2009), semaphorin-3A, Galectin-1 
(Lepelletier et al. 2010), Galectin-9 (Gieseke et al. 2013), adenosine (Sattler et al. 2011) 
and TSG-6 (Lee et al. 2009) which suppress the proliferation and cytotoxic function of 
activated T cells.  The immune suppression ability of MSC is not restricted to naïve T cell 
activation and proliferation; MSC are also capable of inhibiting the response of antigen 
specific memory T cells to their cognate peptide (Krampera et al. 2003). 
An alternative concept of how MSC modulate T cell function is the induction of 
T cell apoptosis, first described in vitro by Plumas et al. (Plumas et al. 2005).  A few 
years later, Akiyama et al. demonstrated that, following MCP-1 mediated chemo-
attraction, MSC induced T cell apoptosis through Fas/FasL signalling in vivo  (Akiyama 
et al. 2012).  The authors further suggested that the subsequent increase in TGF-β, 
produced by macrophages in response to T cell apoptosis, significantly up-regulates the 
generation of regulatory T cells  and supports immune tolerance (Akiyama et al. 2012). 
 MSC can modulate T cell function and potentially play a role in generating 
tolerance through the generation of Treg cells in vitro and in vivo (Casiraghi et al. 2008; 
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English et al. 2009; Kavanagh & Mahon 2011).  MSC support of Treg cells in vitro is 
dependent on cell contact, PGE2 and TGF-β1 and results in fully functional regulatory T 
cells capable of suppressing alloreactivity (English et al. 2009).  Selmani et al. proposed 
a mechanism by which cell contact between CD4+ T cells and MSC results in HLA-G 
production by the MSC which results in Treg generation (Selmani et al. 2008).  The 
generation of Treg cells following MSC administration has also been observed in vivo in 
a wide range of disease models.  MSC therapy generates significantly increased Treg cell 
numbers in animal models of asthma (Kavanagh & Mahon 2011), acute renal injury (Hu 
et al. 2013; Kilpinen et al. 2013), kidney transplantation (Ge et al. 2010), skin 
transplantation (Lee et al. 2013) and colitis (Zuo et al. 2013).  A recent small scale phase 
I clinical trial examining the ability of MSC therapy to support renal transplantation 
(Mudrabettu et al. 2014), has also reported significantly increased Treg cell expansion 
and reduced allo-responsive T cell proliferation following MSC therapy. 
  
1.4.2 MSC AND B CELLS 
In contrast to the detailed understanding of how MSC modulate T cell function, 
the effect of MSC on B cell biology in vitro is poorly characterised and studies into MSC 
modulation of B cell biology have presented conflicting results (Corcione et al. 2006; 
Tabera et al. 2008; Rasmusson et al. 2007; Traggiai et al. 2008; Comoli et al. 2008; 
Franquesa et al. 2012). While the majority of the published data suggest that MSC inhibit 
B cell  function (Franquesa et al. 2012; Corcione et al. 2006; Tabera et al. 2008), other 
publications have demonstrated a supportive role for MSC in B cell expansion and 
differentiation (Rasmusson et al. 2007; Traggiai et al. 2008).  The mechanism by which 
MSC either support or inhibit B cell function has yet to be identified; however a 
requirement for cell contact has been suggested (Rasmusson et al. 2007; Traggiai et al. 
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2008).  Possible explanations for the variability observed between these studies are the 
different experimental conditions utilised in each study, in particular the ratio of MSC to 
B cells, the purity of B cell populations, the activation status and indeed the maturational 
stage of the B cell population.   
 
1.5 B CELL DEVELOPMENT 
 1.5.1 PRO-B CELL DEVELOPMENT 
 Mature B cells and the antibodies they produce represent an essential element of 
the adaptive immune response.  B cells develop from pluripotent hematopoietic 
progenitor cells in the fetal liver and postnatal bone marrow (Kiel & Morrison 2008).  In 
adults, early B cell development occurs within the bone marrow and consists of tightly 
controlled stepwise processes culminating in the functional rearrangement of 
immunoglobulin gene segments (Tonegawa et al. 1974; Matthyssens et al. 1976.; Hardy 
& Hayakawa 2001).  Progenitor cells programmed to differentiate through the B cell 
lineage begin this transition as pro-B cells.  The sole function of the pro-B cell is the 
immunoglobulin gene rearrangement which leads to the generation of a functional B cell 
receptor (BCR) complex.  The BCR complex is responsible for antigen recognition and 
is composed of 2 identical heavy and light chains which can be further divided in to 
variable and constant regions (Schatz & Ji 2011).  The variable domain of the heavy chain 
is encoded by Variable, Diversity and Joining (VDJ) gene segments and the functional 
rearrangement of the VDJ gene segments for the immunoglobulin heavy chain signals the 
progression of the pro-B cell to the pre-B cell phase of development (Pieper et al. 2013).   
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1.5.2 PRE-B CELL DEVELOPMENT 
In humans, the pre-B cell undergoes 1 or 2 phases of cell division with the purpose 
of rearranging the immunoglobulin light chain.  In the case of the immunoglobulin light 
chain, the focus is on rearranging the κ gene segment.  If the rearrangement of the κ gene 
segment fails to make a viable chain, the rearrangement of the λ chain occurs (van Zelm 
et al. 2007).  Successful rearrangement of the immunoglobulin light chain results in the 
cell surface expression of the BCR.  At this stage, the B cell is classified as an immature 
B cell and expresses cell specific surface IgM.  The immature B cell then completes its 
maturation process by leaving the bone marrow and migrating to the secondary lymphoid 
organs as a transitional B cell (Sims et al. 2005).  
 
1.6 B CELL ACTIVATION 
 The ability of B cells to recognise and produce specific antibodies against 
invading pathogens is one of the fundamental mechanisms by which the humoral immune 
response functions.  Upon recognition of specific pathogens, B cell activation is generally 
dependent on the presence of activated helper T cells (Kubota et al. 1991; Parker 1993); 
however under particular circumstances B cell activation can occur in the absence of T 
cell help (Mond et al. 1995; Vos et al. 2000). 
 
 1.6.1 T CELL DEPENDENT B CELL ACTIVATION 
 Signalling through the BCR is essential for B cell development and antigen 
recognition; however, aberrant B cell activation and recognition of self-antigens result in 
the development of auto-immune disease (Tuscano et al. 2003).  To reduce the risk of this 
from occurring the immune system has evolved a series of complex checkpoints which 
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must be passed during development and activation of B cells (Tussiwand et al. 2009).  In 
general, antigen recognition is not enough to induce B cell activation and proliferation 
and B cells require the help of T cells which have also been activated against the same 
antigen (Parker 1993).  Antigen bound to B cells is internalised and processed into 
peptides which can be presented to T cells via major histocompatibility complex (MHC) 
class II molecules (Lanzavecchia & Bove 1985; Stern et al. 1994; Forquet et al. 1999).  
Helper T cells which recognise this peptide then provide cell contact signals and cytokines 
to B cells which induce proliferation and differentiation of B cells into antibody secreting 
plasma cells or long lived memory B cells (Parker 1993).  
 
 1.6.2 T CELL INDEPENDENT B CELL ACTIVATION 
 While the majority of B cell activation is dependent on T cell help, there are 
certain circumstances where B cell activation can occur in the absence of MHC class II 
restricted T cell signalling.  T cell independent B cell activation occurs in response to T 
cell independent (TI) antigens, which are classified as either TI-1 or TI-2 antigens (Zhang 
et al. 1988; Mond et al. 1995).  TI-1 antigens are generally mitogenic and include LPS 
expressed on the outer membrane of gram negative bacteria.  These antigens are 
recognised by Toll like receptors (TLRs) and induce polyclonal B cell expansion. TI-2 
antigens are generally simple polysaccharide structures with repeating subunits.  B cells 
activation in response to TI-2 antigens is caused by the crosslinking of these repeating 
subunits to a number of B cell receptors (Mond et al. 1995).  The activation of B cells 
following exposure to TI antigens is restricted to IgM production and requires IL-3, 
GMCSF or IFN-γ to induce isotype class switching and IgG production (Snapper et al. 
1992; Mond et al. 1995; Vos et al. 2000).  
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1.6.3 ISOTYPE CLASS SWITCHING  
 Somatic hypermutation is essential in the development of high affinity antibodies 
during T cell dependent B cell activation.  B cells which have bound antigen undergo 
point mutations in the variable regions of the heavy and light chains at a very high rate.  
These mutations result in an altered immunoglobulin molecule which binds the antigen 
with a much higher affinity than the original surface molecule.  In parallel with somatic 
hypermutation, B cells also undergo isotype class switching.  Human B cells produce 5 
major classes of antibody (IgM, IgD, IgG, IgA and IgE) but also produce 4 sub-classes 
of IgG and 2 sub-classes of IgA (Janeway 2001).  During isotype class switching the 
variable region of the BCR does not change, therefore retaining the specificity against the 
particular antigen.  Instead, changes in the constant region allow the antibodies to interact 
with different effector cells.  The induction of isotype switching in activated B cells 
requires both CD40 ligation and cytokine signalling; with the sub-class of secondary 
isotype produced dependent on the cytokines present.  In this study B cell activation is 
driven by a cocktail containing CD40L and CpG, and is supplemented with B cell 
supportive cytokines IL-10, IL-2 and IL-21.  Binding of CD40L to CD40 on B cells 
results in the activation of several transcription factors including NFκB and CREB 
(Francis et al. 1995; Zhu et al. 2002).  CpG Oligodeoxynucleotide (CpG) are single 
stranded synthetic DNA molecules which are recognised by TLR9 (Bauer et al. 2001).  
Stimulation of peripheral B cells with CD40L in conjunction with CpG is known to 
enhance B cell activation (Carpenter et al. 2009).  The production of IL-10, IL-2 and IL-
21 by T cells enhances B cell activation, proliferation and influences immunoglobulin 
class switching (Malisan et al. 1996; Ettinger et al. 2005; Cerutti 2008; Tangye et al. 
2013) (Table 1.1).  The addition of these cytokines to the B cell media was designed to 
mimic the in vivo environment. 
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Table 1.1. Effect of Th1, Th2 and Tfh cytokines on Immunoglobulin class expression 
 
1.6.4 CLONAL SELECTION 
 Immune recognition and the subsequent expansion of B cells specific for the 
recognised pathogen are fundamental to the development of immune memory and 
acquired immunity.  The exponential expansion and long lasting memory against specific 
pathogens is a result of B cell clonal selection (Burnet 1959).  The B cell clonal selection 
principle states that only B cells which are specific for the detected antigen will proliferate 
in response (Hodgkin et al. 2007).  Activated B cells capable of binding the antigen 
subsequently undergo affinity maturation, a process designed to improve the BCR affinity 
to the antigen.  B cells which express the highest antibody affinity to the detected antigen 
are selected to undergo rapid proliferation and differentiate into antibody secreting 
plasma cells or long lived memory cells.  Long lived plasma cells circulate the body 
indefinitely after antigen exposure and upon reinfection these cells can rapidly 
differentiate to plasma cells capable of producing high affinity antibodies (Yu et al. 2008). 
 
  Immunoglobulin Isotypes 
T Helper Cell Cytokines IgG1 IgG2a IgG2b IgG3 IgA IgE 
Th1 IFN-γ       
 IL-2       
Th2 IL-4       
 IL-5       
 IL-10       
Tfh IL-21       
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1.7 CENTRAL B CELL TOLERANCE 
 The randomised nature of BCR heavy and light chain variable domain 
recombination is fundamental to the development of a vast naïve B cell repertoire.  
However, randomised recombination will also result in the generation of BCRs which are 
capable of reacting with self-antigens (Wardemann et al. 2003).  Therefore, the immune 
system has evolved stringent selection processes which are designed to remove auto-
reactive B cells (MacLennan 1995).  The first checkpoint for B cell auto-reactivity occurs 
at the immature B cell stage and determines whether or not immature B cells migrate to 
the periphery.  B cells which are not detected as auto-reactive continue development and 
migrate to the periphery as transitional B cells (Loder et al. 1999; Allman et al. 2001; 
Tarlinton et al. 2003).  Studies on the early B cell repertoire have reported that between 
50 and 75% of immature B cells in the bone marrow are capable of recognising self-
antigens (Grandien et al. 1994; Wardemann et al. 2003).  These studies also examined 
the auto-reactivity of transitional and mature B cells recovered from the periphery and 
found a lower frequency of auto-reactive B cells (20-40%). While considerably lower 
than the proportion of auto-reactive B cells in the bone marrow, the presence of auto-
reactive B cells in the periphery highlights the limitations associated with this system.  
Patients suffering from auto-immune disorders such as Systemic Lupus Erythematosus 
or Rheumatoid Arthritis also display a higher proportion of auto-reactive transitional and 
mature B cells than healthy patients (Samuels et al. 2005; Yurasov et al. 2005), indicating 
a potentially defective central B cell selection.  Central B cell tolerance is mediated 
through a number of steps including clonal deletion, receptor editing and the positive 
selection of immature B cells (Pelanda & Torres 2012), which are explained in more detail 
below. 
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 1.7.1 CLONAL DELETION 
 The clonal selection theory was first proposed over 50 years ago and suggested 
that immune cells capable of auto-reactivity were eliminated to prevent auto-immune 
responses (Burnet 1959).  In order to discover the fate of newly generated auto-reactive 
B cells, several research groups delivered IgM and IgD responsive antibodies to new-
born mice and rabbits  (Lawton et al. 1972; Manning & Jutila 1972; Finkelman et al. 
1983; Pelanda & Torres 2012).  The injected antibodies mimicked ‘self-antigens’ and the 
administration of IgM and IgD responsive antibodies resulted in the elimination of IgM 
and IgD expressing B cells (Lawton et al. 1972; Manning & Jutila 1972; Finkelman et al. 
1983; Pelanda & Torres 2012).  The development of transgenic mice allowed more 
complex studies on clonal deletion to be performed.  Some of the first immunoglobulin 
transgenic mice to be developed were the anti-hen’s egg lysosome (HEL) and anti-H-
2Kk,b mice which furthered the understanding of the fate of auto-reactive B cells in the 
bone marrow (Pelanda & Torres 2012).  These studies were the first to show that upon 
the detection of strongly auto-reactive B cells, the differentiation process is halted and B 
cell apoptosis is induced (Nemazee & Buerki 1989; Hartley et al. 1991; Hartley et al. 
1993). Around the same time, it was also discovered that the differentiation of weakly 
auto-reactive B cells was not blocked and these were allowed to migrate from the bone 
marrow; however these cells had a shorter life-span due to auto-reactive cell deletion in 
the periphery (Goodnow et al. 1988).  Clonal deletion plays a major role in central B cell 
tolerance but subsequent studies have proved that it is not the primary mechanism of 
preventing auto-reactive B cell development but only operates after receptor editing has 
failed (Halverson et al. 2004). 
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 1.7.2 RECEPTOR EDITING 
 The concept of receptor editing was derived by two separate research groups who 
hypothesised that the immune system could selectively dispose of auto-reactive BCRs 
while preserving the cell originally producing this specificity (Gay et al. 1993; Radic et 
al. 1993; Tiegs et al. 1993).   Using transgenic mice, it was possible to show that auto-
reactive immature B cells were given the opportunity to edit their antigen specificity 
towards a non-self-antigen (Gay et al. 1993; Radic et al. 1993; Tiegs et al. 1993).   Auto-
reactive immature B cells were capable of essentially discarding their self-specific BCRs 
and re-activating the immunoglobulin light chain gene rearrangement program. The 
rearranged light chain would re-associate with the heavy chain to form a new BCR; this 
time however, specific for a different antigen (Gay et al. 1993; Radic et al. 1993; Tiegs 
et al. 1993).  Re-edited immature B cells which were no longer auto-reactive could then 
progress into the periphery to continue development.  At the time of conception, the 
phenomenon of receptor editing was very controversial and sceptically regarded as an 
artefact of transgenic animal models (Pelanda & Torres 2012). However, receptor editing 
has since been conclusively demonstrated through the use of immunoglobulin ‘knock-in’ 
mice (Pelanda et al. 1997; Hippen et al. 2005).  Although this process mainly involves 
rearrangement of the immunoglobulin light chain, editing of the immunoglobulin heavy 
chain alleles can also occur (Chen et al. 1995).  There are some potential hazards 
associated with receptor editing, mainly the production of intermediate B cells which 
express both the original auto-reactive BCR and the new rearranged BCR (Li et al. 2002).  
Through mechanisms which remain undetermined, some of these dual receptor B cells 
are selected into the periphery and continue their development to mature B cells (Rezanka 
et al. 2005). These dual receptor B cells can constitute up to 10% of mature B cells in 
mice and Casellas et al. suggest that dual receptor auto-reactive B cells are more potent 
than regular auto-reactive B cells (Casellas et al. 2007). 
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1.8 PERIPHERAL B CELL TOLERANCE 
 Although the mechanisms controlling central B cell tolerance are tightly 
regulated, they are not completely effective and some auto-reactive B cells manage to 
escape detection and enter the periphery.  Therefore, the immune system has adapted an 
alternative mechanism for controlling auto-reactive B cells in the periphery.  In the 
majority of cases, B cell activation is dependent on T cell help (Parker 1993).  This is also 
the case for auto-reactive B cells.  Auto-reactive B cells activate upon recognition of self-
antigens; however, the absence of specific T cell help results in apoptosis or functional 
inactivation of the auto-reactive B cells (Gavin et al. 2004).  Therefore, functional central 
tolerance in the T cell compartment will reduce the auto-reactivity of B cells. 
 
1.9 MSC IN B CELL MEDIATED DISEASE 
 As described above, the immune system has developed a number of stringent 
selection processes designed to remove potentially auto-reactive B cells from 
development before they leave the bone marrow (MacLennan 1995).  However these 
selection processes are not perfect and as much as 20% of auto-reactive B cells reach 
circulation (Grandien et al. 1994; Wardemann et al. 2003).  The activation of auto-
reactive B cells and subsequent production of auto-reactive antibodies can result in the 
development of auto-immune disorders such as rheumatoid arthritis (RA) Multiple 
Sclerosis (MS) or Systemic Lupus Erythematosus (SLE).  The current gold standard of 
treatment for auto-immune disorders depends on the specific disease and symptoms but 
generally consist of anti-inflammatory and immuno-suppressive drugs designed to 
control rather than cure the disease.  The potent immune modulatory ability of MSC has 
made them an attractive candidate for novel cell therapy for treatment for auto-immune 
disorders such as RA, MS and SLE.  
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Pre-clinical models of collagen induced arthritis have been used to investigate the 
potential of MSC therapy as a treatment for RA; however these studies have provided 
conflicting results (Augello et al. 2007; González et al. 2009b; Zheng et al. 2008; Djouad 
et al. 2005; Papadopoulou et al. 2012).  The majority of these studies suggest that MSC 
reduced the severity of disease and resulted in lower levels of pro-inflammatory 
cytokines, increased anti-inflammatory cytokines and the development of regulatory T 
cells (Augello et al. 2007; Liu et al. 2010; González et al. 2009b; Zheng et al. 2008).  
However, other research groups have reported no beneficial effects of MSC therapy in 
murine models of RA (Djouad et al. 2007; Papadopoulou et al. 2012).  Despite conflicting 
results,  MSC therapy has undergone clinical trials for the treatment of rheumatoid 
arthritis and have demonstrated positive results (Liu et al. 2010; Wang et al. 2013).  These 
studies demonstrated that MSC therapy did not result in adverse effects up to 6 months 
after administration.  MSC therapy in conjunction with anti-rheumatic drugs significantly 
decreased the presence of pro-inflammatory cytokines TNF-α and IL-6 and increased 
regulatory T cell production (Wang et al. 2013).   
Experimental autoimmune encephalomyelitis (EAE) is currently the most 
applicable mouse model in which to study MS.  The administration of MSC therapy to 
murine models of EAE has demonstrated beneficial effects (Rafei et al. 2009; Zappia et 
al. 2005; Bai et al. 2012; Fisher-Shoval et al. 2012; Guo et al. 2013); however there have 
also been reports where MSC therapy exacerbated disease (Grigoriadis et al. 2011; Glenn 
et al. 2014).  Despite the concerns raised by these studies, MSC therapy has progressed 
to small scale clinical trials as a treatment for MS.  In early trials, the administration of 
autologous MSC to MS patients was well tolerated but did not result in significant 
improvements (Yamout et al. 2010; Karussis et al. 2010).  However recent phase II trials 
have demonstrated efficacy of MSC therapy using autologous (Llufriu et al. 2014) or 
allogeneic MSC (Li et al. 2014). 
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The ability for MSC therapy to treat SLE has also been examined using murine 
models and has again produced conflicting results (Zhou et al. 2008; Sun et al. 2009; Gu 
et al. 2010; Youd et al. 2010).  The majority of published studies suggest that MSC 
therapy results in significant improvement in SLE pathology, joint pain and antibody 
production (Zhou et al. 2008; Sun et al. 2009; Gu et al. 2010); however the administration 
of MSC therapy to SLE mice has also been reported to exacerbate disease (Youd et al. 
2010).  As a result of the inconsistencies observed in animal models, the administration 
of human MSC as a cell therapy to Lupus patients has been limited.  However, the clinical 
studies which have been conducted to date provide promising results (Sun et al. 2010; 
Liang et al. 2010; Wang et al. 2014).  The administration of MSC therapy to SLE patients 
did not result in adverse effects for the 18 month duration of follow up studies.  Significant 
improvements in disease score, levels of auto-antibody, proteinuria, renal function and 
increased presence of regulatory T cell were observed in SLE patients following MSC 
therapy (Sun et al. 2010; Liang et al. 2010; Wang et al. 2014). Interestingly MSC isolated 
from Lupus patients demonstrate slower proliferation and limited cytokine production 
compared to MSC isolated from healthy donors (Sun et al. 2007).  These results suggest 
that allogeneic MSC isolated from healthy donors may be more useful in treating auto-
immune disorders. 
 While acute GvHD (aGvHD) is considered to be a T cell mediated disease, the 
progression of chronic GvHD (cGvHD) shares a number of key features with the 
pathology of autoimmune disorders such as scleroderma or SLE (Ratanatharathorn et al. 
2001; Zhang et al. 2006). In contrast to acute aGvHD, cGvHD pathology is mediated by 
Th2 cytokines and results in B cell dysregulation and elevated serum antibody levels 
(Ratanatharathorn et al. 2001).  Clinical approaches to controlling cGvHD have focused 
on the administration of the monoclonal antibody rituximab during disease development, 
designed to deplete CD20+ B cells (Ratanatharathorn et al. 2000; Cutler et al. 2006; 
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Clavert et al. 2013).  Eliminating CD20+ B cells significantly reduced disease pathology 
with some patients reporting the alleviation of clinical cGvHD symptoms (Clavert et al. 
2013).  As a result of the beneficial effects observed following MSC therapy in models 
of autoimmune disorders, pre-clinical models of cGvHD were established to determine 
possibility of MSC as a cell therapy.  The results were promising and MSC promoted Th1 
and Th2 balance in cGvHD mice in addition to alleviating cGvHD symptoms.   
MSC therapy for cGvHD has rapidly progressed to clinical trials (Weng et al. 
2010).  This study demonstrated MSC therapy was safe and also effective in treating 
cGvHD patients, with 78% of patients demonstrating partial or full resolution of 
symptoms in the skin, gut and liver (Weng et al. 2010).  More recently, another clinical 
trial successfully administered MSC therapy to 23 refractory cGvHD patients. 20/23 
patients reported partial or complete responses (Peng et al. 2014).  The authors suggested 
that the decrease in pathology was mediated by MSC induction of IL-10 producing CD5+ 
regulatory B cells.  MSC therapy significantly increased the survival and enhanced the 
proliferation capacity of these cells through a mechanism involving IDO production 
(Peng et al. 2014). 
 
1.10 MAJOR HISTOCOMPATIBILITY COMPLEX IN TRANSPLANTATION 
 The major histocompatibility complex (MHC), human leukocyte antigen (HLA) 
in humans, is an integral part of the immune system and contains important polymorphic 
genes which encode proteins that present antigen to self-restricted T cells (Snell 1948).  
MHC are essential in the discrimination of self from non-self (Doherty & Zinkernagel 
1975b; Doherty & Zinkernagel 1975a) and the induction of immune tolerance, first 
proposed by Peter Medawar in 1953.  The exact pattern of MHC gene expression, known 
as the haplotype, is almost unique to each individual; therefore transplanted allogeneic T 
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cells which do not recognise the recipient’s MHC molecules become activated (Snell 
1948).  As a result of this, immune cells recognise non-self MHC as foreign and attempt 
to clear these cells from the body.  
 MHC recognition is one of the major limiting factors affecting the success of both 
solid organ and bone marrow transplantation. Donor derived cells which express different 
MHC molecules are subject to recognition and clearance by the recipient’s immune 
system in a similar manner to an invading pathogen. The identification and 
characterisation of MHC molecules by Gorer, Snall and Daussett and others in the first 
half of the 20th century has been essential to the progression made in understanding the 
immune system and its manipulation during transplantation.  Gorer first identified natural 
antibodies in human sera which were capable of distinguishing between red blood cells 
isolated from 3 different strains of mice (Gorer 1936).  Around the same time, Snell had 
identified tumor transplantation resistant genes that he termed histocompatibility or H 
genes. Together with Gorer, Snell discovered the major histocompatibility (MHC) 
antigen, which resulted in rapid transplant rejection compared to minor histocompatibility 
molecules (miHA) (Gorer 1936; Snell 1948; Snell & Higgins 1951). 
 The above studies propelled MHC genes to the forefront of transplant research 
and their role in human transplantation.  In 1958, the first human HLA was identified 
following the screening of patients who had undergone multiple blood transfusions 
(Degos 2009).  This study discovered that administering sera from some donors resulted 
in clumping of leukocytes and they subsequently discovered an anti-sera capable of 
detecting allogeneic antigen expressed by human leukocytes, which he termed MAC but 
is now known as HLA-A2 (Degos 2009).  From these studies, Daussett hypothesised that 
MAC, along with then uncharacterised antigens, would be essential in the success of 
human bone marrow transplantation between MHC mismatched donors.   
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 The discovery of HLA genes and subsequent understanding of their importance 
in transplant rejection supported the concept of immunological tolerance and tissue 
transplantation derived by Billingham, Medawar and Brent (Billingham et al. 1953) and 
contributed hugely to the fields of solid organ and bone marrow transplantation.  These 
fields were further advanced following the discovery of powerful immunosuppressants 
(cyclosporine A and tacrolimus) which have permitted solid organ transplantation 
between MHC mismatched patients (Messina et al. 2008). 
 
1.11 HAEMATOPOIETIC STEM CELL TRANSPLANTATION 
 Haematopoietic stem cell transplantation (HSCT) is the current gold standard of 
treatment for patients suffering with haematological malignancies and inherited blood 
disorders (Reddy & Ferrara 2003).  HSCT has become common practice with over 25,000 
procedures carried out globally (Ferrara et al. 2009).  Patients of HSCT first undergo a 
conditioning regimen which can consist of chemotherapy, radiotherapy and/or T cell 
depletion (Shlomchik 2007).  Pre-conditioning regimens are designed to eliminate the 
patient’s T and B cells leaving them highly immunocompromised and more permissive 
to the engraftment of donor bone marrow.  The engraftment of activated donor T cells 
has an effect on the remaining leukaemia (Graft versus Leukaemia (GvL)) or tumor cells 
(Graft versus Tumor (GvT)) (Horowitz & Bortin 1990; Trenado et al. 2003).  This 
represents a double edged sword however, as active donor T cells may also cause 
pathology (GvHD) as a result of donor/host MHC mismatch at both MHC and miHA 
level (Korngold & Sprent 1978).  GvHD can be considered a mirror image of solid organ 
transplant rejection in that donor cells reject the recipient’s cells by recognising 
recipient’s MHC as foreign. 
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1.12 PATHOPHYSIOLOGY OF GVHD 
 Graft versus host disease is a major complication associated with HSCT which 
results in target tissue apoptosis.  In order for the development of GvHD to occur, the 
recipient must be immunodeficient (unable to mount a successful immune response 
against the graft), the donor graft must contain immunocompetent cells and the tissue 
antigens (HLA) expressed by the patient must be recognised by the donor’s HSC (the 
graft) (Billingham 1966.).  Over the last number of years, improvement in donor selection, 
conditioning regimens, GvHD prophylaxis and treatment, and attention to infectious 
complications means that the majority of transplant related mortality is caused by a 
relapse of primary malignancies (Markey et al. 2014).  Despite the recent advances, 
GvHD still remains a major cause of treatment failure, and mortality in approximately 
20% of transplant patients; and a study of HSCT transplant patients from 2003 – 2007 
showed that 70% of patients developed some level of GvHD (Gooley et al. 2010).   
Originally characterised as a cytokine storm (in particular TNF-α) (Ferrara & 
Deeg 1991), the development of GvHD occurs in 3 phases: (1) pre-transplant 
conditioning regimen and associated inflammation, (2) donor T cell priming and 
differentiation and (3) the effector phase of tissue apoptosis mediated by inflammatory 
cytokines and effector cells (Figure 1.1).   
As mentioned above HSCT patients undergo a pre-conditioning regimen of 
myeloablative chemotherapy, with or without total body irradiation.  Although necessary 
to facilitate the engraftment of donor immune cells, the intensity of the pre-conditioning 
regimen can influence the timing and nature of GvHD development.  Pre-conditioning 
regimens are known to affect the permeability of the gut which results in the leakage of 
LPS into the system and a subsequent inflammatory response (Ferrara et al. 2009).  There 
have been attempts to improve the integrity of the GI tract by the administration of IL-11 
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and keratinocyte growth factor (KGF) (Hill & Ferrara 2000).  Despite promising results 
in animal models, toxicity and incomplete efficacy in patients has hampered progression 
(Antin et al. 2002).   
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Figure 1.1. Pathophysiology of GvHD during murine model occurs in 3 phases.  In phase 1, the pre-
conditioning regimen damages host tissue resulting in the secretion of pro-inflammatory cytokines TNF-α 
and IL-1.  Increased expression of these cytokines leads to host antigen presenting cell (APC) activation.  
The pre-conditioning regimen can also damage intestinal mucosa leading to leakage of lipopolysaccharide 
(LPS) into the periphery.  During phase 2, activated host APC activate mature donor T cells.  The donor T 
cells then proliferate and differentiate to effector T cells.  Donor derived effector T cells then migrate to 
target tissues.  In phase 3, effector T cells infiltrate small intestine, lungs and liver and can directly induce 
apoptosis.  Subsequent increases in TNF-α result in necrosis and apoptosis.  
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The priming and differentiation of donor T cells is the hallmark of the second 
phase of GvHD pathogenesis.  Donor T cells contained within the graft become activated 
by the inflammatory environment created by the conditioning regimen.  The priming and 
differentiation of donor T cells is dependent on direct interaction with both host and donor 
derived antigen presenting cells (APC) (Ferrara et al. 2009).  The current understanding 
is that CD8+ T cells become activated after encountering the host’s haematopoietic APC 
while CD4+ T cells are activated by non-haematopoietic APC in the gut.  Donor APC can 
further contribute to T cell priming.  To date, a number of steps have been taken to try to 
inhibit the activation and expansion of donor T cells.   Ablative cell therapies have been 
explored but studies have shown that no single recipient APC subset is essential for the 
development of GvHD; however donor DC appear to be the critical APC in the 
presentation of allogeneic antigen and maintenance of GvHD (Markey et al. 2014).  
Studies investigating blocking of co-stimulatory molecules (CD40-CD154 or CD80/86-
CD28/CTLA4) in renal transplant patients have demonstrated some efficacy (Kinnear et 
al. 2013); however this strategy is only now being explored for bone marrow 
transplantation.  Upon activation, donor T cells proliferate and differentiate to pro-
inflammatory cytokine producing cells with cytolytic function.  Novel methods to control 
the activation and differentiation of donor T cells after HSCT have focused on controlling 
the naïve T cell population.  Mouse models have suggested a role for naïve T cells in 
aGvHD development and there has been some human data to support this (Dutt et al. 
2007).  Therapies focusing on ablating naïve T cells in the graft before administration are 
currently under clinical investigation in the US.  However, the current standard of 
treatment against GvHD is to use immunosuppressants to prevent T cell expansion and 
differentiation but GvHD still occurs, suggesting novel methods of treatment need to be 
identified. 
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The combined effect of the inflammatory environment created by pre-
conditioning regimens along with donor T cell activation and differentiation results in an 
uncontrolled immune response in which inflammatory cytokines and cytotoxic T cells 
mediate antigen dependent and independent destruction of target tissues (Ferrara et al. 
2009).  TNF-α, IL-1 and IFN-γ are some of the main cytokines involved in driving GvHD 
and can induce apoptosis of target tissues without direct interaction.  Pro-inflammatory 
cytokine production is mediated by differentiated T cells which amplifies the production 
from monocytes or macrophages (Hill & Ferrara 2000).  In contrast GvHD driven by 
CD8+ T cells is dependent on cognate interaction between CD8+ T cells and target tissues.  
CD8+ T cells induce tissue apoptosis through perforin & granzyme molecules, TNF 
signalling and the Fas/FasL pathway (Graubert et al. 1997; Hattori et al. 1998; Maeda et 
al. 2005). 
While efforts to control GvHD have examined the possibility of interfering with 
the progression of disease at this phase, these activated T cells are required to attack 
remaining leukaemia (GvL) through perforin granzyme, TNF-related apoptosis inducing 
ligand and Fas/FasL mediated apoptosis pathways (Pan et al. 1999; Schmaltz et al. 2003; 
Hill et al. 1999).  Therefore inhibiting the apoptotic abilities of these cells may be 
deleterious to the GvL function of the graft; however this may offer a viable option for 
patients who have already cleared the leukemic cells but are presenting severe GvHD 
symptoms. 
 
1.13 CLINICAL FEATURES OF GVHD 
 GvHD is a systemic condition characterised by the targeted apoptosis of the skin, 
liver and GI tract.  Although idiopathic pneumonia syndrome is commonly associated 
with the progression of GvHD, it is regarded as a manifestation of the lung rather than 
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apoptosis (Markey et al. 2014).  The most common clinical symptom occurs in the skin 
(81%) followed by the GI tract (54%) (Martin et al. 1990).  The painful maculopapular 
rash which develops on the skin of aGvHD patients is caused by necrosis of the epithelial 
cells and presents on the palms of the hands or soles of the feet in most patients (Ferrara 
et al. 2009).  In severe cases, the rash can lead to blistering and ulcer formation causing 
excruciating pain and discomfort to patients.  Targeted apoptosis of the epithelial cells 
which line the GI tract results in severe abdominal pain and diarrhoea (Martin et al. 1990).  
As the damage to the GI tract progresses it can lead to bloody diarrhoea, vomiting, and 
extreme weight loss in patients.  Damage to the liver is more difficult to diagnose and 
quantify during GvHD and is difficult to distinguish from other causes of damage during 
HSCT (secondary effects from pre-conditioning regimen or drug toxicity) (Ferrara et al. 
2009).  Damage of hepatic tissue is generally detected as hyperbilirubinaemia and 
jaundice (Ferrara et al. 2009; Tolar et al. 2011). 
 aGvHD progression is classified as grade I to grade IV (mild, moderate, severe 
and very severe) depending on the number of target organs involved and the extent of 
damage in each.  Each grade of disease correlates directly with the chance of survival 
(Ferrara et al. 2009).  The average long term survival rate for patients diagnosed with 
grade III aGvHD is ~25%; however this survival rate drops to 5% for patients diagnosed 
with grade IV aGvHD (Cahn et al. 2005).  The therapeutic prevention of aGvHD has 
focused on the reduction of pathology in an attempt to prolong survival.  
 
1.14 THERAPEUTIC PREVENTION OF GVHD 
 1.14.1 THERAPEUTIC PREVENTION OF AGVHD 
 Despite the recent advances and the level of research currently being dedicated to 
controlling the development of aGvHD, the progress made in terms of eliminating the 
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disease has been modest.  In Europe, the current standard of treatment remains the 
administration of glucocorticosteroids (methylprednisolone) in combination with 
immunosuppressive drugs (cyclosporine A or Tacrolimus) (Dhir et al. 2014). The 
combination of steroid therapy and immunosuppressant drugs is designed to trigger 
lymphocyte lysis and promote an anti-inflammatory environment (steroid therapy) while 
dampening down the activation of immune cells by keeping the patient in an 
immunocompromised state. The type and dose of steroid therapy and immunosuppressant 
drugs are personalised for each patient and patient responsiveness is generally dependant 
on the severity of disease (MacMillan et al. 2002; Van Lint et al. 2006).  However a 
typical course of treatment for patients diagnosed with aGvHD is the administration of 
methylprednisolone (2 mg/kg) for 7-14 days with a gradual reduction depending on 
patient responsiveness (Van Lint et al. 1998; Messina et al. 2008).  The administration of 
these drugs have resulted in significant increases in survival and provided huge 
improvements to the standard of living for GvHD patients (Van Lint et al. 1998; 
MacMillan et al. 2002; Van Lint et al. 2006) and depending on the patient’s response and 
severity, the dose and period of treatment can be reduced.  However, there are major 
limitations to these treatments including the risk of infection, hyperglycaemia, 
osteoporosis, potentially life threatening growth defects and the financial burden of life 
long treatment (Reddy et al. 2009).  The biggest problem with this therapy is the 
development of steroid resistant GvHD in certain patients who no longer respond to 
treatment.  In these patients a second line of treatment is required. 
 The decision to progress from the primary course of treatment to a secondary line 
of treatment is dependent on the progression of the disease.  A secondary line of treatment 
is deemed necessary for patients where there is a worsening in disease pathology in any 
organ over 3 days, if there has been no improvement in condition over 7 days or if there 
is incomplete response to treatment over 14 days (Deeg 2007).  The most commonly 
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prescribed secondary line of treatments consist of monoclonal or polyclonal antibodies 
(Doney et al. 1985; Carpenter et al. 2002).  To date, there have been a number of 
approaches taken in an attempt to prevent the development of aGvHD including the 
partial depletion or elimination of specific T cells from the graft before administration to 
patients; however the depletion of T cell subsets from the graft resulted in inconsistent 
results and increased the possibility of graft failure or leukemic relapse (Horowitz & 
Bortin 1990).  Over the last few decades, the potent immunosuppressant anti-thymocyte 
globulin (ATG) has been administered to patients of aGvHD.  ATG has been successful 
in reducing the frequency of aGvHD development in related-donor HSCT patients 
without increasing the risk of tumor relapse (Doney et al. 1985; Kröger et al. 2002).  
However, the administration of ATG has proven clinically problematic with patients 
presenting high levels of variability as well as the development of adverse effects 
(hypotension, anaphylactic reactions) in up to 80% of patients.  The median long term 
survival for patients receiving ATG remained ~5-32% (MacMillan et al. 2002; Graziani 
et al. 2002).   
Another technique developed to prevent the development of GvHD was to induce 
apoptosis of activated T cells using the anti-CD3 monoclonal antibody Visilizumab.  
Initial results from clinical trials were very promising and it was determined that outcome 
of treatment was dependent on the initial dose administered (Carpenter et al. 2002).  
However, as with ATG, there were complications associated with the use of Visilizumab 
clinically.  Patients who received Visilizumab were prone to reactivation of Ebstein Barr 
Virus (EBV) which led to post transplant lymphoproliferative disease (Carpenter et al. 
2002).  The monoclonal antibody Alemtuzumab binds to CD52 and induces apoptosis of 
lymphocytes, monocytes and DC.  Initial results from phase II clinical trials found that 
administration of Alemtuzumab lowered the frequency of both acute and chronic GvHD 
development (Pérez-Simón et al. 2005).  However, subsequent studies reported 
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complications with infection and increased relapse rates leading to graft failure (Delgado 
et al. 2006).   
One of the most successful second line treatments developed to date has been in 
targeting the production of TNF-α during aGvHD.  Elevated levels of TNF-α have long 
been associated with severe GvHD development (Holler et al. 1990; Kitko et al. 2008).  
2 different drugs targeting TNF-α have been investigated in clinical trials, etanercept 
which binds trimeric and membrane bound TNF-α, and infliximab, a monoclonal 
antibody designed to bind monomeric, trimeric soluble and membrane bound TNF-α 
(Ehlers 2005).  The phase II clinical trial of etanercept (in combination with steroid 
therapy) resulted in complete resolution of symptoms in 70-80% of patients of GI tract or 
skin aGvHD (Levine et al. 2008).  Despite this result, the adverse effects associated with 
etanercept make it difficult to use as a treatment (MacMillan et al. 2002; Graziani et al. 
2002; Carpenter et al. 2002; Levine et al. 2008).  The efficacy of infliximab was 
investigated in a small scale clinical trial of 11 steroid refractory aGvHD patients 
(Jacobsohn et al., 2003).  The results from the study were not promising as only 2 out of 
11 patients treated completely responded to infliximab treatment.  Another 5 patients 
partially responded to the treatment however 4 patients were unresponsive to infliximab 
(Jacobsohn et al. 2003).  One result which was of note was that the 2 patients which 
responded to infliximab had acute GI GvHD, suggesting that infliximab treatment may 
be appropriate under certain circumstances (Jacobsohn et al. 2003).  Infliximab 
administration also increased patient susceptibility to infection with 6 of the 11 patients 
presenting fungal infections at the time of death (Jacobsohn et al. 2003). More recently, 
a large scale trial investigated the efficacy of infliximab therapy in conjunction with 
corticosteroid treatment in 52 refractory aGvHD patients (Pidala et al. 2009). The 
complete response rate of aGvHD patients was not significantly higher than the initial 
trial and infliximab administration again resulted in extensive bacterial and fungal 
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infection (Pidala et al. 2009). The incomplete efficacy and adverse effects of monoclonal 
antibodies as second line treatments for aGvHD patients indicate that a more effective 
therapy needs to be designed.  Recent approaches to treating aGvHD have focussed on 
designing cellular therapies for inflammatory mediated disease. 
 
 1.14.2 THERAPEUTIC PREVENTION OF CGVHD 
 The pathophysiology of cGvHD can affect almost every organ and generally 
requires lengthy and intensive immune suppression.  As with aGvHD, the current 
approach to treating cGvHD patients is to administer strongly immune suppressive 
corticosteroids in combination with calcineurin inhibitors (Dhir et al. 2014).  The dosing 
concentration and frequency is generally tailored for each individual patient and is 
dependent on the severity of disease (Dignan et al. 2012); however a standard course of 
treatment is the daily administration of Prednisolone (1mg/kg) in combination with 
cyclosporine reduced to alternative day dosing after 1-2 months (Dhir et al. 2014).  
However, the side effects associated with long term administration of cyclosporine, long 
term toxicity and renal failure, emphasise the need to identify alternative treatment 
(Hingorani et al. 2005).  In addition, the nature of this therapy can result in the 
development of steroid refractory GvHD.   
 A number of different approaches have been examined as potential second line 
treatments for cGvHD including mTOR inhibitors, pentostatin and extracorporeal 
photophoresis (ECP).  The ability to modulate cGvHD through the administration of the 
mTOR inhibitor Sirolimus has demonstrated promising results in a phase II clinical trial.  
Refractory cGvHD patients which received Sirolimus in combination with Tacrolimus 
and corticosteroids demonstrated a 60% complete response rate (Couriel et al. 2005); 
however there are significant side effects associated with the use of mTOR inhibitors 
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including toxicity and renal failure (Schwarz et al. 2010) making them unsuitable for 
routine clinical use.  Pentostatin is a chemotherapeutic agent used in the treatment of hairy 
cell leukemia (Maloisel et al. 2003).  A phase II clinical trial investigating the 
administration of Pentostatin to refractory cGvHD patients demonstrated promising 
results with over 50% of patients demonstrating complete response (Jacobsohn et al. 
2009).  However, infusion of Pentostatin led to high incidence of serious infection and 
may not be suitable for long term clinical use (Jacobsohn et al. 2009).  A more promising 
method of treating refractory cGvHD patients may well be extracorporeal photophoresis 
(ECP).  ECP is an apheresis based therapy originally designed to treat cutaneous T cell 
lymphoma (Edelson et al. 1987) but has since been tested in patients with solid organ 
allograft rejection (Barr et al. 1998), Crohn’s disease (Abreu et al. 2009) and GvHD (F L 
Dignan et al. 2012; Tsirigotis et al. 2012).  The concept of ECP therapy is that patient’s 
blood is passed through UV light which induces apoptosis of mononuclear cells.  Upon 
subsequent re-infusion, these apoptotic cells are processed by DC which induce anti-
imflammatory cytokine production and the generation of Treg cells.  Clinical trials which 
have investigated ECP therapy for cGvHD patients have demonstrated promising results 
with very few side effects (Flowers et al. 2008; Greinix et al. 2011). 
 
1.15 CELL THERAPIES FOR GVHD 
 1.15.1 REGULATORY T CELLS 
 Regulatory T cells (Treg) are a subset of CD4+ T cells which possess potent 
immunomodulatory ability and are defined as CD4+CD25highFoxP3+.  The expression of 
CD127 has been used to separate immune suppressive Treg cells (CD127low) from 
activated effector T cell populations (CD127high) (Seddiki et al. 2006; Hartigan-O’Connor 
et al. 2007).  Treg cells can be thymus derived (natural Treg) or generated in the periphery 
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and whose activation is dependent on T cell receptor engagement and cytokines (induced 
Treg).  It is believed that natural Treg cells hold a more stable and potent role in promoting 
self-tolerance and preventing auto-immunity (Safinia et al. 2013).  Treg cells also express 
CD27, CD45RA, CD39, CD122 and glucocorticoid-induced tumor necrosis factor 
receptor (GITR) (Fletcher et al. 2009; Dieckmann et al. 2001; Jonuleit et al. 2001).   
 Treg cells are potent regulators of the inflammatory response and modulate 
immune cells through the production of the anti-inflammatory cytokines IL-10, TGF-β 
and IL-35 and by signalling directly through cell contact (Chen et al. 2003; Roncarolo et 
al. 2006; Collison et al. 2007).  The ability of Treg cells to directly induce T cell apoptosis 
through a perforin-granzyme dependant mechanism has also been demonstrated 
(Grossman et al. 2004; Gondek et al. 2005).  Co-culture of Treg cells in the presence of 
DC reduced the antigen presentation ability and co-stimulatory function of DC through 
cyclic adenosine monophosphate (cAMP) production by the Treg cell and subsequently 
reduced the expression of the co-stimulatory molecules CD80 and CD86 on DC (Safinia 
et al. 2013; Fassbender et al. 2010). 
 Adaptive immunity is a term first coined by Billingham and colleagues in 1953 to 
describe the successful generation of a tolerant immune system following the transfer of 
active immune cells but it wasn’t until 1990 that CD4+CD25+ T cells were identified as 
the cells responsible (Wood & Sakaguchi 2003; Hall et al. 1990).  The study of Hall et 
al. determined that the adoptive transfer of CD4+CD25+ T cells generated tolerance in 
rats which received cardiac allograft (Hall et al. 1990).  Since this there has been a number 
of studies which have investigated a role for Treg cells as a cell therapy against the 
rejection of solid organ transplants.  Sakaguchi et al. used Treg cells from naïve mice to 
prevent the rejection of allogeneic skin grafts in T cell deficient nude mice (Sakaguchi et 
al. 1995).  Subsequent studies have highlighted that the presence of Treg cells at the time 
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of transplantation is critical for the inducing and maintaining tolerance to the graft (Wood 
& Sakaguchi 2003).   
 Despite the difficulties associated with the isolation and expansion of Treg cells, 
a number of clinical trials have been undertaken to determine the therapeutic values of 
Treg cells.  The first clinical trial to report beneficial effects of Treg cell therapy on 
allograft survival was conducted by Trzonkowski et al.  This small scale study 
demonstrated the ability of Treg cells to reduce pathology in GvHD patients.  This small 
scale study followed 2 patients (Trzonkowski et al. 2009).  The first patient developed 
cGvHD within 2 years of receiving the transplant.  The patient received 1 x 105/kg 
autologous Treg cells which had been FACS purified and expanded ex vivo.  GvHD 
symptoms were reduced and the patient was removed from immunosuppressive treatment 
without recurrence (Trzonkowski et al. 2009).  The second patient was diagnosed with 
acute GvHD within the first month following transplantation and received several 
infusions of autologous Treg cells.  Despite initial improvements, the patient succumbed 
to the disease (Trzonkowski et al. 2009).  Although these results were sub-optimal, this 
study demonstrated that ex vivo expanded Treg cells were tolerated by the patient and 
gave rise to further large scale clinical trials. 
 A larger phase I/II clinical trial involving 23 patients undergoing umbilical cord 
blood stem cell transplantation who received escalating doses of Treg cells (1 x 105 to 30 
x 105 Treg cells) was subsequently completed (Brunstein et al. 2011)  CD4+CD25high Treg 
cells were isolated from third party umbilical cord blood and expanded ex vivo using anti-
CD3/CD28 coated beads and recombinant IL-2 for 18 days.  The administration of Treg 
cells reduced the instances of grade II – IV acute GvHD in comparison to historic 
controls; however, overall GvHD occurrence was not significantly reduced (Brunstein et 
al. 2011). 
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 A third clinical trial (phase I/II) investigated the effect of Treg cell therapy on 
GvHD development after HSCT to treat haematological malignancies (Di Ianni et al. 
2011).  This study also focused on the administration of donor Treg cells as well as donor 
conventional T cells to HSCT patients without the use of adjuvants or patient 
immunosuppression.  Different dosing conditions were implemented at the beginning 
with patients receiving doses of between 5 x 105/kg conventional T cells with 2 x 106/kg 
Treg cells to 2 x 106/kg conventional T cells with 4 x 106/kg Treg cells.  However 2 
patients receiving the highest dose of treatment developed GvHD; therefore the authors 
recommended a dose of 1 x 106/kg conventional T cells with 2 x 106/kg Treg cells (Di 
Ianni et al. 2011).  Patients which received Treg cell therapy had accelerated immune 
engraftment, reduced reactivation of latent cytomegalovirus (CMV) with a lower instance 
of GvHD compared to historic controls.  However, the survival rate of GvHD patients 
who had received Treg cell therapy remained at 50% (Di Ianni et al. 2011). 
 
1.15.2 MESENCHYMAL STROMAL CELLS  
 Over the last number of years, the array of potential applications for MSC therapy 
has grown significantly.  Allogeneic MSC therapies have been tested in clinical trials for 
the prevention or treatment of GvHD, Crohn’s disease, Multiple Sclerosis and critical 
limb ischemia.  The first indication that MSC could be developed into a cell therapy came 
from a study by Lazarus et al. where they reported that the administration of autologous 
MSC to cancer patients resulted in accelerated haematopoietic recovery (Lazarus et al. 
1995).  In 2002, Bartholomew et al. demonstrated that MSC derived from baboons were 
capable of prolonging survival of autologous, donor or allogeneic skin graft 
transplantations in a primate model (Bartholomew et al. 2002).  Since this study, both 
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autologous and allogeneic MSC have been administered to patients receiving HSCT for 
haematological malignancies in clinical trials. 
 By far the most successful results for MSC therapy have been observed in the 
treatment of aGvHD after allogeneic stem cell transplantation.  In 2004, the first 
transplantation of MSC as an allogeneic cell therapy for patients with steroid resistant 
grade IV GvHD was performed by Le Blanc et al. and demonstrated remarkable 
immunosuppressive effects (Le Blanc et al. 2004).  A 9 year old patient who had received 
a MHC-matched HSC transplant from a non-related donor to treat leukaemia was 
diagnosed with severe steroid-resistant acute GvHD of the gut and the liver.  A cell 
therapy of haplo-identical MSC was generated and administered over 2 doses.  However 
the exact mechanisms by which the MSC therapy mediated this effect was not determined 
(Le Blanc et al. 2004). Importantly this study demonstrated that MSC therapy was safe, 
MSC did not inhibit the engraftment of the transplanted graft and complete chimerism 
was observed in the patient (Le Blanc et al. 2004).  In a later study, the same research 
group demonstrated that the source of MSC (autologous or allogeneic) had no effect on 
their ability to treat GvHD (Le Blanc et al. 2008).   
 Despite this very promising progress into the development of MSC therapy to 
treat aGvHD, the results of a large scale phase III clinical trial by Osiris Therapeutics 
provided a setback for the field.  Osiris Therapeutics developed an MSC-like cell therapy 
called Prochymal™ which demonstrated safety for human administration and benefit to 
patients with aGvHD during phase II clinical trials (Kebriaei et al. 2009). In a large scale 
phase III clinical trial, Prochymal™ significantly increased response rates in patients with 
steroid refractory liver GvHD and steroid refractory gastrointestinal disease over patients 
treated with placebo. However overall the study did not reach its primary endpoint to 
significantly increase the complete response rates in steroid refractory GvHD patients for 
at least 28 days in comparison to placebo controls (Martin et al. 2010).  Notably, 
38 
 
Prochymal cell therapy showed good progression in reducing aGvHD in the liver and 
gastro-intestinal tract of patients but did not demonstrate any improvement against skin 
aGvHD symptoms (Martin et al. 2010).  The potential for MSC to preferentially work in 
one organ over another is very interesting and raises a lot of questions behind the 
mechanism of action.  The development of novel models of aGvHD are essential to the 
discovery of why this may happen.  Overall, these results highlighted the potential of 
allogeneic MSC as a candidate therapy to treat acute steroid refractory GvHD when 
administered after donor T cell recognition but also further emphasized the large gap in 
our understanding of how MSC mediate their beneficial effect in a clinical setting.   
 
1.16 ANIMAL MODELS OF GVHD 
 Despite the recent advances in understanding and developing therapies against 
GvHD, only modest improvements have been achieved.  This underlines the necessity for 
more accurate and reproducible animal models to further advance the understanding of 
the disease and to develop novel therapies. Although non-human primates are currently 
being used as disease models, these animals are subject to much more vigorous ethical 
restraints and are far more expensive.  Therefore murine models of human disease have 
become a more feasible and informative option for human observation, in particular when 
investigating hypotheses.  The majority of murine models available to study GvHD are 
designed for the transplantation of donor lymphocytes to irradiated hosts.  In these 
scenarios the severity of GvHD development is dependent on the dose of pre-
conditioning, and the amount and type of transplanted lymphocytes.  The most commonly 
used and straightforward murine models of GvHD involve the transplantation of MHC 
mismatched lymphocytes into a murine host; however in recent years the development of 
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humanised mouse models has provided a more clinically relevant system in which to 
analyse potential cell therapies. 
The current knowledge available regarding the stages leading up to GvHD 
development have largely been identified through the use of murine models (Schroeder 
& DiPersio 2011).  Importantly, the pathogenesis of GvHD in murine models is very 
similar to that observed in humans.  As with human GvHD patients, murine models of 
GvHD present apoptosis and destruction of the lungs, liver, skin and GI tract.  Similar to 
humans, pre-conditioning regimens and GvHD development results in extensive damage 
to the integrity of the GI tract in mice, resulting in diarrhoea and significant weight loss.  
The tissue specific apoptosis observed in human patients can also be observed in murine 
models through histological analysis.  The reproducibility of murine GvHD models 
allows the development of a standardised and well defined scoring system to determine 
the severity of GvHD development within each mouse (Tobin et al. 2013).  As with all 
models of disease, there are a number of caveats associated with murine models of GvHD.  
Fundamental differences in murine immunology, including subpopulations of immune 
cells, MHC molecule expression, costimulatory molecule expression and function, 
cytokine expression, lymphocyte differentiation as well as immune signalling 
components, must be considered when interpreting and translating results (Mestas & 
Hughes 2004).  More specifically to GvHD, the pre-conditioning regimen varies between 
the fractionated administration utilised in humans and the single dose generally used for 
mouse models.  The pre-conditioning regimen results in tissue damage and subsequent 
pro-inflammatory environment which influences the development of disease (Ferrara et 
al. 2009).  Disparities between pre-conditioning regimens may impact experimental 
outcomes.  The source of donor immune cells is also an important difference.  In humans 
HSCT are generally conducted using mobilized stem cells in circulation while BMT 
conducted in murine models can contain material from the bone marrow and spleen or 
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peripheral blood in humanised mouse models.  The differences in transplanted cell 
populations is likely to influence GvHD pathology (Schroeder & DiPersio 2011). Despite 
these differences, murine GvHD models remain the most suitable in vivo system currently 
available in which to study GvHD. 
 
1.16.1 MHC MISMATCH MODELS 
The identification of the MHC and miHA have facilitated the development of 
murine models of aGvHD and cGvHD.  While the rejection of foreign cells and tissues is 
generally mediated through allogeneic MHC recognition, differences in miHA can also 
result in graft rejection (Schroeder & DiPersio 2011).  In contrast to the variability 
observed between humans, the MHC of inbred mouse strains are very similar; however 
the recognition of allogeneic miHA can lead to GvHD development in murine models. 
The most commonly used MHC mismatch model of aGvHD is the transplantation 
of whole lymphocyte/purified T cells from a C57BL/6 mouse (H2b) to a sub-lethally 
irradiated BALB/c mouse (H2d).  All MHC mismatch models use pre-conditioning 
regimens to mimic the process in humans and the most common conditioning regimen is 
irradiation.  Mice can be irradiated in a single dose or in fractionated doses (3-8 hours 
apart) if the required dose exceeds 1100 Gy.  Most of these models are dependent on the 
administration of CD4+ and CD8+ T cells to develop GvHD. 
The C3H/HEJ (H2k) into C57Bl/6 (H2b) model of aGvHD is similar to the model 
described above in that it is a complete mismatch of MHC I and II as well as miHA.  In 
general, it requires significantly more splenocytes to trigger lethal aGvHD (25-30 x 106) 
and aGvHD generally occurs between days 21-30 (Blazar et al. 1991).   
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Another MHC mismatch model of aGvHD is the ‘parent-to-F1 model’.  In 
contrast to the previous model this model of aGvHD can be performed with or without 
the sub-lethal irradiation conditioning regimen.  Utilising the model without irradiation 
is designed to mimic situations where a patient receives no or reduced intensity 
conditioning regimens. The development of aGvHD is dependent on class I and class II 
antigen dependent activation of CD4+ and CD8+ T cells (Hakim et al. 1991).  
Transplanted mice which did not receive myeloablative conditioning display less severe 
symptoms than mice which received irradiation.  Transplanted mice which did not receive 
irradiation display reduced skin pathology and limited weight loss.  In these mice, aGvHD 
pathology correlated with immune deficiency and did not result in full chimerism.  There 
is also a lower rate of morbidity associated with no irradiation. 
 
 1.16.2 MURINE MODELS OF CGVHD 
 The clinical features and kinetics of cGvHD vary significantly from aGvHD as 
cGvHD patients develop chronic inflammation and fibrotic regions in a similar manner 
to patients suffering from auto-immune disorders; however cGvHD and aGvHD mostly 
target the same organs.  The most commonly used cGvHD models currently available are 
generally classified as sclerodermatous (pro-fibrotic), or auto-antibody mediated 
(lupus/like) cGvHD models (Jaffee and Claman, 1983; Rolink and Gleichmann, 1983). 
The sclerodermatous models of cGvHD mimic scleroderma in human cGvHD patients 
(~15% of cGvHD patients) and are characterised by fibrotic damage to the dermis and 
also targeted apoptosis in the lungs and liver (Jaffee & Claman 1983; Claman et al. 1985; 
Howell et al. 1989; McCormick et al. 1999; Skert et al. 2006).  Sclerodermatous models 
of cGvHD are MHC matched but disparities in miHA result in cGvHD.  Pathology is 
dependent on donor CD4+ T cell activation and secretion of Th2 cytokines and subsequent 
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stimulation of pro-fibrotic cytokines IL-13 and TGF-β (Hamilton 1987; Korngold & 
Sprent 1987).  There are 2 commonly used sclerodermatous models of cGvHD.  The first 
is the transplantation of whole splenocytes with bone marrow from B10.D2 mice into 
sub-lethally irradiated BALB/c mice (Jaffee & Claman 1983) and the second is the 
transplantation of LP/J cells into irradiated C57Bl/6 mice (DeClerck et al. 1986).  
Sclerodermatous cGvHD models have provided valuable information regarding the 
progression of cGvHD; however there are some limitations associated with the model.  
Fibrotic damage in human cGvHD patients is systemic but in this mouse model fibrosis 
is localised to the skin; this may indicate a different mechanism of action.  Finally, 
sclerodermatous cGvHD models do not give the full spectrum of clinical symptoms 
observed in humans (Schroeder & DiPersio 2011). 
 The auto-antibody mediated mouse model of cGvHD results in a similar 
pathology to lupus.  Symptoms associated with this model of cGvHD include nephritis, 
salivary gland fibrosis, lymphadenopathy, splenomegaly, auto-antibody production and 
skin pathology, although at a much lower extent than sclerodermatous model (Schroeder 
& DiPersio 2011).  The auto-antibody mediated mouse model of cGvHD is a MHC 
mismatched mode of parent-F1 transplantation which results in mixed chimerism (Rolink 
& Gleichmann 1983).  Similar to the sclerodermatous model of cGvHD, pathology is 
dependent on donor CD4+ T cells and Th2 associated cytokines; however in this particular 
model of cGvHD the recipient B cells play a major role in pathology.  Recipient B cells 
are activated following interaction with donor T cells, through cell surface MHC 
molecules and recognition of IL-4 and IL-10 (Morris et al. 1990; Durie et al. 1994; Via 
et al. 1996; Kim et al. 2008).  The activation of recipient B cells results in 
lymphadenopathy, splenomegaly and auto-antibody production (Rolink & Gleichmann 
1983; Hakim et al. 1991).  Auto-antibody mediated mouse models of cGvHD are similar 
to human cGvHD pathology in relation to the production of antibodies; however there are 
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also differences between them.  Nephritis is commonly associated with this cGvHD 
mouse model but is very rare in humans, the repertoire of antibodies produced during 
human cGvHD is much more diverse than in murine cGvHD models, and 
lymphadenopathy and splenomegaly do not occur in human patients. 
 
1.17 HUMANISED MOUSE MODELS FOR AGVHD 
 The major limiting factors associated with murine models of aGvHD is that 
disease progression and pathology are not identical between mice and humans.  In murine 
models of aGvHD, pathology is driven by a different effector cell (murine vs human) and 
these models were not established to investigate the efficacy of human cell therapies.  The 
development of humanised mouse models which are based on severely immunodeficient 
mice, have addressed some of these issues.  The development of humanised mice is a step 
forward in linking animal models with clinical relevance and is testament to how research 
tools have progressed over the past decades. 
 
1.17.1 CB17SCID HUMANISED MOUSE 
 The development of humanised mouse models of disease was facilitated by the 
identification of the Prkdcscid (protein kinase, DNA activated, catalytic peptide; severe 
combined immunodeficiency) mutation in CB17 mice (Bosma et al. 1983).  Mice lacking 
Prkdc expression were unable to support VDJ rearrangement and as a result lacked fully 
mature T or B cells (Lieber et al. 1988).  While this represented a dramatic step forward 
in the development of humanised mice, the engraftment of human lymphocytes and 
stability of the mouse were problematic.  The engraftment of human lymphocytes was 
very low (0.01-0.1%) (Mosier et al. 1988) and the CB17scid mouse was ‘leaky’, i.e. the 
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mouse can develop clones of functional T and B cells.  The development of functional T 
and B cells can lead to enhanced immune activity which may explain the low levels of 
human lymphocyte engraftment.  Therefore, the scid mutation was introduced to other 
mouse strains and subsequently the development of the Non-obese Diabetic (NOD)-scid 
mouse (Hesselton et al. 1995).  The NOD-scid mouse facilitated significantly higher 
engraftment of human lymphocytes compared to other murine strains (up to 10 fold) and 
quickly became the gold standard of humanised mouse model. 
 
1.17.2 NOD-SCID HUMANISED MOUSE 
 The NOD mice have inherited immune defects, such as impaired macrophage 
development and function, reduced complement activity and decreased NK activity, 
which made them attractive candidates for the development of humanised mouse models 
(Kataoka et al. 1983; Baxter & Cooke 1993; Serreze et al. 1993) (Kataoka et al., 1983; 
Baxter et al., 1993; Serreze et al., 1993).  As seen with the CB17scid mouse, introducing 
the scid mutation resulted in the absence of fully mature T or B cells.  However, the NOD-
scid mouse was much more stable than its predecessor, only ~10% of 6 month old mice 
developing mature T or B cells.  The NOD-scid humanised mouse model also 
demonstrated significantly higher levels of human lymphocyte engraftment than the 
CB17 mouse; however the engraftment of human lymphocytes remained very low 
(~10%) (Hesselton et al. 1995).  Schultz et al. hypothesised that the low levels of 
lymphocyte engraftment may be caused by residual NK cell activity (Shultz et al. 1995).  
Another major limitation of the NOD-scid mouse was the short lifespan (~ 8 months) 
associated with these mice; the impaired life span of NOD-scid mice was a result of the 
frequent development of lethal thymic lymphomas (Shultz et al. 1995).  Therefore, 
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studies into further developing the NOD-scid humanised mouse model focussed on 
increasing life span as well as incorporating novel methods of blocking NK cell function. 
 
 1.17.3 NOD-SCID Β2MNULL AND RAG1NULL PRF1NULL HUMANISED MOUSE 
 In an attempt to control residual NK activity, the NOD-scid β2microglobulinnull 
(β2mnull) mouse was developed.  The NOD-scid β2mnull mouse lacked NK cell activity 
and demonstrated reduced innate immunity when compared to NOD-scid mice 
(Christianson et al. 1997).  The absence of NK cell activity in NOD-scid β2mnull mice 
resulted in a significant increase in the engraftment of human lymphocytes compared to 
NOD-scid mice (~7 fold) (Christianson et al. 1997).  However, NOD-scid β2mnull mice 
were also very susceptible to lethal thymic lymphomas, resulting in a much shorter 
lifespan (~5 months) than NOD-scid humanised mice.  Another humanised mouse model 
developed with defective NK cells was the NOD-Rag1null Prf1null mouse.  Within these 
mice, NK cells were present but non-functional due to the absence of the prf1 gene (Shultz 
et al. 2000).  The prf2 gene encodes perforin, a cytolitic protein found in the granules of 
NK cells, which mediates killing ability of NK cells (Shultz et al. 2000).  The lifespan of 
the NOD-Rag1null Prf1null mouse was significantly greater than the NOD-scid β2mnull and 
NOD-scid mice and the lack of functional NK cells resulted in significantly higher 
engraftment of human lymphocytes (Shultz et al. 2000).  However, the level of 
lymphocyte engraftment was highly variable between human donors and subsequently 
the reproducibility of the model was inconsistent.  Therefore the focus switched again to 
developing more robust and reproducible humanised mouse models. 
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 1.17.4 RAG-2-/-IL-2Rγ-/- HUMANISED MOUSE 
 The next wave of humanised mouse models focused on targeting mutations in the 
cytokine receptor common γ-chain. In humans, X linked SCID occurs due to mutations 
in the gene which encodes the IL-2rγ chain.  This gene contributes to IL-2, IL-4, IL-7, 
IL-9, IL-15 and IL-21 signalling (Kovanen & Leonard 2004).  Patients suffering from this 
disease are characterised by absent or markedly reduced mature T cells as well as reduced 
NK cell activity (Sugamura et al. 1996).  The previously developed RAG-2-/- strain of 
mice lacked functional T, B and NK cells (Shinkai et al. 1992) and it was hypothesised 
that introducing the IL-2rγ mutation to the RAG-2-/- strain of mice would facilitate 
significantly higher human lymphocyte development.  The RAG-2-/-IL2rγ-/- mice were 
infused with human CD34+ progenitor cells.  Indeed, human lymphocyte engraftment was 
significantly increased in the RAG-2-/-IL2rγ-/- mice and this mouse model also 
demonstrated greater multilineage development compared to previous models. 
 
 1.17.5 NOD-SCID IL-2RγNULL HUMANISED MOUSE  
 In terms of human lymphocyte engraftment, longevity and reduced NK function, 
the NOD-scid humanised mouse model was the most complete model developed up to 
this point.  Therefore it was hypothesised that introducing a similar IL-2rγ mutation to 
the NOD-scid strain would result in a humanised mouse model deficient in mature T or 
B cells, with reduced NK activity, and more amenable to the engraftment of human 
lymphocytes (Pearson et al. 2008).  The subsequent NOD-scid IL-2rγnull humanised 
mouse model was indeed deficient for mature T and B cells, demonstrated reduced NK 
cell activity and the engraftment of human lymphocytes was 6 fold higher than observed 
in the NOD-scid mouse model.  In addition to this, the lifespan of the NOD-scid IL-2rγnull 
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humanised mouse model was considerably longer than the NOD-scid mouse model, 
making it ideal for long-term studies. 
 In 2005, the development of a complete human immune system in a NOD-scid 
IL-2rγnull humanised mouse following the administration of peripheral blood CD34+ cells 
was first describe by Schultz et al., demonstrating the validity of the NOD-scid IL-2rγnull 
humanised mouse model for studying functional immune disease.  Since this study, the 
NOD-scid IL-2rγnull humanised mouse models has been deemed the most suitable 
humanised mouse model for studying GvHD (Ali et al. 2012) and there has already been 
a number of GvHD studies using this model (Hippen et al., 2012; Tobin et al., 2013; 
Miller et al., 2014).  For the purpose of this thesis the NOD-scid IL-2rγnull humanised 
mouse model was used to investigate stem cell therapies for the treatment of aGvHD. 
 
1.18 AIMS & OBJECTIVES 
 This chapter has highlighted the current understanding of how MSC interact with 
and regulate cells of the innate and adaptive immune response and the potential of 
delivering MSC therapy to GvHD patients.  This thesis aims to investigate two distinct 
areas in MSC research which remain to be addressed: 
(1) How MSC affect B cell biology and to elucidate the mechanisms by which 
effects are mediated.  
(2) Can novel more clinically relevant animal models be developed to 
investigate possible mechanisms by which MSC protect from GvHD.   
Despite the advances made in our understanding of how MSC modulate the 
immune system, the effect of MSC on B cell biology remains controversial.  The goal of 
Chapter 3 is to determine how MSC regulate the activation, proliferation and function of 
CD19+ peripheral B cells and to elucidate the mechanism by which the effect is mediated.   
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Chapters 4 and 5 of this thesis focus on the development of novel animal models 
of GvHD which more closely resemble clinical pathology and to use these optimised 
models of GvHD to investigate the efficacy of MSC therapy.  These models of GvHD 
will subsequently be used to examine a number of hypotheses focused on elucidating how 
MSC therapy exerts a protective effect during GvHD.  These hypotheses include: 
(1) MSC impair the engraftment of transplanted cells. 
(2) MSC prevent the polarisation of transplanted T cells to effector or central 
memory phenotype. 
(3) MSC reduce the production of pro-inflammatory cytokines during GvHD. 
(4) MSC therapy results in increased numbers of regulatory T cells. 
(5) Pre-licencing MSC with IFN-γ enhances protection in GvHD mice. 
(6) The administration of two consequitive MSC doses increases efficacy of 
cell therapy. 
 
Overall this study is designed to further the current knowledge of immune 
regulation by MSC and provide important information regarding the selection of MSC 
therapy for B cell mediated or idiopathic disease. This study will also contribute to the 
clinical application of MSC therapy for the treatment of GvHD by providing a more 
refined and clinically relevant model of disease. Taken together this thesis will advance 
our basic understanding of how MSC mediate their effects in vivo and will benefit the 
development of future clinical trials utilising allogeneic human MSC therapy in GvHD. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
  
50 
 
2.1  ETHICAL APPROVAL AND ANIMAL LICENSING 
 All procedures involving animals or human material were performed by licenced 
personnel.  Ethical approval for all work was granted from the Department of Health and 
Health Products Regulatory Agency, formerly Irish Medicines Board, and controlled by 
the ethics committee of NUI Maynooth. 
 
2.2 ANIMAL STRAINS 
 The following mouse strains were used for the experiments presented throughout 
this thesis: BALB/c (Harlan), C57Bl/6 (Harlan) and NOD.Cg-PrkdcscidIL2tmlWjl/Szj 
(Jackson Labs).  All mice were housed in accordance to regulations presented by the 
Department of Health and the Irish Medical Board and experiments were performed under 
ethically approved licences.  Sample size for animal experiments were determined by 
statistical power calculation. 
 
2.3 ISOLATION AND CULTURE OF CELLS 
2.3.1 HUMAN MESENCHYMAL STROMAL CELLS 
 Bone marrow MSC were isolated and kindly provided by collaborators in NUI 
Galway.  In brief, bone marrow aspirates were taken from the iliac crest of donor patients 
in accordance to approved clinical protocol (Murphy et al. 2002).  Isolated human MSC 
were re-suspended in complete Dulbecco’s Modified Eagle’s Media (cDMEM, Sigma-
Aldrich, St. Louis, USA) supplemented with 10% (v/v) foetal bovine serum (BioSera) 
and 1% (v/v) Penicillin/Streptomycin (Sigma-Aldrich).  Human MSC were seeded at 
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1x106 cells per T175 flask and cultured in a 37°C incubator set to 20% O2 and 5% CO2. 
Complete media was replaced every 48-72 hours until cells had reached 70-90% 
confluence.  When 90% confluent, cells were detached using 4ml of 0.25% trypsin/1mM 
EDTA (Invitrogn-Gibco), counted and either re-seeded or cryo-preserved. 
 
2.3.2 HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC) SEPARATION 
 Buffy packs were obtained from the Irish blood transfusion service.  Each buffy 
pack was transferred to a sterile T75 flask and mixed with 60 ml of sterile PBS.  15 ml of 
Lymphoprep (StemCell Technologies, Vancouver, Canada) was added to 4 sterile 50 ml 
tubes and 25 ml of diluted blood was carefully layered on to the Lymphoprep.  Samples 
were centrifuged at 2400 RPM for 25 minutes at room temperature (acceleration = 0, 
brake = 1).  The PBMC layer was then removed using sterile 3 ml transfer pipette and 
placed in a fresh 50 ml tube.  Samples were then centrifuged at 1800 RPM for 10 minutes 
at 4°C.  The supernatant was carefully discarded and the samples were re-suspended in 
sterile PBS.  Samples were washed twice more in PBS by centrifuging at 1500 RPM for 
5 minutes at 4°C.  Red blood cells were then removed from each sample by re-suspending 
the pellet in 5 ml of 1X RBC lysis buffer (BioLegend, San Diego, USA) for 5 minutes. 
Complete Roswell Park Memorial Institute (cRPMI, Table 2.1) media was added to 
neutralise the lysis and samples were spun down at 1000 RPM for 10 minutes at 4°C.  
Isolated PBMC were then re-suspended in 25 ml of cRPMI and counted. 
 
2.3.3 CD19+ PERIPHERAL B CELL ISOLATION 
 CD19+ B cells were purified from PBMC populations using positive selection 
CD19+ MACS beads (Miltenyi Biotech, Cologne, Germany).  3 x 108 PBMC were 
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washed twice in sterile PBS and once in MACS buffer (PBS with 0.5 % BSA (Sigma) 
and 2 mM EDTA (Sigma)) by centrifuging at 300 g for 5 minutes.  PBMC were then re-
suspended in 900 µl of MACS buffer and 100µl of CD19+ MACS beads were added to 
each sample.  Samples were placed at 4°C for 20 minutes before 10 ml MACS buffer was 
added and cells were spun down at 300 g for 5 minutes at 4°C.  PBMC populations were 
re-suspended in 2 ml of MACS buffer and passed through a 40µM cell strainer and 
collected in a fresh 15 ml tube.  Samples were then passed through LS columns (Miltenyi 
Biotech) in accordance with manufacturer’s specifications before purified CD19+ B cell 
populations were collected in a fresh 15 ml tube.  The purity of peripheral CD19+ B cell 
isolations was verified using flow cytometry for human CD20.  Only isolations yielding 
greater than 95% were used for experiments. 
 
2.3.4 CRYO-PRESERVATION AND RECOVERY OF CELLS FROM LIQUID NITROGEN 
 MSC were cryo-preserved in liquid nitrogen for long term storage.  Trypsinised 
MSC were counted and pelleted by centrifugation.  Pellets were re-suspended in freezing 
media (Table 2.1) at 2 x 106 per ml and 500 µl of cell suspension was added to labelled 
1.5 ml cryo-tube (Thermo Fisher Scientific, Massachusetts, USA).  Cells were gradually 
cooled at 1°C per minute to -80°C and then transferred to liquid nitrogen for long term 
storage.  To retrieve cells, cryo-vials were quickly thawed using a heated water bath set 
to 37°C.  Before completely thawed, cells were transferred to 10 ml of warmed cDMEM 
and centrifuged at 400 g for 5 minutes.  Supernatant was discarded and cells were re-
suspended in 1 ml cDMEM.  Cells were counted and analysed for viability. 
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Table 2.1. Description of media for cell culture 
Media Components Supplier Cell Type 
    
cDMEM Dulbecco’s Modified Eagle’s Media 
(DMEM) containing 1000 mg/ml 
glucose 
FBS (10% v/v) 
Pen/Strep (1% v/v) 
Sigma-Aldrich 
 
BioSera 
Sigma-Aldrich 
 
MSC 
cRPMI RPMI 1640 
Heat inactivated FBS (10% v/v) 
Pen/Strep (1% v/v) 
L-Glutamine (1% v/v) 
β-mercapthoethanol (0.1% v/v) 
Sigma-Aldrich 
BioSera 
Sigma-Aldrich 
Sigma-Aldrich 
Invitrogen-Gibco 
 
PBMC 
cIMDM Iscove’s Modified Dulbecco’s Media 
(IMDM) 
Heat inactivated FBS (10% v/v) 
Pen/Strep (1% v/v) 
L-Glutamine (1% v/v) 
β-mercapthoethanol (0.01% v/v) 
Sigma-Aldrich 
 
BioSera 
Sigma-Aldrich 
Sigma-Aldrich 
Invitrogen-Gibco 
 
B cells 
Freezing 
media 
cDMEM (70% v/v) 
FBS (20% v/v) 
DMSO (10% v/v) 
Sigma-Aldrich 
BioSera 
Sigma-Aldrich 
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2.4 CELL VIABILITY AND APOPTOSIS ASSAYS 
2.4.1 MEASUREMENT OF CELL VIABILITY 
 Cells were re-suspended in complete media and 10 µl of sample was removed and 
diluted with 40 µl of complete media.  10 µl of diluted sample was then mixed with 10 µl 
of 2% (w/v) ethidium bromide/acridine orange (EB/AO) (Sigma-Aldrich).  10 µl of cells 
were then pipetted onto a glass haemocytometer chamber and visualised under a 
fluorescent microscope.  Live cells (fluoresced green) were counted while dead cells 
(fluoresced orange) were excluded. 
 
2.4.2 IN VITRO APOPTOSIS ASSAY 
 B cell apoptosis was detected by the positive expression of Annexin V and 
Propidium Iodide (PI) as measured by flow cytometry.  B cells were harvested and 
centrifuged at 300 g for 5 minutes.  Supernatant was discarded and cells were washed in 
sterile PBS.  Samples were re-suspended in FACS buffer (PBS with 2% (w/v) BSA).  
Cells were transferred to a V bottom 96 well plate and spun down at 300 g for 5 minutes.  
Supernatant was discarded and cells were stained with 0.3 µl of CD20 for 15 minutes in 
the dark at 4°C.  Cells were washed once in FACS buffer and once in 1 X Annexin V 
binding buffer. 2 µl of Annexin V was added to each well and cells were incubated for 
15 minutes in the dark at room temperature.  Cells were washed twice in 1 X binding 
buffer and re-suspended in 50µl of counting beads (Becton Dickinson, New Jersey, USA).  
1 µl of PI was added to each well and cells were incubated at room temperature for 5 
minutes.  CD20+ B cells were then analysed for expression of apoptotic markers Annexin 
V and PI using Acurri C6 flow cytometer. 
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2.5 FLOW CYTOMETRIC ANALYSIS OF PROTEIN EXPRESSION 
 2.5.1 CELL SURFACE FLOW CYTOMETRY 
 To analyse the expression of surface bound proteins by flow cytometry, cells were 
harvested, washed twice in PBS and re-suspended in FACS buffer to a concentration of 
1 x 106 cells /ml.  100 µl of cell suspension was transferred to V-bottom 96 well plate 
(Lennox, Dublin, Ireland) and cells were centrifuged at 950 RPM for 5 minutes at 4°C.  
Supernatant was discarded and fluorochrome labelled antibodies or isotype controls were 
added directly to the cells.  Samples were incubated in the dark at 4°C for 15 minutes.  
150 µl of FACS buffer was then added to each well and samples were centrifuged at 950 
RPM for 5 minutes at 4°C.  Supernatant was discarded and samples were washed again 
with 150 µl of FACS buffer. The supernatant was discarded and cells were re-suspended 
in 50 µl of counting beads (BD) and analysed on a BD Accuri C6 flow cytometer. 
 
 2.5.2 INTRA-CELLULAR FLOW CYTOMETRY 
 In order to determine the expression of intra-cellular transcription factors or pro-
inflammatory cytokines, intra-cellular flow cytometry was performed.  To analyse the 
expression of constitutively expressed transcription factors, cells were harvested from co-
culture assays, washed twice in PBS and re-suspended in FACS buffer to a concentration 
of 1 x 106 cells /ml.  100 µl of cell suspension was transferred to V-bottom 96 well plate 
(Lennox) and surface proteins were labelled exactly as described in section 2.5.1.  After 
cell surface protein staining, 100 µl of Fix/Perm buffer (eBioscience, San Diego, USA) 
was added to each well and samples were incubated in the dark at 4°C overnight.  200 µl 
of Permeabilisation buffer was added to each well and samples were centrifuged at 950 
RPM for 5 minutes at 4°C.  Supernatant was discarded and samples were blocked in 3 µl 
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of 2% rat serum (Sigma Aldrich) for 20 minutes at 4°C.  1 µl of fluorochrome labelled 
antibodies or isotype controls were added directly to the cells and samples were incubated 
in the dark at 4°C for 1 hour.  150 µl of FACS buffer was then added to each well and 
samples were centrifuged at 950 RPM for 5 minutes at 4°C.  Supernatant was discarded 
and samples were washed again with 150 µl of FACS buffer. The supernatant was 
discarded and cells were re-suspended in 50 µl of counting beads (BD) and analysed on 
a BD Accuri C6 flow cytometer. 
 In order to detect the expression of pro-inflammatory cytokines in lymphocytes 
ex vivo, lymphocytes were isolated from lung, liver and spleen of mice as described in 
section 2.10.4.  Lymphocytes were seeded at 1 x 105 cells/well in cRPMI.  PBMC were 
stimulated with 100 ng/ml Phorbol Myristate Acetate (PMA, Sigma) and 1 µg/ml 
Ionomycin (Sigma) for 5 hours in the presence of 1 X Golgi Stop (eBioscience).  After 
stimulation samples were transferred to a V-bottom 96 well plate (Lennox) and cells were 
centrifuged at 950 RPM for 5 minutes at 4°C.  Samples were washed twice in FACS 
buffer before cell surface proteins were stained as previously described in section 2.5.1.  
After cell surface protein staining, 100 µl of Fix/Perm buffer (eBioscience) was added to 
each well and samples were incubated in the dark at 4°C overnight.  200 µl of 
Permeabilisation buffer was added to each well and samples were centrifuged at 950 RPM 
for 5 minutes at 4°C.  Supernatant was discarded and samples were blocked in 3 µl of 2% 
rat serum for 20 minutes at 4°C.  1 µl of fluorochrome labelled antibodies or isotype 
controls were added directly to the cells and samples were incubated in the dark at 4°C 
for 1 hour.  150 µl of FACS buffer was then added to each well and samples were 
centrifuged at 950 RPM for 5 minutes at 4°C.  Supernatant was discarded and samples 
were washed again with 150 µl of FACS buffer. The supernatant was discarded and cells 
were re-suspended in 50 µl of counting beads (BD) and analysed on a BD Accuri C6 flow 
cytometer. 
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2.6 CHARACTERISATION OF DIFFERENTIATION 
 2.6.1 OSTEOGENIC DIFFERENTIATION 
 MSC were seeded at a density of 1.8 x 105 cells/well in a 6 well tissue culture 
plate (Sarstedt, Numbrecht, Germany) in 3 ml of cDMEM and incubated at 37°C.  Once 
MSC had reached 70% confluence, cDMEM was removed and MSC were incubated in 
either cDMEM (negative control) or osteogenic differentiation media (Table 2.2).  Media 
was changed every 72 hours for 21 days.  On day 21, media was removed and MSC 
washed gently 3 times with sterile PBS.  Cells were then fixed in 10% (v/v) neutral 
buffered formalin for 20 minutes at room temperature.  Formalin was removed and cells 
were gently washed twice in PBS.  1 ml of 1% Alizarin Red (Table 2.3) was added to 
each well and cells were stained for 20 minutes at room temperature.  Excess stain was 
removed and cells were gently washed twice with dH2O.  1 ml of dH2O was added to 
each well and cells were examined under light microscope for the presence of positively 
stained osteocyte like cells. 
 
 2.6.2 ADIPOGENIC DIFFERENTIATION 
 MSC were seeded at a density of 1.8 x 105 cells/well in a 6 well tissue culture 
plate (Sarstedt) in 3 ml of cDMEM and incubated at 37°C.  Once MSC had reached 70% 
confluence, cDMEM was removed and MSC were incubated in either cDMEM (negative 
control) or adipogenic differentiation media (Table 2.2).  Media was changed every 72 
hours for 21 days.  On day 21, media was removed and MSC washed gently 3 times with 
sterile PBS.  Cells were then fixed in 10% (v/v) neutral buffered formalin for 20 minutes 
at room temperature.  Formalin was removed and cells were gently washed twice in PBS.  
1 ml of filtered 0.5% Oil Red O (Table 2.3) was added to each well and cells were 
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incubated for 20 minutes at room temperature.  Excess stain was removed and cells were 
gently washed twice with PBS.  1 ml of PBS was added to each well and cells were 
examined under light microscope for positively stained fat globules which indicate the 
presence of adipogenic differentiation. 
 
 2.6.3 CHONDROGENIC DIFFERENTIATION 
 MSC were seeded at 2.5 x 105 cells/pellet culture in 15 ml tube.  MSC were 
centrifuged at 200 g for 8 minutes and pellets were re-suspended in either cDMEM 
(negative control) or in chondrocyte differentiation media (Table 2.2).  Samples were 
incubated for 21 days at 37°C with caps loosened to allow for gaseous exchange.  Media 
was changed every 72 hours for 21 days.  On day 21, all media was removed and pellets 
were washed twice with PBS.  Cell pellets were harvested in 1 ml TriReagent and stored 
at -20°C overnight.  Chondrocyte differentiation was determined by the expression of 
collagen II and aggrecan by Reverse Transcription PCR (Section 2.8.4) 
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Table 2.2. Description of media for cell differentiation 
Media Name Components Supplier 
   
   
Osteogenic 
Differentiation 
media 
Dulbecco’s Modified Eagle’s Media (DMEM) 
containing 1000 mg/ml glucose 
1 mM dexamethasone 
20 mM β-glycerolphosphate 
50 µM L-ascorbic acid-2-phosphate 
50 ng/ml L-thyroxine sodium pentahydrate 
Sigma-Aldrich 
 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Adipogenic 
Differentiation 
media 
Dulbecco’s Modified Eagle’s Media (DMEM) 
containing 4500 mg/ml glucose 
5 µg/ml insulin (dissolved in 0.1N acetic acid) 
50 µM indomethacin 
1 µM dexamethasone 
0.5 µM 3-Isobutyl-1-methylxanthine (IBMX) 
Sigma-Aldrich 
 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Chondrocyte 
Differentiation 
media 
Dulbecco’s Modified Eagle’s Media (DMEM) 
containing 1000 mg/ml glucose 
100 nM dexamethasone 
50 µg/ml ascorbic-acid-2-phosphate 
40 µg/ml proline 
1 mM sodium pyruvate 
1% (v/v) Insulin Transferrin Selenium X 
10 ng/ml TGF-β3 
Sigma Aldrich 
 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
Sigma-Aldrich 
BD Biosciences 
BD Biosciences 
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Table 2.3. Description of reagents used to detect osteocyte and adipocyte 
differentiation 
Reagent Components Concentration Supplier 
    
MSC Osteoblast 
Differentiation 
Alizarin Red S stain 
dH2O 
pH 4.1 – 4.3 
1% (w/v) 
100 ml 
Sigma-Aldrich 
MSC Adipocyte 
Differentiation 
Oil Red O 
Isopropanol 
0.5% (w/v) 
30 ml 
Sigma-Aldrich 
Sigma-Aldrich 
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2.7 ENZYME LINKED IMMUNOSORBENT ASSAY 
 Samples were stored at -80°C until cytokine expression was analysed by ELISA.  
96 well NUNC Maxisorb plates (Thermo Fisher Scientific) were used for all ELISA 
experiments.  Plates were coated with 100 µl of capture antibody and stored at 4°C 
overnight under gentle agitation.  Plates were washed 3 times with wash buffer (PBS with 
0.05% (v/v) Tween-20) and dried by forcefully inverting the plates onto absorbent tissue 
paper.  Plates were blocked for 1 hour at room temperature using reagent diluent.  Plates 
were then washed 3 times again using wash buffer and samples or standards were added 
to each well.  Samples were incubated overnight at 4°C under gentle agitation.  Samples 
were aspirated off and plates washed 3 times with wash buffer.  100 µl of detection 
antibody was added to each well and samples were incubated for 1 hour at room 
temperature.  Plates were washed 3 times as before and 100 µl Avidin-HRP was added to 
each well and left for 30 minutes at room temperature.  Samples were washed 5 times 
with wash buffer and dried as before.  100 µl of substrate solution was added to each well 
for 15 minutes or until strong colour change was detected.  50 µl of stop solution (2N 
H2SO4) was then added to each well and the OD for each sample was determined using 
an ELx800TM microplate reader with Gen5 analysis software.  Cytokine concentrations 
for each sample were extrapolated from a standard curve which related the observed OD 
to a known protein concentration.  Data analysis was performed using Graphpad PRISM5 
software. 
 
2.8 MOLECULAR IMMUNOLOGICAL TECHNIQUES 
2.8.1 RNA ISOLATION 
            For mRNA analysis on MSC, cells were seeded at 1.8 x 105 cells/well in a 6 well 
plate and stimulated as desired before harvesting.  Total RNA was isolated using 1 ml of 
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Trizol Reagent according to manufacturer’s specifications.  Briefly, media was removed 
from wells and samples washed twice with sterile PBS.  1 ml of TriReagent was added to 
each well and cells were degraded by pipetting up and down.  Trizol samples were 
transferred to RNAse free 1.5 ml tubes and left for 2 minutes at room temperature.  300 
µl of chloroform was added and samples were vortexed until in uniform solution.  
Samples were incubated at room temperature for 5 minutes before being centrifuged at 
12,000 g for 15 minutes at 4°C.  The RNA containing upper aqueous phase was 
transferred to fresh RNAse free 1.5 ml tubes.  Equal amounts of Isopropanol was added 
to each tube and samples were again mixed by vigorous shaking.  Samples were incubated 
at room temperature for 10 minutes before being spun down at 12,000 g for 10 minutes 
at 4°C.  Supernatant was discarded and pellet was re-suspended in 1 ml of ice cold 75% 
(v/v) ethanol and vortexed for 10 seconds.  Samples were centrifuged at 7,500 g for 5 
minutes at 4°C and supernatant discarded.  Samples were left to air dry for approximately 
5 minutes.  RNA samples were re-suspended in 20-50 µl of nuclease free H2O depending 
on the size of the pellet.  The concentration of RNA was determined using Nanodrop 
Spectrophotometer (Nanodrop, Delaware, USA) measuring wavelengths at 260 and 280 
nm where the absorbance of 1 unit at 260 nm is 40µg/ml.  Only RNA precipitations which 
yielded an OD260/280 ratio of 1.8 – 2.0 were used for cDNA synthesis.  RNA was stored at 
-80°C until required. 
 
2.8.2 SYNTHESIS OF CDNA FROM RNA 
 Before beginning to generate full length first strand cDNA, genomic DNA was 
removed from RNA samples by treating 2 µg of RNA with amplification grade DNase I 
(Invitrogen).  1 µl of DNase I was added to each sample and samples were incubated at 
room temperature for 15 minutes.  DNase I reaction was neutralised using 1 µl of 25 mM 
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EDTA (Promega) to each mixture and samples were heated to 65°C for 10 minutes.  The 
generation of cDNA was carried out using Tetro cDNA synthesis kit (Bioline).  1 µl of 
Oligo (dT) and 1 µl of 10mM dNTP were added to each sample and samples were then 
heated to 60°C for 5 minutes.  Samples were cooled on ice before a 10µl of reverse 
transcriptase master mix was added to each sample.  cDNA synthesis was then performed 
at 45°C for 50 minutes and then 70°C for 15 minutes.  Samples were then stored at 4°C 
until required. 
 
2.8.3 REAL TIME POLYMERASE CHAIN REACTION (REAL-TIME PCR) ANALYSIS 
 cDNA generated as described above, was diluted 1/5 with nuclease free H2O, was 
used for quantitative Real-Time PCR analysis using primers specific from gene sequences 
of interest as outlined in table 2.17.  For real-time PCR analysis, a reaction mix was 
prepared and 9 µl of reaction mix was placed into specialised optical 48 well plates 
(Illumina, MSC, Dublin, Ireland) followed by 1 µl of template DNA.  Each sample was 
heated to 95°C for 10 minutes, followed by between 40-50 cycles of 95°C for 30 seconds, 
58°C for 30 seconds and 72°C for 45 seconds.  Amplification of one specific product was 
determined through melt curve analysis where the presence of one single melting peak 
indicated the absence of primer-dimer association.  Melt curve analysis was performed 
by heating the products to 95°C after all cycles were completed.  Real-time PCR was 
performed in an illumina Eco Real-Time PCR system (MSC).  The relative quantification 
of target gene expression was determined in relation to GAPDH expression using the 
ΔCT method. The ΔCT method was determined by subtracting the GAPDH value from 
the target CT value for each sample.  The fold change in relative gene expression was 
determined by calculating the 2-ΔCT values. 
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2.8.4 REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION 
 PCR was used to determine the presence of specific DNA sequences by targeting 
specific primers against cDNA templates. Expression of the housekeeping gene, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a positive control.  
PCR reactions contained 2.5 mM MgCl2 (Promega, Wisconsin, USA), 25 mM dNTP 
(Promega), 1 x GoTaq reaction buffer (Promega), 40 U/ml Taq polymerase (Promega) 
and 1 pM of specific forward and reverse primers.  The reaction mastermix was adjusted 
to a final volume of 24 µl per sample with nuclease free H2O.  Each sample was subjectd 
to an initial incubation of 95°C for 10 minutes followed by 29 cycles of 95°C for 30 
seconds, 55-60°C (depending on primers) for 30 seconds and 72°C for 1 minute.  Samples 
were then incubated at 72°C for 10 minutes and stored at 4°C. 
 
2.8.5 AGAROSE GEL ELECTROPHORESIS 
 Agarose gels were prepared by adding 1.3 g (w/v) agarose (Sigma-Aldrich) to 1 
X TAE buffer (Table 2.16) and heating in a microwave until completely dissolved.  The 
solution was left to cool to below 50°C and 6 µl of Gel Red (Biotium, California, USA) 
was added and the solution was poured into a gel tray.  When solidified, agarose gels 
were submerged in TAE buffer and subjected to electrophoresis at 90V for 70 minutes.  
Samples were run simultaneously to a 100 base pair molecular weight (Promega).  
Nucleic acid products were visualised under UV light and images acquired using a Gel 
Logic 212 Pro gel documentation system. 
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2.8.6 WESTERN BLOT ANALYSIS 
2.8.6.1 PROTEIN HARVEST 
 In order to isolate intra-cellular proteins from adherent cells, 6 well plates were 
placed on ice and supernatant removed.  Cells were washed with 1ml of ice cold PBS.  
Cells were then scraped in 1ml fresh ice cold PBS and transferred to 1.5ml tube.  For non-
adherent cells, media containing the suspension cells was transferred to a 15 ml tube.  
Samples were centrifuged at 6500g for 10 minutes at 4°C.  PBS was discarded and cell 
pellet was re-suspended in 90µl of cell lysis buffer (Table 2.5) and mixed well by 
pipetting. Samples were placed on ice under constant agitation for 10 minutes.  Samples 
were mixed well again by pipetting and returned to ice for another 10 minutes under 
constant agitation.  Protein lysates were then centrifuged at 12,000g for 10 minutes at 
4°C.  80µl of supernatant, which contains the solubilised intra-cellular proteins, was 
transferred to a new pre-cooled and labelled 1.5ml tube and stored at -20°C.  Prior to 
loading protein lysates, samples were mixed with 4X sample buffer (Table 2.10) (to 1X 
sample buffer) and heated to 100°C for 5 minutes. 
 
 2.8.6.2 BRADFORD ASSAY 
 In order to determine the concentration of protein harvested and to equalise the 
amount of protein to load for each sample, a Bradford assay was performed as previously 
described (Bradford 1976).  BSA standards of known protein concentration and samples 
were diluted in 10µl lysis buffer and mixed with 190µl of Bradford assay reagent (Bio-
Rad, California, USA) and the protein concentration was determined by the level of 
colorimetric change.  The OD was measured for each sample at 590nm using an 
ELx800TM microplate reader with Gen5 Data Analysis software (Bio-Tek, New 
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England, USA.  The protein concentrations of each sample were extrapolated from 
standard curve generated from known BSA concentrations.  Standard samples were 
analysed in duplicate to create the standard curve.  Data analysis was performed using 
GraphPad Prism 5 software. 
 
 2.8.6.3 SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
 SDS-PAGE was carried out based on methods designed by Laemmli and 
modified by Studier (Laemmli 1970; Studier 1973). Samples were loaded into individual 
0.75 mm wells.  A pre-stained molecular ladder (10-180 kDA) was also loaded to each 
gel.  Electrophoresis was performed at 70V through a 5% polyacrylamide stacking gel 
and then at 90V through an 8-15% polyacrylamide resolving gel for 1.5-2 hours.  The 
percentage of acrylamide gel used was based on the size of the target proteins being 
analysed.  Proteins under 30 kDa in size were electrophoresed on a 15% acrylamide gel, 
proteins between 30 kDa-80 kDa were analysed on a 10% gel while an 8% gel was used 
to examine proteins greater than 80kDa in size. 
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Table 2.4. Lysis Buffer (Stock) 
Final Volume 1 Litre 
  
HEPES (pH 7.5) 50 mM 
EDTA 1 mM 
Glycerol 10% (v/v) 
CHAPS 0.05% (w/v) 
Triton X 0.5% (v/v) 
Sodium Chloride (NaCl) 250 mM 
H2O Up to 1 Litre 
 
 
Table 2.5. Cell Lysis Buffer (Working solution)  
Final Volume 5 ml 
  
Lysis Buffer 4.75 ml 
100 mM Sodium orthovanadate (NaVO3) 50 µl 
100 mM Phenylmethanesulfonylfluoride (PMSF) 100 µl 
Protease Inhibitor 100 µl 
 
 
 
 
 
68 
 
 2.8.6.4 IMMUNOBLOTTING 
 Following protein separation by SDS-PAGE, proteins were transferred 
electrophoretically from the polyacrylamide gels to nitrocellulose membranes using a 
Hoefer TE 70 Semiphore semi dry transfer unit (GE Healthcare, Buckinghamshire, 
England) at 100mA for between 40 and 80 minutes depending on protein size.  3 layers 
of Whatmann blotting paper (Sigma-Aldrich) were submerged in transfer buffer before 
being placed on the bottom surface of the transfer unit.  One layer of nitrocellulose paper 
(GE Healthcare) was carefully placed on top followed by the polyacrylamide resolving 
gel.  Finally 3 more layers of Whatmann blotting paper were submerged in transfer buffer 
and carefully placed on top of the gel and the transfer unit was closed.  When protein 
transfer was complete, non-specific antibody binding was blocked by incubating the 
nitrocellulose membrane in 1 X TBST containing 5% (w/v) skimmed milk powder for 1 
hour under gental agitation.  Milk was subsequently removed and membranes were 
washed with 1 X TBST for 5 minutes under constant agitation (repeated 3 times).  The 
membranes were then incubated at 4°C overnight under gentle agitation with primary 
antibodies diluted in 1 X TBST containing 5% (w/v) BSA or skimmed milk powder 
depending on manufacturer’s recommendations.  The membranes were again washed 3 
times in 1 X TBST.  Secondary antibodies specific for target antibody (anti-rabbit, anti-
goat or anti-mouse) were diluted in 1 X TBST containing 5% (w/v) skimmed milk powder 
and membranes incubated with secondary antibodies for 1 hour in the dark at room 
temperature, again under gentle agitation.  The membranes were then washed 3 times for 
5 minutes each with 1 X TBST in the dark.  The immune-fluorescent bands were detected 
using the Odyssey infrared imaging system (Licor Bioscences, Nebraska, USA) or by 
using enhanced chemilluminescence development. 
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2.9 IN VITRO MSC FUNCTIONAL ASSAYS 
 2.9.1 STIMULATION OF MSC WITH INFLAMMATORY CYTOKINES 
 MSC were stimulated with pro-inflammatory cytokines IFN-γ or TNF-α in order 
to stimulate immune suppressive abilities of MSC.  For IFN-γ stimulation MSC were 
cultured with 50 ng/ml of recombinant human IFN-γ (Peprotech, New Jersey, USA) for 
24 or 48 hours.  TNF-α stimulation was performed by stimulating cells at 30 ng/ml 
recombinant human TNF-α (Peprotech) for 48 hours.   
 
2.9.2 IN VITRO CO-CULTURE OF CD19+ B CELLS WITH MSC 
 MSC were trypsinised from T175 flasks, washed 3 times in sterile PBS.  MSC 
were re-suspended in cIMDM and counted.  MSC were seeded into either 96 well (1 x 
104 cells) or 6 well (1.8 x 105 cells) plates.  Isolated CD19+ cells were counted and re-
suspended in cIMDM and seeded into 96 well (5 x 104 cells) or 6 well (9 x 105 cells) 
plates with or without MSC.  B cell activating cocktail (Table 2.13) was added to 
appropriate wells.  For cell contact dependence assays, trans-well membrane inserts 
(Greiner bio-one, Kremsmunster, Austria) were used in 6 well plates. 
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Table 2.6. 10X TBST 
Final Concentration 
 
100 mM Tris 
1.5 M NaCl 
dH20 
pH 7.5 
 
Table 2.7. 4X Lower Tris Buffer 
Final Concentration 
 
1.5 M Tris 
0.4% SDS 
dH2O 
pH 8.8 
 
Table 2.8. 4X Upper Tris Buffer 
Final Concentration 
 
0.5 M Tris 
0.4% SDS 
dH2O 
pH 6.8 
 
Table 2.9. Resolving (Lower) gel 
% Acrylamide Gel 8% 10% 15% 
dH2O 12.1 ml 10.5 ml 6.25 ml 
4X Lower Tris Buffer 6.25 ml 6.25 ml 6.25 ml 
Protogel 6.67 ml 8.35 ml 12.5 ml 
10% APS 130 µl 130 µl 130 µl 
TEMED 14 µl 40 µl 40 µl 
Total Volume 25 ml 25 ml 25 ml 
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Table 2.10. Stacking (Upper) gel 
% Acrylamide Gel 5% 
  
dH2O 5.8 
4X Upper Tris Buffer 2.5 
Protogel 1.7 
10% APS 40 
TEMED 20 
Total Volume 10 ml 
 
 
Table 2.11. 4X Sample Buffer 
Final Concentration 
 
0.25 M Tris 
6% SDS 
40% Sucrose 
0.04% Bromophenol Blue 
dH2O 
2-mercaptoethanol (add just prior to use) 
 
 
Table 2.12. 10X Running buffer 
Final Volume 1 Litre 
  
Tris Base 30.2 g 
Glycine 144 g 
SDS 10g 
dH2O Up to 1 Litre 
pH 8.3 
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Table 2.13. Transfer Buffer 
Final Concentration 
 
25 mM Tris Base  
20 mM Glycine 
20% (v/v) Methanol 
dH2O 
 
 
Table 2.14. B cell activating cocktail 
Final Concentration 
 
100 Units/ml Recombinant IL-2 
100 ng/ml Recombinant IL-21 
25 ng/ml Recombinant IL-10 
ITS (1:1000) 
250 ng/ml Recombinant CD40 ligand 
2.5 µg/mlCpG 
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2.10 ANIMAL MODELS OF DISEASE 
2.10.1 SYNGENEIC BONE MARROW TRANSPLANT MODEL 
 Syngeneic bone marrow transplantations were established as negative controls to 
chronic and acute GvHD.  BALB/c mice were exposed to a conditioning dose of 7 gray 
(Gy) whole body gamma irradiation.  Mice were injected with 5x106 bone marrow cells 
and whole splenocytes limited to 1x106 CD4+ cells isolated from age matched BALB/c 
mice.  Human MSC were administered i.v. to mice at days 1 and 3 post transplantation. 
Animals were returned to their cages and were closely monitored for the first hour and at 
regular intervals for signs of distress or ill health.  Mice were weighed every 7 days and 
changes in weight were recorded.  Development of GvHD was determined by examining 
features including weight loss, ruffled fur and hunched posture (Section 2.10.5).  Animals 
which displayed greater than 25% weight loss were sacrificed humanely. 
 
2.10.2 MINOR MHC MISMATCH TRANSPLANT MODEL 
 A murine model of chronic GvHD was established in this study using a minor 
MHC mismatched transplant, originally developed by Korngold and Sprent (Korngold & 
Sprent 1978).  BALB/c mice were exposed to a conditioning dose of 7 Gy whole body 
gamma irradiation.  Mice were injected i.v. with 5x106 bone marrow cells and whole 
splenocytes limited to 1x106 CD4+ cells isolated from age matched B10/D2 mice.  Human 
MSC were administered i.v. to mice at days 1 and 3 post transplantation. Animals were 
returned to their cages and were closely monitored for the first hour and at regular 
intervals for signs of distress or ill health.  Mice were weighed every 7 days and changes 
in weight were recorded.  Development of GvHD was determined by examining features 
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including weight loss, ruffled fur and hunched posture (Section 2.10.5).  Animals which 
displayed greater than 25% weight loss were sacrificed humanely. 
 
2.10.3 MAJOR MHC MISMATCH TRANSPLANT MODEL 
 A murine model of acute GvHD was established in this study using a major MHC 
mismatched transplant.  BALB/c mice were exposed to a conditioning dose of 7 Gy whole 
body gamma irradiation.  Mice were injected with 5x106 bone marrow cells and whole 
splenocytes limited to 1x106 CD4+ cells isolated from age matched C57BL/6 mice.  
Human MSC were administered to mice at days 1 and 3 post transplantation. Animals 
were returned to their cages and were closely monitored for the first hour and at regular 
intervals for signs of distress or ill health.  Mice were weighed every 7 days and changes 
in weight were recorded.  Development of GvHD was determined by examining features 
including weight loss, ruffled fur and hunched posture (Section 2.10.5).  Animals which 
displayed greater than 25% weight loss were sacrificed humanely. 
 
2.10.4 HUMANISED MOUSE MODEL OF AGVHD 
 A humanised mouse model previously developed (Tobin et al. 2013) in the lab 
was optimised for the administration of PBMC isolated from buffy packs.  NOD.Cg-
PrkdcscidIL2tmlWjl/Szj (NOD-Scid IL-2rγnull) (NSG) mice were exposed to a conditioning 
dose of 2.4 Gy whole body gamma irradiation.  PBMC, isolated as described in section 
2.3.2, were administered via tail vein injection using a 27 gauge needle and 1 ml syringe 
6 – 8 hours after irradiation (Section 2.10.6).  8 x 105 gram-1 PBMC were administered 
via tail vein injection using a 27 gauge needle and 1 ml syringe 6 – 8 hours after 
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irradiation.  Animals were returned to their cages and were closely monitored for the first 
hour and at regular intervals for signs of distress or ill health.  Mice were weighed every 
2 days until day 7 and every day thereafter and changes in weight were recorded.  
Development of acute GvHD was determined by examining features including weight 
loss, ruffled fur and hunched posture (Section 2.10.5).  During initial optimisation 
experiments animals which displayed greater than 20% weight loss were sacrificed 
humanely; however, in accordance with alterations agreed between the lab and the NUI 
Maynooth ethics committee, the weight loss threshold was lowered to 15%. 
 
2.10.5 PATHOLOGICAL SCORING SYSTEM FOR GVHD 
 Development of GvHD was assessed using a series of pathological features.  
Weight loss in excess of 15% total body weight on successive days were deemed to have 
acute GvHD and humanely sacrificed.  Other pathological features which were taken into 
consideration were posture (hunching), activity, grooming and diarrhoea.  Any animal 
which scored a cumulative score of 7 or higher were considered to have acute GvHD and 
sacrificed humanely.  The scoring system used to assess experimental mice was as 
follows: 
 Posture: 0; normal posture while walking, 0.5; slight hunching that straightens out 
while walking, 1; animal stays hunched while walking, 1.5; animal does not straighten 
out, 2; mouse tends to walk on rear toes. 
 Activity: 0; normal, very mobile and difficult to catch, 0.5; slower than normal 
and a little easier to catch, 1; no spontaneous activity but will move freely when touched, 
1.5; no spontaneous movements and very little when touched, 2; no movements even 
when touched. 
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 Fur: 0; normal, well groomed, 0.5; ridging of fur on side of belly and neck, 1; 
ridging throughout belly and neck, 1.5; fur is matted and ruffled, 2; badly matted and 
unkempt fur on belly and back. 
 Diarrhoea: 0; normal bowel movements, 1; change in bowel movement frequency 
and consistency, 2; extensive diarrhoea. 
  
2.10.6 FH-TEG STIMULATION OF PBMC 
 PBMC were isolated from buffy packs as described above.  PBMC were seeded 
at 2 x 106/ml in T175 flasks and stimulated with Fh-Teg at 10 µg/ml or left untreated.  
PBMC were incubated at 37°C overnight.  The next day, PBMC were harvested and 
counted.  Cells were washed 3 times in sterile PBS and before infusion. 
 
2.10.7 INTRA-VENOUS ADMINISTRATION OF PBMC OR MSC 
 Prior to administration, PBMC or MSC were washed 3 times with sterile PBS.  
PBMC were administered at 8 x 105 gram-1 and MSC were administered at 6 x 104 gram-
1.  PBMC or MSC were administered through a tail vein injection using a 27G needle and 
a 1 ml syringe with each mouse receiving a maximum of 300 µl.  PBMC were infused on 
day 0 while MSC were delivered on day 7 or 9.   Following injection, animals were 
returned to their cages and were monitored as described above. 
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2.10.8 PREPARATION OF BUSULFAN 
 Prior to administration, Busulfan (Sigma-Aldrich) was weighed out in a fume 
hood and diluted to a 2mg/ml using sterile PBS.  Diluted Busulfan was filter sterilised in 
a fume hood and was administered at a final concentration of 25mg/kg via tail vein 
injection using a 27G needle and a 1 ml syringe with each mouse receiving a maximum 
of 300 µl.  Busulfan was administered at 48 and 24 hours before PBMC infusion.  Mice 
which received Busulfan were closely monitored after administration. 
 
2.11 CFSE LABELLING OF CELLS 
 Purified CD19+ B cells were washed twice in sterile PBS and re-suspended in 1 
ml of PBS.  Cells were stained with 10 µM Carboxyfluorescein succinimidyl ester (CFSE) 
for 10 minutes at room temperature in the dark.  2 ml of ice cold PBS was added and cells 
were centrifuged at 300 g for 5 minutes and washed twice with cold PBS.  Labelled 
CD19+ B cells were re-suspended cIMDM and counted. 
 
2.12 HISTOLOGICAL ANALYSIS 
2.12.1 TISSUE PREPARATION 
 The lungs, liver, spleen and small intestine were harvested from experimental 
mice at day 12 and fixed in 10% (v/v) neutral buffered formalin for 24 hours.  Samples 
were transferred to 70% ethanol for a further 24 hours.  Samples were processed for 
histology using an automated processor (Shannon Pathcentre) which immersed the tissues 
in fixatives and sequential dehydration solutions including ethanol (70%, 80%, 95% x 2, 
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100% x 3) and xylene (x 2) (Sigma-Aldrich).  After processing, tissues were embedded 
in paraffin wax using a Shandon Histocentre 2 (Thermo Fisher Scientific) and left to set 
at 4°C overnight.  A Shandon Finesse 325 microtome (Thermo Fisher Scientific) was 
used to cut 5 µm sections of each tissue.  Sections were placed in cold water before being 
transferred to a hot water bat (60°C) to remove any folding of the sections.  Tissue 
sections were placed onto microscope slides (Thermo Fisher Scientific) and left to air dry 
overnight.  Samples were then stained with H&E (Section 2.12.2) and blindly scored 
using the system outlined in section 2.12.3.  
 
2.12.2 HAEMOTOXYLIN/EOSIN STAINING 
 Before commencing with H&E staining, slides were heated to 60°C for a 
minimum of 1 hour to aid wax clearance.  Slides were then transferred to Xylene (Sigma) 
for 10 minutes and again to fresh xylene for a further 10 minutes.  Samples were then re-
hydrated following immersion in 3 decreasing concentrations of ethanol for 5 minutes 
each (100% x 2, 90% and 80%) for 5 minutes each.  Samples were then transferred to 
dH2O for 5 minutes before being immersed in Haemotoxylin (Sigma) for 3 minutes.  
Samples were then washed under H2O for 2 minutes before being placed in 1% acid 
alcohol for no longer than 20 seconds.  Samples were washed again under H2O before 
being immersed in Eosin Y (Sigma-Aldrich) for 3 minutes and back to washing under 
H2O again.  Slides were dehydrated through immersion in a series of increasing ethanol 
concentrations (80%, 90%, 100%) for 5 minutes each.  Samples were air dried and 
mounted with DPX mounting media (BDH) and examined under a light microscope. 
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Table 2.15. Histological staining solutions 
Reagent Components Concentration Supplier 
    
Harris Hemotoxylin Hemotoxylin Neat Sigma-Aldrich 
Eosin Eosin Y 
Potassium 
dichromate 
dH2O 
1% (w/v) 
1.6% (w/v) 
100 ml 
Sigma-Aldrich 
Sigma-Aldrich 
Acid alcohol Hydrochloric acid 
2-propanol 
dH2O 
1%  (v/v) 
69.3% (v/v) 
29.7% (v/v) 
VWR 
Sigma-Aldrich 
 
Table 2.16. TAE Buffer (50X Stock) 
Final Volume 1 Litre 
  
TRIS Base 242 g 
Acetic acid 57.1 ml 
EDTA (0.5 M, pH 8.8) 100 ml 
dH2O Up to 1 Litre 
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2.12.3 HISTOLOGICAL SCORING 
 Following H&E staining, slides were coded without reference to treatment groups 
and examined blindly.  A semi-quantitative scoring chart was used to assess disease 
progression in the lungs, liver, spleen and small intestine (Tobin et al. 2013).  Pathological 
scoring was carried out as follows: 
 Lung: 0; normal, 1; scattered areas of mononuclear cells, 2; mild focussed areas 
of mononuclear cell infiltration, 3; moderate levels of cellular infiltration and damage to 
lung architecture, 4; extensive mononuclear cell infiltration and extensive damage to lung 
architecture. 
 Liver: 0; normal, 1; sporadic collections of mononuclear cells in the parenchyma, 
2; endothelialitis present around at least one periportal vein and marked increase in 
mononuclear cell infiltration, 3; endothelialitis present in more than one vessel and further 
increase in mononuclear cell infiltration, 4; endothelialitis present in virtually all vessels 
with extensive levels of mononuclear cell infiltration. 
 Small intestine: 0; normal, 1; mild necrotic cells with minor mononuclear cell 
infiltration, 2; widespread but mild villous blunting, necrosis and increased cell 
infiltration, 3; widespread and moderate villous blunting, necrosis and further increased 
cell infiltration, 4; widespread and severe villous blunting, necrotic cells and extensive 
mononuclear cell infiltration. 
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Table 2.17. Antibodies used for flow cytometry 
Antibody Conjugate Clone Supplier 
    
CD3 APC UCHT1 eBioscience 
CD4 FITC SK3 eBioscience 
CD4 PE SK3 eBioscience 
CD4 PercP SK3 eBioscience 
CD4 APC SK3 eBioscience 
CD8 FITC RPA-T8 eBioscience 
CD8 PE RPA-T8 eBioscience 
CD8 PercP RPA-T8 eBioscience 
CD8 APC RPA-T8 eBioscience 
CD19 FITC HIB19 eBioscience 
CD19 APC HIB19 eBioscience 
CD20 FITC 2H7 eBioscience 
CD20 APC 2H7 eBioscience 
CD25 PE BC96 eBioscience 
CD27 FITC 0323 eBioscience 
CD29 FITC TS2/16 eBioscience 
CD34 PE 4H11 eBioscience 
CD44 FITC IM7 eBioscience 
CD44 PE IM7 eBioscience 
CD45 Percp 2D1 eBioscience 
CD45 APC HI30 eBioscience 
CD45ro APC UCHL1 eBioscience 
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Table 2.17. (continued): Antibodies used for flow cytometry 
Antibody Conjugate Clone Supplier 
    
CD54 FITC RR1/1 eBioscience 
CD62L PE DREG-56 eBioscience 
CD69 FITC FN50 eBioscience 
CD80 PE 2D10.4 eBioscience 
CD86 PE IT2.2 eBioscience 
CD90 FITC eBio5E10 eBioscience 
CD105 APC SN6 eBioscience 
CD106 PE STA eBioscience 
CD117 PE YB5.B8 eBioscience 
CD154 FITC 24-31 eBioscience 
HLA-DR PE L243 eBioscience 
HLA-ABC FITC W6/32 eBioscience 
TNF-α FITC MAb11 eBioscience 
TNF-α PE MAb11 eBioscience 
IL-2 PE MQ1-17H12 eBioscience 
FoxP3 FITC 236A/E7 eBioscience 
FoxP3 APC 236A/E7 eBioscience 
B220 APC RA3-6B2 eBioscience 
CXCR4 APC 12G5 eBioscience 
Bcl-2 PE BCL/10C4 BioLegend 
IFN-γ FITC 4S.B3 BioLegend 
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Table 2.18. Summary of primer sequences for Reverse transcriptase PCR 
Primer Forward 5’ – 3’ Reverse 3’ – 5’ Product 
size (bp) 
Annealing 
Temp. (°C) 
     
GAPDH ACAGTTGCCATG
TAGACC 
TTTTTGGTTGAGCA
CAGG 
90 58 
Collagen II GCCCAAGAGGTG
CCCCTGGAATA 
CCTGAGAAAGAGG
AGTGGACATA 
703 57 
Aggrecan TGAGGAGGGCTG
GAACAAGTACC 
GGAGGTGGTAATT
GCAGGGAAC 
350 55 
     
 
Table 2.19. Summary of primers for Real Time PCR 
Primer Forward 5’ – 3’ Reverse 3’ – 5’ Annealing Temp. 
(°C) 
    
GAPDH ACAGTTGCCATGTA
GACC 
TTTTTGGTTGAGCA
CAGG 
58 
BAFF AATTTAACAGACAG
CCACAG 
TGTCCTTCCTCCAA
GATAAG 
58 
IL-18 CCTTTAAGGAAATG
AATCCTCC 
CATCTTATTATCAT
GTCCTGGG 
58 
IL-21 AGAAACACAGACT
AACATGC 
GTAGATACCTTTTG
GAGAAGTG 
58 
NFKB1 GCTTAGGAGGGAG
AGCCCA 
TATGGGCCATCTGT
TGGCAG 
60 
84 
 
Table 2.20. Primary antibodies used for western blot 
Antibody Dilution Factor Diluent Supplier 
    
BAFF 1:500 5% BSA in TBST R&D  
(Minneapolis, USA) 
AKT 1:1000 5% BSA in TBST Cell Signalling 
Phoshorylated AKT 1:1000 5% BSA in TBST Cell Signalling 
Cleaved Caspase 3 1:500 5% BSA in TBST Cell Signalling 
β-actin 1:5000 5% milk in TBST Sigma-Aldrich 
 
 
Table 2.21. Secondary antibodies for western blot 
Antibody Dilution Factor Diluent Supplier 
    
IRDye 800CW 
Donkey Anti-Goat 
1:5000 5% Milk in TBST Licor 
IRDye 800CW Goat 
Anti-Rabbit 
1:5000 5% Milk in TBST Licor 
IRDye 800CW Goat 
Anti-Mouse 
1:5000 5% Milk in TBST Licor 
Anti-Rabbit HRP 1:1500 5% Milk in TBST Cell Signalling 
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CHAPTER 3 
 
MSC PROTECT AGAINST CASPASE 3 MEDIATED 
APOPTOSIS OF CD19+ PERIPHERAL B CELLS THROUGH 
CONTACT DEPENDENT UP-REGULATION OF VEGF 
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3.1 INTRODUCTION 
B cell development is a complex and tightly controlled process which occurs in 
the bone marrow and culminates in the migration of naïve B cells to secondary lymphoid 
organs via the blood and lymphatic system (Nuñez et al. 1996; Cyster 1999).  In 
secondary lymphoid organs, the controlled activation, proliferation and differentiation of 
B cells upon recognition of foreign antigen represent the cornerstone of the adaptive 
immune system and are essential in the development of life long memory within the 
immune system (Yu et al. 2008).   Consequently, the success of novel cell therapies can 
depend greatly on how they interact with B cells after administration.  For MSC to 
progress further towards clinical application, it will be essential to clarify exactly how 
MSC interact with B cells.  While the ability of MSC to suppress T cell proliferation 
(English et al. 2007; Tobin et al. 2013), DC maturation, antigen presentation (Wang et 
al. 2008; English et al. 2008; Spaggiari et al. 2009) and NK cell function (Spaggiari et 
al. 2008; Noone et al. 2013) have been extensively characterised, the immune-modulatory 
capabilities of MSC with regard to B cells is poorly understood. 
 The effect of human MSC on the B cell component of the adaptive immune 
response has received some attention in recent years; however these studies have reported 
contrasting and sometimes conflicting results (Franquesa et al. 2012; Corcione et al. 
2006; Tabera et al. 2008; Rasmusson et al. 2007; Traggiai et al. 2008; Rosado et al. 2014; 
Comoli et al. 2008). While most of the published data indicated that MSC inhibit B cell 
proliferation, differentiation and antibody secretion (Franquesa et al. 2012; Corcione et 
al. 2006; Tabera et al. 2008), other publications have demonstrated a supportive role for 
MSC in B cell expansion and differentiation (Rasmusson et al. 2007; Traggiai et al. 
2008).  The variability observed between studies is probably derived from the different 
experimental conditions used in each study, in particular the ratio of MSC to B cell and 
purity of B cell populations.  However, the source of B cells and stage of maturity may 
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also be factors.  Recently Rosado et al. (2014) have demonstrated that MSC can either 
inhibit or support B cell proliferation and antibody production depending on the presence 
of T cells in co-culture (Rosado et al. 2014).  When peripheral blood lymphocyte 
populations were used, MSC suppressed the proliferation of stimulated B cells, however 
when cultured with purified B cell populations, MSC enhanced the proliferation and 
antibody production of stimulated B cells (Rosado et al. 2014).   
 The capacity of MSC to potently modulate the immune system offers considerable 
possibilities for regenerative medicine and a potential treatment for a variety of immune 
disorders including allograft rejection (Breitbart et al. 2010).  However, in order to further 
the development of MSC towards clinical application it is essential to clarify exactly how 
MSC interact with all cells of the immune response.  In this study, we sought to determine 
how MSC alter B cell biology in terms of activation, proliferation and survival and to 
elucidate the mechanisms involved. 
 The objectives for this chapter were: 
1. To determine the effect of MSC on B cell function; activation, proliferation and 
antibody production. 
2. To elucidate the mechanism of action behind MSC modulation of B cell function. 
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Table 3.1. Summary of major published works on the effect of MSC on peripheral B cells in vitro. 
      
Cell 
source 
B cell 
isolation 
Ratio  
B cell:MSC 
B cell 
stimuli 
Effect of MSC Reference 
      
Healthy 
human 
PBMC 
T cell depletion 
and CD19+ 
positive 
selection 
(MACS) 
1:1 
2:1 
rhCD40L + 
CpG + anti-
Ig + IL-2 + 
IL-4 +/- IL-
10 
Inhibition of proliferation 
(not apoptosis) of cell cycle 
G0/G1. Mediated by 
soluble factors. Inhibition 
of IgG, IgA, IgM secretion. 
Inhibition of migratory 
chemokines 
Corcione et al. 
(2006) 
      
Healthy 
human 
splenocytes 
or PBMC 
Enriched B cell 
population 
(MACS) 
10:1 LPS 
CMV 
VZV 
Cell contact dependent 
increased IgG production.  
Rasmusson et 
al. (2007) 
      
Healthy 
human 
PBMC 
Partial CD4 and 
full CD8 T cell 
depletion 
(MACS) 
4:1 
20:1 
MLC 
CD40 
agonist 
IL-10 
MSC inhibit IgG, IgA, IgM 
production in MLC. No 
effect with transwell inserts 
Comoli et al. 
(2008) 
      
PBMC 
from Buffy 
coat 
CD19+ and 
CD3+ selection 
(MACS) 
5:1 
10:1 
CpG 
Anti-Ig 
CD40L 
IL-4 
Promotes B cell viability, 
cause B cell cycle arrest in 
G0/G1. Inhibit plasma cell 
induction mediated by 
Erk1/2 phosphorylation. 
Tabera et al. 
(2008) 
      
Healthy 
and PBMC 
from lupus 
patients 
CD19+ selection 
(MACS) 
1:1 CpG 
IL-2 
CD40L 
Anti-Ig 
Induced survival and 
proliferation of B cell 
subsets. No increase in IgA 
or IgG. Increased IgM and 
IgG in B cells from SLE 
patients. 
Traggiai et al. 
(2008) 
      
Healthy 
human 
PBMC 
Whole PBMC or 
CD19+ separated 
B cells 
10:1 CpG-ODN MSC suppressed B cell 
proliferation when cultured 
with whole PBL but 
supported proliferation of 
purified CD19+ B cells 
Rosado et al., 
2014 
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3.2 MSC ENHANCED CD19+ PERIPHERAL B CELL ACTIVATION 
 B cell activation following antigen recognition and appropriate CD4+ T cell 
signalling, triggers B cell clonal expansion, isotype switching and the development of 
antibody producing plasma cells and memory B cells (Pieper et al. 2013).  Previous 
studies investigating the ability of MSC to modulate B cell activation, proliferation and 
antibody production have provided contradictory results (Table 3.1) (Franquesa et al. 
2012; Corcione et al. 2006; Tabera et al. 2008; Comoli et al. 2008; Rasmusson et al. 
2007; Traggiai et al. 2008; Rosado et al. 2014).  This study was designed to determine 
how MSC directly affect purified CD19+ B cells.  To determine the direct effect of MSC 
on B cell activation, PBMC were isolated from buffy-coat packs obtained from healthy 
donors.  CD19+ B cells were purified from PBMC using immunomagnetic beads 
(Miltenyi Biotec) (Figure 3.1) and co-cultured with MSC (5:1 ratio B cell: MSC) for 48 
hours in cIMDM containing the B cell activating cocktail described in Table 2.14 (human 
IL-10, IL-2, IL-21 and activating molecules CD40L and CpG).  B cell activation was 
characterised by increased expression of the early lymphocyte activation marker CD69, 
co-stimulatory molecules CD86 and CD80, and also CD25 by flow cytometry.   
As expected, B cells cultured in cIMDM without the activation cocktail expressed 
very low levels of CD69, CD80, CD25 and CD86 after 48 hours (Figure 3.2 A – D 
respectively).  Notably, when cultured in the presence of MSC, resting B cells did not up-
regulate these activation markers, indicating that MSC do not directly activate peripheral 
B cells (Figure 3.2).  Stimulation of CD19+ B cells significantly increased CD69 
expression and also enhanced the expression of CD80, CD25 and CD86 on B cells after 
48 hours (Figure 3.2).  When activated in the presence of MSC, significantly more 
peripheral B cells expressed CD69 (Figure 3.2).  The expression of CD80, CD86 and 
CD25 was also higher when B cells were activated in the presence of MSC (Figure 3.2), 
suggesting that MSC support but do not induce B cell activation.  
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Figure 3.1. CD19+ MACS isolation of B cells from buffy packs results in a single pure B cell 
population. B cells were purified from PBMC populations using CD19+ MACS beads.  The purity of 
isolated B cells was determined using B cell specific marker CD20 following CD19+ B cell isolation using 
flow cytometry.  CD19+ MACS separation resulted in a single lymphocyte population (A) which were 
positive for CD20 (B).  Only B cell isolations which yielded at least 95% purity, as determined by CD20 
expression, were used in experiments.   
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Figure 3.2: MSC support the activation of CD19+ peripheral B cells.  CD19+ B cells were purified from 
PBMC populations using CD19+ MACS beads.  9 x 105 B cells were cultured in cIMDM in the presence 
or absence of 1.8 x 105 MSC (5:1) and were activated with a cytokine cocktail of 25 ng/ml recombinant IL-
10, 100 U/ml recombinant IL-2, 100 ng/ml recombinant IL-21, ITS (1:1000), 250 ng/ml recombinant 
CD40L and 2.5 µg/ml CpG for 48 hours.  The expression of activation markers CD69 (A), CD80 (B), CD25 
(C) and CD86 (D) were analysed after 48 hours by flow cytometry.  n=5 for (A) and n=3 for (B – D).  
Statistical analysis was carried out using a paired student t test. *** indicates p-value < 0.001.  
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3.3 MSC PROMOTE THE EXPANSION OF ACTIVATED CD19+ PERIPHERAL B CELLS IN A 
CELL CONTACT DEPENDENT MANNER 
The rapid proliferation of activated B cells following the recognition of foreign 
antigen or danger signals is critical to the development of an effective immune response.  
As described in Table 3.1, previous studies examining how MSC regulate the 
proliferation of peripheral B cells has provided conflicting results.  To determine whether 
MSC suppressed or supported the proliferation of activated B cells, CD19+ B cells were 
labelled with proliferation dye (CFSE) and cultured in the presence or absence of MSC 
for 5 days.  B cell proliferation was induced using the same activating cocktail as in 
section 3.2.  After 5 days, B cells proliferation was analysed by flow cytometry.   
Activation of CD19+ B cells with the activation cocktail alone potently induced B 
cell proliferation with approximately 80% of activated B cells undergoing at least one 
phase of proliferation (Figure 3.3 A & C).  However, in the presence of MSC, there were 
significantly less non-proliferating (0 divisions) B cells and significantly more B cells 
had gone through at least 5 divisions compared to B cells activated without MSC (Figure 
3.3 A & C).   Thus B cells activated in the presence of MSC undergo significantly more 
divisions.  The dependence of cell contact in MSC support of B cell proliferation was 
examined using a transwell co-culture system, separating B cells from the MSC.  
Inhibition of cell contact completely abrogated the MSC support of B cell proliferation 
suggesting that the increase in B cell proliferation after co-culture with MSC is mediated 
through a cell contact dependant mechanism (Figure 3.3 D & E). 
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Figure 3.3: MSC enhance the expansion of activated CD19+ peripheral B cells in a cell contact 
dependent manner.  CD19+ B cells were purified from PBMC populations using CD19+ MACS beads and 
labelled with 10µM CFSE.  9 x 105 B cells were cultured in cIMDM in the presence or absence of 1.8 x 105 
MSC (5:1) and were activated with a cocktail of 25 ng/ml recombinant IL-10, 100 U/ml recombinant IL-2, 
100 ng/ml recombinant IL-21, ITS (1:1000), 250 ng/ml recombinant CD40L and 2.5 µg/ml CpG.  (A) 
Representative image of CFSE fluorescence by activated B cells after 5 days.  (B) Representative image of 
CFSE fluorescence by activated B cells cultured in the presence of MSC.  (C)  Percentage of activated B 
cells which have undergone cell division in the presence or absence of MSC for 5 days. n=8 PBMC donors 
with 2 MSC donors.  Transwell membrane inserts (0.4 µm pore size) were used to prevent cell contact 
between MSC and CFSE labelled B cells during co-culture.  (D)  Representative image of CFSE 
fluorescence by activated B cells cultured using transwell inserts after 5 days.  (E) Representative image of 
CFSE fluorescence by activated B cells separated from MSC using transwell inserts for 5 days.  (F)  
Percentage of activated B cells which have undergone cell division in the presence or absence of MSC for 
120 hours using transwell membranes. n=8 PBMC donors with 2 MSC donors.  Statistical analysis was 
carried out using a paired student t test. * < 0.05, *** < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
95 
 
3.4 IgG AND IgM PRODUCTION BY CD19+ B CELLS WAS NOT AFFECTED BY MSC 
 The production of antibodies and isotype switching by B cells is fundamental to 
maintaining memory against pathogens. However, the production of antibodies is highly 
regulated and dysregulation of antibody production can result in severe autoimmune 
disease (Vinuesa et al. 2009).  Corcione et al. and Comoli et al. reported that MSC inhibit 
B cell secretion of IgG and IgM (Corcione et al. 2006; Comoli et al. 2008) while 
Rasmusson et al. demonstrated that co-culture with MSC resulted in enhanced IgG 
secretion (Rasmusson et al. 2007).  The effect of MSC on IgG and IgM production by 
CD19+ peripheral B cells was examined after 72 hours by ELISA.  Purified CD19+ B cells 
were co-cultured in the presence or absence of MSC (5:1) and activated using B cell 
activation cocktail described above.  A transwell co-culture system was designed to 
investigate whether MSC modulation of antibody production was dependent on cell 
contact or mediated by soluble factors. 
 Supernatant recovered from B cells cultured alone contained approximately 30 
ng/ml of IgG (Figure 3.4 A).  The levels of IgG produced by B cells was not affected by 
the presence of MSC (Figure 3.4 A). Separation of B cells from MSC using transwell 
membranes also had no effect on IgG production (Figure 3.4 A). Similarly the production 
of IgM by activated B cell populations was unaffected by the presence of MSC in the co-
culture (Figure 3.4 B).  These results suggest that MSC neither supported nor inhibited 
antibody production by peripheral B cells. 
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Figure 3.4: MSC had no effect on the production of IgG or IgM by CD19+ B cells. CD19+ B cells were 
purified from PBMC populations using CD19+ MACS beads.  9 x 105 B cells were cultured in cIMDM in 
the presence or absence of 1.8 x 105 MSC (5:1) and were activated with 25 ng/ml recombinant IL-10, 100 
U/ml recombinant IL-2, 100 ng/ml recombinant IL-21, ITS (1:1000), 250 ng/ml recombinant CD40L and 
2.5 µg/ml CpG for 72 hours.  Transwell membrane inserts (0.4 µm pore size) were used to prevent cell 
contact between MSC and B cells during co-culture.  Supernatant was collected and analysed for the 
expression of IgG (A) or IgM (B) by ELISA.  White bars represent B cells cultured alone while black bars 
represent B cells co-cultured with MSC.  n= 2 PBMC donors and 2 MSC donors.  Statistical analysis was 
carried out using a paired student t-test. 
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3.5 MSC SUPPORT OF B CELL PROLIFERATION IS NOT DEPENDENT ON B CELL 
ACTIVATING FACTOR (BAFF) 
As demonstrated above, MSC supported the activation and proliferation of CD19+ 
peripheral B cells (Figure 3.2 & 3.3).  MSC support of B cell proliferation was mediated 
through a cell contact signal (Figure 3.3).  One of the most potent inducers of B cell 
proliferation is B cell activating factor (BAFF).  BAFF is a member of the TNF 
superfamily of receptors, which functions both as a surface bound protein and soluble 
factor, and is known to bind TNSFR13 on B cells and support proliferation, activation 
and survival (Schneider et al. 1999).  The expression of BAFF by human adipose derived 
MSC has also previously been shown (Wang et al. 2011).  Therefore to determine the 
importance of BAFF in mediating the support of B cell survival and proliferation by MSC, 
the ability of MSC to produce BAFF was probed by real time PCR and verified by 
immunoblotting.  MSC were seeded into 6 well plate at 1.8x105 cells per well overnight 
before being stimulated with IFN-γ or TNF-α for 6, 8, 12 or 24 hours and harvested as 
described in chapter 2.   
MSC significantly up-regulated BAFF mRNA expression after 6 hours when 
stimulated with IFN-γ or TNF-α as measured by real time PCR (Figure 3.5 A).  
Interestingly, BAFF mRNA expression is differentially regulated by IFN-γ or TNF-α 
after 24 hours.  IFN-γ stimulated MSC continue to up-regulate BAFF expression after 24 
hours while TNF-α induced BAFF expression is lower after 24 hours than observed after 
6 hours (Figure 3.5 A) suggesting BAFF expression on MSC may be differentially 
regulated depending on the environment of the cell. 
The expression of BAFF by MSC was then verified at the protein level by western 
blotting.  MSC constitutively expressed low levels of membrane bound BAFF but not 
soluble BAFF (Figure 3.5 B).  Similar to the results observed with real time PCR, 
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expression levels of both membrane bound and soluble BAFF were markedly increased 
by MSC after IFN-γ or TNF-α stimulation for 8, 12 and 24 hours (Figure 3.5 B).  In 
correlation with results observed at the mRNA level, TNF-α stimulated MSC did not 
continue to up-regulate membrane bound BAFF at 24 hours while IFN-γ stimulated MSC 
showed increased BAFF expression at this time-point (Figure 3.5 B).  These results 
illustrate that MSC constitutively express membrane bound BAFF protein which can be 
significantly up-regulated following the correct signal, which suggests that BAFF may be 
the contact signal required for MSC support of B cell proliferation.   
Constitutive expression of membrane bound BAFF highlighted the potential that 
BAFF represented the contact signal required by B cells to enhance proliferation.  To 
investigate whether BAFF-BAFFR was the signal used by MSC to promote B cell 
proliferation, BAFF signalling was neutralised during B cell:MSC co-culture.  The 
efficacy of the BAFF neutralising antibody was determined by examining the expression 
of NFKB1 on purified CD19+ B cells following stimulation with recombinant human 
BAFF (rhBAFF) after 6 hours.  B cells which were stimulated with rhBAFF in the 
presence of BAFF inhibitor showed a significant decrease in NFKB1 expression (Figure 
3.5 C).  Purified and CFSE stained B cells were activated and cultured with or without 
MSC (5:1), as described in section 3.3, in the presence or absence of BAFF inhibitor (50 
µg/ml).  After 5 days, B cells proliferation was analysed by flow cytometry.  As observed 
in section 3.3, activation of CD19+ B cells with the activation cocktail potently induced 
B cell proliferation with approximately 75% of B cells entering at least one phase of 
proliferation (Figure 3.6) and as expected, the proliferation of B cells activated in the 
presence of MSC was significantly increased (Figure 3.6).  However, the addition of 
BAFF inhibitor did not reverse MSC support of B cell proliferation, demonstrating that 
MSC support of B cell proliferation was independent of BAFF signalling. 
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Figure 3.5: Constitutive expression of BAFF by MSC is enhanced by IFN-γ or TNF-α.  (A) MSC were 
seeded at 1.8x105 cells/well and incubated overnight in a 6 well plate and stimulated with 50 ng/ml IFN-γ 
or 20 ng/ml TNF-α for 6 or 24 hours.  The expression of BAFF mRNA was examined by real time PCR. 
White bars represent IFN-γ stimulated MSC while black bars represent TNF-α stimulated MSC.  n= 3 MSC 
donors. GAPDH expression was used as a house-keeping control.  (B) MSC were seeded at 1.8x105 
cells/well and incubated overnight in a 6 well plate and stimulated with 50 ng/ml IFN-γ or 20 ng/ml TNF-
α for 8, 12 or 24 hours.  The expression of soluble BAFF protein (top segment) and membrane bound BAFF 
(middle segment) was analysed by western blot. β-actin (bottom segment) was used as a loading control. 
Image representative of 2 MSC donors. (C) The neutralising ability of BAFF antibody was analysed by 
examining the expression of NFKB1 by real time PCR.  Isolated CD19+ B cells were stimulated with 
recombinant human BAFF (10 ng/ml) in the presence or absence of BAFF inhibitor (50 µg/ml) for 6 hours. 
n=4 donors. 
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Figure 3.6: Inhibition of BAFF signalling does not prevent MSC from enhancing B cell proliferation.  
Purified B cell populations were isolated from PBMC using CD19+ MACS beads and labelled with 10µM 
CFSE.  9 x 105 B cells were cultured in cIMDM in the presence or absence of 1.8 x 105 MSC (5:1) and 
were activated with 25 ng/ml recombinant IL-10, 100 U/ml recombinant IL-2, 100 ng/ml recombinant IL-
21, ITS (1:1000), 250 ng/ml recombinant CD40L and 2.5 µg/ml CpG for 5 days.  (A-D) Representative 
image of the CFSE expression profile of (A) B cells activated alone, (B) B cells activated in the presence 
of MSC, (C) B cells activated in the presence of MSC and BAFF inhibitor and (D) B cells activated in the 
presence of MSC and isotype control.  (E) Graphical representation of the percentage of activated B cells 
which have undergone cell division after 5 days.  White bars represent B cells activated alone, black bars 
represent B cells activated in the presence of MSC, striped bars represent B cells activated in the presence 
of MSC and BAFF inhibitor and grey bars indicate B cells activated in the presence of MSC and isotype 
control. n=2 PBMC donors with 1 MSC donors. 
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3.6 MSC SIGNIFICANTLY INCREASED B CELL SURVIVAL IN VITRO THROUGH A CONTACT 
DEPENDENT MECHANISM 
 A role for MSC in maintaining the haematopoietic stem cell niche has previously 
been identified (Méndez-Ferrer et al. 2010).  MSC are capable of supporting the survival 
of immune cells through contact dependent and soluble mechanisms (English & Wood 
2013).  The ability of MSC to support B cell viability in vitro may explain the enhanced 
activation and proliferation of B cells after co-culture with MSC (Figure 3.2 & 3.3).  To 
investigate the effect of MSC on the survival of CD19+ B cells, purified B cells were 
cultured in the presence or absence of MSC (5:1) for 72 hours.  In the absence of MSC, 
the viability of B cells was very low with approximately 20% of cells negative for 
apoptosis markers Annexin V/PI, as analysed by flow cytometry (Figure 3.7).  However, 
B cells cultured in the presence of MSC demonstrated significantly increased viability 
illustrated by the percentage and number of Annexin V-PI- B cells (Figure 3.7).  
Preventing cell contact using transwell membranes (0.4 µm pore) abrogated the protection 
of CD19+ B cell survival by MSC and the percentage and cell number of Annexin V and 
PI negative cells was restored to a similar level of B cells cultured alone (Figure 3.7), 
suggesting that MSC support of B cell survival requires cell contact. 
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Figure 3.7: MSC support B cell survival through a contact dependent mechanism.  Purified B cell 
populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in 
cIMDM in the presence or absence of 1.8 x 105 MSC (5:1) for 72 hours and B cell survival was determined 
by analysing the expression of Annexin V and propidium iodide (PI) on CD45 APC gated B cells. Transwell 
membrane inserts (0.4 µm pore size) were used to prevent cell contact between MSC and B cells during 
co-culture.  (A) Represents the percentage of live (Annexin V- PI-) B cells and (B) represents the total 
number of live B cells.  White bars indicate B cells cultured alone while black bars represent B cells co-
cultured with MSC.  n=3 PBMC donors with 3 MSC donors.  Statistical analysis was carried out using a 
paired student t test. * < 0.05, ** < 0. 01. 
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3.7 LICENCING OF MSC WITH IFN-γ HAS NO EFFECT ON THEIR SUPPORT OF B CELL 
SURVIVAL 
 Pre-stimulation or “licencing” of MSC with IFN-γ has been demonstrated to 
significantly increase MSC inhibition of T cell function both in vitro (Ryan et al. 2007) 
and in vivo (Tobin et al. 2013).  The increased suppression of T cell proliferation by IFN-
γ stimulated MSC is mediated in part by an altered proteomic profile of IFN-γ stimulated 
MSC (Krampera et al. 2006; Ryan et al. 2007; Polchert et al. 2008). MSC do not 
constitutively express indoleamine 2,3-dioxygenase (IDO), however significant up-
regulation in IDO production is induced following IFN-γ stimulation (Ryan et al. 2007).  
Therefore, it was hypothesised that IFN-γ licenced MSC may differentially regulate B 
cell survival compared to resting MSC.  CD19+ B cells were cultured with or without 
MSC or IFN-γ licensed MSC (γMSC) for 72 hours and B cell viability was determined 
using Annexin V and PI staining.  Viable B cells were distinguished from MSC by gating 
on CD45+ cells before Annexin V and PI analysis.  IFN-γ licencing of MSC was 
performed as described in section 2.9.1. 
 There was no difference in B cell viability when B cells were cultured with γMSC 
compared to cells cultured with resting MSC.  CD19+ B cells cultured alone for 72 hours 
had a survival rate of 22% (Figure 3.8).  As expected, the viability of B cells which were 
cultured in the presence of MSC was significantly enhanced (60%); however, there was 
no significant difference in viability when B cells were co-cultured with γMSC (62%) 
(Figure 3.8).  There was also no difference in the total number of viable B cells recovered 
from co-cultures with γMSC compared to resting MSC.  These results suggested that the 
survival signal between MSC and B cells was not altered by IFN-γ stimulation. 
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Figure 3.8: Pre-stimulation of MSC with IFN-γ has no effect on their support of B cell survival.  
Purified B cell populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were 
cultured in cIMDM in the presence or absence of 1.8 x 105 MSC or MSC pre-stimulated with 50 ng/ml 
IFN-γ for 48 hours.  B cell survival was determined by analysing the expression of Annexin V and 
propidium iodide (PI) on CD45 APC gated B cells after 72 hours co-culture. (A) Represents the percentage 
of live (Annexin V- PI-) B cells and (B) represents the total number of live B cells.  n=3 PBMC donors with 
2 MSC donors.  Statistical analysis was carried out using a paired student t test. ** < 0. 01. 
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3.8 MSC SUPPORT OF B CELL SURVIVAL IS NOT DEPENDENT ON NOTCH SIGNALLING 
Notch signalling is a highly conserved immune regulatory pathway which is 
known to influence cell development, proliferation, differentiation and survival (Fiúza & 
Arias 2007). Notch signalling is essential for interactions between immune cells and their 
environment (Radtke et al. 2004) and is critical for the development of peripheral B cells 
(Thomas et al. 2007).  Notch signalling is known to up-regulate the anti-apoptotic Bcl-2 
pathway and support B cell survival (Nwabo Kamdje et al. 2011).  Over the last number 
of years, the importance of the notch signalling pathway in immune modulation by MSC 
has been clearly identified.  The roles for notch signalling in MSC modulation of DC 
maturation and antigen presentation (Chen et al. 2007) and in the induction of regulatory 
T cells (Del Papa et al. 2013) have now been established.  Therefore it was hypothesised 
that notch signalling between MSC and CD19+ B cells up-regulated Bcl-2 expression and 
increased B cell viability. Purified CD19+ B cells were cultured in the presence or absence 
of MSC for 72 hours.  Bcl-2 expression by B cells was analysed by intra-cellular flow 
cytometry and B cell viability was determined using Annexin V and PI staining.  Notch 
signalling was inhibited during co-culture experiments using a notch γ-secretase inhibitor, 
GSI XII (Tocris Bioscience, Bristol, England). 
Bcl-2 expression was up-regulated in CD19+ B cells cultured in the presence of 
MSC (Figure 3.9) suggesting that MSC were capable of up-regulating the anti-apoptotic 
factor Bcl-2 in B cells.  As expected, B cell viability was significantly increased when 
cultured in the presence of MSC (Figure 3.9).  However, the addition of increasing 
concentrations of GSI XII, had no effect on MSC support of B cell survival (Figure 3.9).  
The percentages (Figure 3.9 A) or total numbers (Figure 3.9 B) of viable B cells were not 
reduced when notch signalling was inhibited, suggesting that the ability of MSC to 
support the survival of CD19+ B cells was independent of the notch signalling pathway. 
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Figure 3.9. MSC induce Bcl-2 up-regulation in B cells. Purified B cell populations were 
obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in cIMDM in the 
presence or absence of 1.8 x 105 MSC for 72 hours.  Bcl-2 expression was determined by intra-
cellular flow cytometry of CD45 APC gated B cells after 72 hours co-culture. Black peak 
represents isotype control, red peak represents B cells cultured alone and blue peak represents B 
cells cultured in the presence of MSC. Image representative of 2 separate experiments using 4 
PBMC donors and 2 MSC donors. 
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Figure 3.10. MSC support of B cell survival is not dependent on notch signalling. Purified B cell 
populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in 
cIMDM in the presence or absence of 1.8 x 105 MSC.  Notch signalling was inhibited using specific γ-
secretase inhibitor XII at 1µM, 2.5 µM, 5 µM or 10 µM.  B cell survival was determined by analysing the 
expression of Annexin V and propidium iodide (PI) on CD45 APC gated B cells after 72 hours co-culture. 
(A) Represents the percentage of live (Annexin V- PI-) B cells and (B) represents the total number of live 
B cells.  n=3 PBMC donors with 2 MSC donors.  Statistical analysis was carried out using a paired student 
t test. * < 0.05, ** < 0. 01. 
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3.9 CELL CONTACT DEPENDENT PRODUCTION OF VEGF BY MSC PROMOTES B CELL 
SURVIVAL 
Vascular Endothelial Growth Factor (VEGF) was identified originally as a pro-
angiogenic factor (Gospodarowicz & Lau 1989) and its production has since been 
identified on a number of stromal cells including MSC (Beckermann et al. 2008).  
Understanding of VEGF function has also expanded and one of the most potent functions 
of VEGF is in anti-apoptotic signalling (Gupta et al. 1999).  The anti-apoptotic effect of 
VEGF has previously been demonstrated by Spyridopoulos et al.; they demonstrated that 
the addition of recombinant VEGF (10 ng/ml) was capable of protecting up to 90% of 
epithelial cells from TNF-α induced apoptosis (Spyridopoulos et al. 1997).  Therefore the 
potential role for MSC produced VEGF in protecting B cells from apoptosis was 
examined. 
VEGF production by B cells cultured alone was very low at 24, 48 and 72 hours 
while MSC cultured alone produced 1ng/ml VEGF at these time-points (Figure 3.11 A, 
B & C).  However when MSC were cultured in the presence of B cells VEGF production 
was significantly increased after 48 and 72 hours (Figure 3.11 A, B & C).  Interestingly 
increased VEGF production was not detected in samples where B cells were separated 
from MSC by transwell membranes (Figure 3.11).  To determine the significance of 
increased VEGF production on B cell survival, a VEGF inhibitor (SU5416; R&D) was 
added to B cell:MSC co-cultures for 72 hours before B cell viability was determined by 
Annexin V/PI staining.  Inhibiting VEGF signalling during direct B cell:MSC co-culture 
completely abrogated the promotion of B cell survival by MSC (Figure 3.12).  Inhibiting 
VEGF signalling resulted in a significant reduction in the percentage and number of 
Annexin V and PI negative B cells after MSC co-culture, restoring them to similar levels 
as observed when B cells were cultured alone (Figure 3.12).  These results demonstrate 
that cell contact dependent up-regulation of VEGF by MSC induced B cell survival. 
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Figure 3.11. Cell contact between MSC and B cells induces up-regulation of VEGF by MSC. Purified 
B cell populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in 
cIMDM in the presence or absence of 1.8 x 105 MSC with or without B cell cytokine cocktail for 72 hours.  
Transwell membrane inserts (0.4 µm pore size) were used to prevent cell contact between MSC and B cells 
during co-culture. Supernatant was recovered from co-cultures after 24 (A), 48 (B) and 72 (C) hours and 
VEGF production was determined by ELISA.  n=2 PBMC donors with 2 MSC donors.  Statistical analysis 
was carried out using ANOVA analysis. ** < 0. 01. 
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Figure 3.12. Inhibition of VEGF signalling prevents MSC support of B cell survival.  Purified B cell 
populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in 
cIMDM in the presence or absence of 1.8 x 105 MSC with or without VEGF inhibitor for 72 hours.  B cell 
survival was determined by analysing the expression of Annexin V and propidium iodide (PI) on CD45 
APC gated B cells. (A) Represents the percentage of live (Annexin V- PI-) B cells and (B) represents the 
total number of live B cells.  n=4 PBMC donors with 2 MSC donors.  Statistical analysis was carried out 
using a paired student t test. * < 0.05, ** < 0. 01. 
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3.10 VEGF PRODUCTION BY MSC INCREASES AKT PHOSPHORYLATION AND PREVENTS 
CASPASE 3 ACTIVATION 
Following the demonstration of the importance of MSC derived VEGF, this study 
sought to investigate the signalling cascade involved in promoting B cell survival.  VEGF 
signalling has previously been shown to induce cell survival through the phosphorylation 
of AKT (Abid et al. 2004).  Phosphorylation of AKT (Phospho-AKT) is known to inhibit 
the activation of the caspase cascade preventing the cleavage (activation) of caspase 3 
(Zhou et al. 2000).  Therefore, the levels of Phospho-AKT and cleaved caspase 3 were 
analysed in B cells after 72 hours co-culture with or without MSC by western blot.  The 
role of VEGF signalling in inducing phosphorylation of AKT and the cleavage of caspase 
3 was also determined using VEGF inhibitor.   
CD19+ B cells cultured in the presence of MSC had a marked increase in levels 
of Phospho-AKT and displayed very little cleaved caspase 3 (Figure 3.13).  B cells which 
were cultured alone displayed low levels of Phospho-AKT but high levels of cleaved 
caspase 3 (Figure 3.13).  The inhibition of VEGF signalling during co-cultures with MSC 
clearly reduced the level of AKT phosphorylation and restored levels of cleaved caspase 
3 to that of B cells cultured alone (Figure 3.13).  These data suggest that the increased 
VEGF production by MSC during co-culture with B cells induces the phosphorylation of 
AKT and inhibits the caspase cascade and subsequent cleavage of caspase 3 resulting in 
reduced apoptosis. 
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Figure 3.13. VEGF produced by MSC up-regulates Phospho-AKT and subsequently inhibits caspase 
3 cleavage.  Purified B cell populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B 
cells were cultured in cIMDM in the presence or absence of 1.8 x 105 MSC with or without VEGF inhibitor 
for 72 hours.  B cells were recovered from co-culture and the phosphorylation of AKT (lower band) and 
cleaved caspase 3 were analysed by western blot analysis.  β-actin was used as a loading control.  Image 
representative of 3 separate experiments using 4 PBMC donors and 3 MSC donors. 
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3.11 MSC SUPPORT OF B CELL SURVIVAL IS NOT DEPENDENT ON CXCR4 SIGNALLING 
 In order to elucidate the cell contact signal responsible for the increased VEGF 
production and subsequent support of B cell survival by MSC, CXCR4-CXCL12 
signalling was identified as a possible candidate.  CXCR4 is constitutively expressed on 
peripheral B cells (Nie et al. 2004) and binding of CXCR4 to its ligand CXCL12 has 
previously been shown induce VEGF production (Liang et al. 2007).  The expression of 
CXCL12 on MSC has previously been established and therefore, a competitive inhibitor 
to CXCR4 (AMD3100) was used to inhibit CXCR4-CXCL12 signalling during B 
cell:MSC co-cultures.  CD19+ B cells were isolated from PBMC and cultured in the 
presence or absence of MSC (5:1) in the presence or absence of AMD3100 for 72 hours. 
B cell viability was determined using Annexin V and propidium iodide (PI) viability 
staining and analysed by flow cytometry.   
The capacity for AMD3100 to block CXCR4 on B cells was demonstrated on 
CD19+ B cells (Figure 3.15).  Total CXCR4 binding was achieved by adding 20 µg/ml 
AMD3100 to B cell culture (Figure 3.15).  However, blocking CXCR4-CXCL12 
signalling during B cell:MSC co-cultures had no effect on the ability of MSC to support 
B cell survival (Figure 3.16).  As expected, the percentage of viable cells was significantly 
higher when B cells were cultured in the presence of MSC compared to B cells alone; 
however the addition of 20 µg/ml or 50 µg/ml of AMD3100 did not significantly reduce 
the ability of MSC to support B cell survival (Figure 3.16), suggesting that the B cell-
MSC interaction is not mediated via CXCR4-CXCL12 signalling.  
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Figure 3.14. AMD3100 binds to CXCR4 on CD19+ B cells.  CD19+ peripheral B cells were isolated from 
PBMC using positive selection MACS beads and cultured with or without 20 µg/ml of CXCR4 inhibitor 
AMD3100 for 72 hours.  Binding of AMD3100 was determined by analysing the expression of CXCR4 or 
matched isotype control on CD19+ B cells by flow cytometry. (A) Representative image of CXCR4 
expression on CD19+ B cells cultured without inhibitor for 72 hours, (B) Isotype control and (C) CXCR4 
expression on CD19+ B cells cultured in the presence of 20 µg/ml AMD3100 for 72 hours. 
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Figure 3.15. Inhibition of CXCR4-CXCL12 signalling had no effect on MSC ability to support B cell 
survival.  Purified B cell populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B 
cells were cultured in cIMDM in the presence or absence of 1.8 x 105 MSC.  CXCR4 was neutralised using 
20 µg or 50 µg AMD3100 during B cell:MSC co-cultures. B cell survival was determined by analysing the 
expression of Annexin V and propidium iodide (PI) on CD45 APC gated B cells after 72 hours co-culture.  
n=2 PBMC donors with 2 MSC donors.  Statistical analysis was carried out using a paired student t test. * 
< 0. 05. 
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3.12 MSC SUPPORT OF B CELL SURVIVAL IS NOT DEPENDENT ON EGFR STIMULATION 
Another cell surface receptor involved in VEGF up-regulation upon stimulation 
is the epidermal growth factor receptor (EGFR).  Stimulation of EGFR significantly 
increases the production of pro-angiogenic factors, including VEGF, by bone marrow 
derived human MSC (De Luca et al. 2011).  The stimulation of the EGFR is not limited 
to a specific ligand; in fact a number of ligands present on the surface of peripheral B 
cells might be capable of inducing EGFR signalling.  Hence, binding of the EGFR was 
identified as a candidate for the cell contact signal required by MSC to support B cell 
survival.  Therefore EGFR signalling was inhibited by adding a neutralising antibody 
specific to EGFR to the B cell:MSC (5:1) co-cultures for 72 hours.  B cell viability was 
determined by staining with Annexin V and PI and analysed by flow cytometry.  
Co-culture of CD19+ B cells with MSC resulted in significant increase in B cell 
survival after 72 hours, as expected (Figure 3.17).  The addition of the EGFR neutralising 
antibody to B cell:MSC co-cultures did not significantly reduce the ability of MSC to 
support B cell survival (Figure 3.17), suggesting that B cell stimulation of the EGFR is 
not responsible for the enhancement of B cell survival by MSC. 
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Figure 3.16. Inhibition of EGFR does not prevent MSC from supporting B cell survival.  Purified B 
cell populations were obtained from PBMC using CD19+ MACS beads.  9 x 105 B cells were cultured in 
cIMDM in the presence or absence of 1.8 x 105 MSC.  EGFR was neutralised using 10 nM EGFR 
neutralising antibody during B cell:MSC co-cultures. B cell survival was determined by analysing the 
expression of Annexin V and propidium iodide (PI) on CD45 APC gated B cells after 72 hours co-culture.  
n=2 PBMC donors with 2 MSC donors.  Statistical analysis was carried out using a paired student t test. * 
< 0. 05. 
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3.13 SUMMARY 
 The main aims of this chapter were to (1) determine the effect of MSC on B cell 
function; activation, proliferation and antibody production and (2) to elucidate the 
mechanism by which MSC modulate B cell function.  The activation and proliferation of 
CD19+ B cells were significantly increased after co-culture with MSC (Figures 3.2 & 
3.3); however the production of IgG and IgM were unaffected by the presence of MSC 
(Figure 3.4).  The increase in B cell proliferation was completely dependent on cell 
contact between the B cell and MSC (Figure 3.3).  The viability of CD19+ peripheral B 
cells was significantly increased when B cells were cultured in the presence of MSC.  
MSC support of B cell survival was also mediated through a cell contact dependent 
mechanism (Figure 3.7).  These results demonstrate that MSC were supportive rather than 
suppressive of B cell function. 
The second part of this study was to elucidate the mechanism by which MSC supported 
B cell activation, proliferation and survival.  BAFF-TNSFR13 and notch signalling were 
identified as potential candidates for the cell contact signal between B cells and MSC; 
however neutralisation of BAFF or notch signalling during B cell:MSC co-cultures had 
no effect on MSC support of B cell proliferation or survival (Figures 3.6 & 3.10).   
Therefore the ability of MSC to produce VEGF was investigated.  MSC constitutively 
produced VEGF, however the production of VEGF by MSC was significantly up-
regulated after cell contact with CD19+ peripheral B cells (Figure 3.11).  Neutralisation 
of VEGF signalling during B cell:MSC co-cultures completely abrogated the support of 
MSC on B cell survival suggesting that the increased VEGF production was essential for 
the survival of B cells (Figure 3.12).  Co-culture of CD19+ B cells with MSC resulted in 
a marked increase in the phosphorylation of AKT (pAKT) and subsequent reduction in 
the expression of cleaved caspase 3 (Figure 3.13).  Inhibition of VEGF signalling during 
B cell: MSC co-cultures resulted in reduced pAKT within the B cells and increase in 
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caspase 3 cleavage, to similar levels observed when B cells were cultured alone (Figure 
3.13).   
 Investigations into the cell contact signal driving VEGF production and B cell 
survival have been unsuccessful.  CXCR4-CXCL12 signalling and stimulation of the 
EGFR were considered likely key targets due to their ability to induce VEGF production 
and support survival; however neutralisation of CXCR4 or EGFR during B cell: MSC co-
culture had no effect on the ability of MSC to promote B cell survival (Figures 3.16 & 
3.17). 
 Therefore we propose a model for MSC support of B cell survival where (1) MSC 
contact with B cells (contact signal yet to be identified) results in significant up-regulation 
of VEGF production by MSC.  (2) Soluble VEGF is recognised by B cells and induces 
phosphorylation of AKT.  (3) pAKT inhibits the pro-apoptotic caspase cascade resulting 
in significantly less cleaved caspase 3 and subsequently reduced B cell apoptosis. 
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CHAPTER 4 
 
DEVELOPMENT OF XENOGENEIC MSC THERAPY IN 
MURINE MODELS OF GVHD 
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4.1 INTRODUCTION 
Allogeneic hematopoietic stem cell transplantation (HSCT) was first developed by 
E. Donnall Thomas in 1957 and is now the current treatment of choice for patients with 
both malignant and non-malignant haematological disorders as well as the most 
commonly practiced form of stem cell therapy (Peccatori & Ciceri 2010).  However, the 
development of graft-versus-host disease (GvHD) still represents a life threatening 
complication of HSCT.  Corticosteroids are the primary choice of treatment for patients 
who develop GvHD, however there is no consensus on optimal treatments for patients 
with steroid refractory GvHD (Ho & Cutler 2008).  This has led to huge efforts within 
the field of GvHD research to identify novel methods of modulating GvHD; from which 
the use of MSC has emerged as a potential cell therapy. 
MSC have become an attractive target for use as a cell therapy against steroid 
resistant GvHD because of their potent immune suppressive properties and their ability 
to avoid allogeneic rejection (Ryan et al. 2005; Polchert et al. 2008).  In 2004, the first 
successful transplantation of MSC as an allogeneic cell therapy for patients with steroid 
resistant grade IV GvHD was performed by Le Blanc et al. and demonstrated remarkable 
immunosuppressive effects; however the exact mechanisms by which the MSC therapy 
mediated their effect was not determined (Le Blanc et al. 2004).  More recently, Osiris 
Therapeutics published the results of a phase 3 clinical trial where they administered 
Prochymal™ (a patented MSC like product) to patients with steroid refractory GvHD.  
Prochymal™ significantly increased response rates in patients with steroid refractory 
liver GvHD and steroid refractory gastrointestinal disease over patients treated with 
placebo; however overall the study did not reach its primary endpoint to significantly 
increase complete response rates in steroid refractory GvHD patients for at least 28 days 
in comparison to placebo controls (Martin et al. 2010).  These results highlighted the 
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potential of allogeneic MSC as a candidate therapy to treat acute steroid refractory GvHD 
when administered after donor T cell recognition but also demonstrated the little 
understanding which exists about how MSC mediate their beneficial effect in a clinical 
setting.   
The development of animal models of GvHD which are tailored around the 
administration of MSC would greatly expand our understanding of how MSC work in 
vivo and provide us with a platform to enhance our knowledge of the immunological 
interaction between MSC and the immune system.  The ability to use human MSC in 
murine models of GvHD would expand the resources currently available to researchers 
and allow the further examination of the mechanisms behind how MSC modulate GvHD. 
The objectives of this chapter were: 
1) To determine if human (xenogeneic) MSC therapies could be assessed in murine 
models of acute or chronic GvHD. 
2) To investigate the capacity for human MSC to promote survival in GvHD mice. 
3) To examine the effect of human MSC on GvHD pathology and associated weight 
loss and to determine the effect of human MSC on the engraftment of donor T 
lymphocytes. 
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4.2 XENOGENEIC MSC TRANSPLANTATION HAD NO EFFECT ON THE SURVIVAL OF 
SYNGENEIC CONTROL MICE 
Due to the difficulty in acquisition and precious nature of GvHD patient samples, 
murine models of GvHD have become essential in furthering our understanding and the 
development of novel treatments for GvHD.  Xenogeneic MSC have been used in a 
number of animal models, however the success of these experiments has been varied (Lin 
et al. 2012).  Human bone marrow derived MSC have been shown to successfully engraft 
and migrate to the site of damage in a rat model of spinal cord injury (Pal et al. 2010) as 
well as enhance bone formation and increase bone mass in mouse models (Guan et al. 
2012).  However, two studies by Grinnemo et al, 2004 and 2006, reported that human 
MSC showed very poor engraftment in immune-competent mice (Grinnemo et al. 2004; 
Grinnemo et al. 2006).  
In this study, syngeneic transplant mice were established as a negative control and 
human MSC were also administered to syngeneic transplant mice to identify any potential 
adverse effects associated with administering xenogeneic MSC as a cell therapy.  BALB/c 
mice were sub-lethally irradiated (7 Gy) and transplanted with 5x106 bone marrow cells 
and whole splenocytes limited to 1x106 CD4+ cells isolated from BALB/c mice. Human 
MSC were administered to mice at days 1 and 3 post transplantation (Figure 4.1).  
Transplanted mice were monitored on a regular basis and the development of GvHD was 
defined as total body weight loss of >25% of original starting weight with a series of 
clinical manifestations including posture, reduction in activity, fur texture and diarrhoea 
(according to local ethics committee recommendations in Case Western Reserve 
University, Cleveland Ohio).  These parameters were combined into a clinical score and 
mice which amassed a total score of 6 from 8 or had suffered weight loss in excess of 
25% were considered to have severe GvHD and sacrificed humanely (Table 4.1).   
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Human MSC therapy had no adverse effect on the survival of syngeneic control 
mice (Figure 4.2 A).  Despite an original delay in weight gain, the administration of 
human MSC did not significantly impair weight gain of syngeneic control mice (Figure 
4.2 B).  Human MSC therapy had no effect on the pathological score of syngeneic mice 
throughout this study (Figure 4.2 C).  
The main target organs involved in GvHD pathology are the gut, liver, spleen and 
lung.  The use of MSC therapy to treat GvHD has been shown to reduce pathology in 
target organs with the most significant effect being observed in the gut (Tobin et al. 2013).  
Therefore, histopathology was used to determine if xenogeneic MSC had any adverse 
effects on the pathology of these organs 28 days after transplantation.  Tissue sections 
were stained by H&E and the histological GvHD score was evaluated for each treatment 
group according to criteria previously established in the lab (Tobin et al. 2013). 
Pathology of the gut was determined by the extent of lymphocyte infiltration (L) 
and villous destruction (V) observed in the small intestine of each mouse. As expected, 
syngeneic control mice displayed no distinguishable pathological symptoms within the 
small intestine (Figure 4.3 A).  Administration of human MSC had no adverse effect on 
villi structure but did however lead to increased levels of lymphocyte infiltration resulting 
in a slightly higher pathological score than non-treated mice (Figure 4.3 B). 
Syngeneic bone marrow transplantation did not adversely affect the lung 
architecture of the mice or induce pathology as measured by peribronchial inflammation 
(L) and airway epithelium thickening (T) (Figure 4.3 A&B).  Human MSC did not 
significantly affect lung architecture of syngeneic mice (Figure 4.3 A).  However, human 
MSC therapy significantly increased lymphocyte infiltration and thickening of the airway 
epithelial wall and resulted in a significant increase in pathological score (Figure 4.3 
A&B).   
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Administration of human MSC to syngeneic control mice had no effect on liver 
pathology, as measured by lymphocyte infiltration around hepatic veins (L) (Figure 4.3 
A). Syngeneic control mice which received human MSC displayed no increase in 
lymphocyte infiltration suggesting that administration of human MSC was not 
detrimental to the livers of transplant mice (Figure 4.3 A&B). 
The spleens of syngeneic mice were unaffected by human MSC therapy with no 
evidence of pathology, as measured by splenic structure and germinal centre (GC) 
formation (Figure 4.3 A & B). This suggests that human MSC do not adversely affect 
splenic tissue in syngeneic control mice after 28 days.  Overall, this histological analysis 
suggest that while xenogeneic transplantation of human MSC had no effect on the 
survival, weight loss or pathological score of syngeneic mice, the immunogenicity shown 
by human MSC in a xenogeneic setting may be a problem in xenogeneic transplantation. 
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Figure 4.1. Graphical illustration of syngeneic control transplants, chronic GvHD and acute GvHD 
mouse models. BALB/c mice were irradiated using 7 Gy and 5 x 106 bone marrow cells and whole spleen 
cells (limited to 1 x 106 CD4+ cells) from BALB/c (syngeneic), B10.D2 (chronic GvHD) or C57BL/6 (acute 
GvHD) mice were administered intravenously (i.v.) in 300µl via the tail vein.  1 x 106 Human MSC were 
administered i.v. on days 1 and 3 post transplantation. Development of GvHD was monitored weekly by 
recording the weight and clinical score of each mouse.  Pathological score was determined as described in 
Table 4.1.  Lymphocyte reconstitution was determined using flow cytometry and organ pathology was 
analysed using H&E staining. 
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Table 4.1: Pathological scoring system for GvHD 
Score 
 
0 0.5 1 1.5 2 
Posture Normal – 
No 
hunching 
Slight 
hunching 
but 
straightens 
while 
walking 
Animal 
stays 
hunched 
while 
walking 
Animal 
does not 
straighten 
out 
Animal 
tends to 
stand on 
rear feet 
Activity Normal – 
Very 
mobile 
Less 
movement 
than normal 
– slower 
and easier 
to catch 
Animal 
stays still 
but will 
move when 
touched 
Very little 
activity and 
very little 
movement 
when 
touched 
No activity 
and animal 
does not 
move when 
touched 
Fur Normal – 
no fur 
pathology 
Ridging on 
side of belly 
and neck 
Ridging 
along belly, 
hind legs 
and back 
Fur is 
matted and 
unkempt 
Badly 
matted all 
over body 
Diarrhoea Normal – 
no 
diarrhoea 
Mild 
change in 
bowel 
movements 
Moderate 
changes in 
bowel 
movement 
Severe 
changes in 
bowel 
movement 
Extensive 
diarrhoea 
and redness 
around 
anus 
 
 
128 
 
 
Figure 4.2. Human MSC had no adverse effect on survival, weight gain or clinical score of syngeneic 
control mice.  Graphical representation of (A) survival, (B) percentage weight change and (C) pathological 
score of syngeneic transplant mice (black line) and MSC treated syngeneic transplant mice (red line).  5 x 
106 bone marrow cells and whole spleen cells (limited to 1 x 106 CD4+ cells) from BALB/c mice were 
administered to irradiated BALB/c mice.  1 x 106 human MSC were given as a cell therapy on days 1 and 
3.   Transplanted mice were monitored every 7 days for the duration of the experiment. n=6. 
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Figure 4.3. Human MSC significantly increased pathology in the lung of syngeneic control mice.  5 x 
106 bone marrow cells and whole spleen cells (limited to 1 x 106 CD4+ cells) from BALB/c mice were 
administered to irradiated BALB/c mice.  1 x 106 human MSC were given as cell therapy on days 1 and 3.   
Mice were sacrificed on day 28 and small intestine, lung, liver and spleen harvested and tissue sections 
were analysed by (A) H&E staining and (B) a defined scoring system.  (A) Tissue samples were processed 
and stained with H&E and analysed for lymphocyte infiltration (L), villi destruction (V), thickening of 
epithelial airways (T) or germinal centre formation (GC).  Pathological score determined by 2 independent 
researchers. Tissues samples were stained using H&E and images captured at 100X and 400X.  (B) 
Graphical representation of combined pathological score for syngeneic control mice (white bars) and 
human MSC treated syngeneic mice (black bars). n=3 per group.  Statistical analysis was carried out using 
a paired student t test. ** < 0.01. 
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4.3 XENOGENEIC MSC SIGNIFICANTLY INCREASED CD4+ T CELLS IN THE LUNGS OF 
ALL TRANSPLANT MODELS TESTED. 
This experiment was designed to determine the capacity of human MSC to 
increase survival and lower pathological score in murine models of chronic and acute 
GvHD.  Human MSC were administered to syngeneic bone marrow transplant mice to 
control for effects associated with xenogeneic responses.  Analysis of bronchoalveolar 
lavage (BAL) fluid recovered from the lungs of human MSC treated syngeneic mice 
subsequently demonstrated a significant increase in CD4+ T cells 28 days post 
transplantation (Figure 4.4 A).  However, after 63 days, syngeneic mice which had not 
received human MSC had a similar level of CD4+ infiltration in the lungs compared to 
syngeneic mice which had received human MSC (Figure 4.4 B).  
The administration of human MSC to chronic GvHD mice resulted in a significant 
increase in CD4+ T cells recovered from BAL fluid 28 days (Figure 4.4 C) and 63 days 
(Figure 4.4 D) post transplantation. The administration of human MSC to chronic GvHD 
mice also resulted in increased CD8+ T cell populations in the lungs by day 63 (Figure 
4.4 D), which was not observed in syngeneic control mice (Figure 4.4 B).   
As observed for both syngeneic control mice and chronic GvHD mice, the 
administration of human MSC to acute GvHD mice resulted in a significant increase in 
CD4+ T cells recovered from BAL fluid at 28 days (Figure 4.4 E) and 63 days (Figure 4.4 
F) post transplantation.  The total number of CD8+ T cells was also increased 28 days 
after transplantation (Figure 4.4 E).  Interestingly this increase in CD8+ T cell number 
was lost by day 63 (Figure 4.4 F). 
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Figure 4.4. Human MSC therapy significantly increased CD4+ T cells in the lung. Graphical 
representation of total CD4+ and CD8+ T cell numbers recovered from bronchoalveolar lavage fluid from 
(A) syngeneic mice on day 28, (B) syngeneic mice on day 63, (C) chronic GvHD mice on day 28, (D) 
chronic GvHD mice on day 63, (E) acute GvHD mice at day 28 and (F) acute GvHD mice at day 63 as 
measured by flow cytometry.  Non-treated mice represented by white bars and MSC treated mice 
represented by black bars.  n=3 per group.  Statistical analysis was carried out using the students paired T 
test. * < 0.05, ** < 0.01. 
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4.4 HUMAN MSC REDUCED PATHOLOGY IN THE GUT OF CHRONIC GVHD MICE 
Chronic GvHD (cGvHD) is a major cause of morbidity and mortality in long term 
survivors of HSCT.  The model of cGvHD used in this study was established using a 
minor MHC mismatched transplant, originally developed by Korngold and Sprent 
(Korngold & Sprent 1978).  BALB/c mice were sub-lethally irradiated (7 Gy) and 
transplanted with 5x106 bone marrow cells and whole splenocytes limited to 1x106 CD4+ 
cells isolated from B10/D2 mice. Human MSC were administered to mice at days 1 and 
3 post transplantation (Figure 4.1). As before the mice were monitored on a regular basis 
and the development of GvHD was defined as previously described (Table 4.1).  Mice 
which received a combined pathological score of 6 from 8 or displayed weight loss in 
excess of 25% were considered to have severe GvHD and sacrificed humanely. 
cGvHD had not yet fully developed in any of the mice within the 63 days duration 
of this experiment (this model of cGvHD would normally be run for 120 days, however, 
the duration of this experiment was reduced to facilitate a 3 month laboratory visit to Case 
Western Reserve University, Cleveland).  Although the mice were beginning to display 
symptoms characteristic of GvHD, there were no fatalities in either the human MSC 
treated or non-treated chronic GvHD mice 63 days after transplantation (Figure 4.5).  
cGvHD mice which received human MSC had greater protection from weight loss than 
non-treated mice, which was particularly evident by day 63 (Figure 4.5).  Human MSC 
treated mice also displayed a lower pathological score during the later stages of the 
experiment, evident from day 40 onwards, however this was not statistically different 
(Figure 4.5).  
As before, the level of GvHD pathology in target organs of chronic GvHD mice 
was analysed using H&E staining of tissue sections from the small intestine, lung, liver 
and spleen.  Human MSC therapy significantly reduced the pathological score in the gut 
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of cGvHD mice as measured by less destruction of villi and less lymphocyte infiltration 
to the small intestine (Figure 4.6 A&B).  Non-treated mice presented large localised 
accumulations of lymphocytes and villous destruction in the small intestine (Figure 4.6 
A).  cGvHD mice treated with human MSC did not display these large accumulations of 
lymphocytes but smaller aggregations of lymphocytes were sporadically present at the 
base of villi throughout the organ (Figure 4.6 A).   
cGvHD mice had a significant increase in peribronchial inflammation and much 
greater airway epithelium thickening than syngeneic control mice in the lung (Figure 4.6 
A). As before, the administration of human MSC to murine chronic GvHD mice increased 
lung pathology compared to non-treated mice. Human MSC treated mice had increased 
lymphocyte infiltration, particularly around bronchi, and more profound airway 
epithelium thickening than non-treated mice (Figure 4.6 A). Similar to results observed 
with the syngeneic transplant mice, the administration of human MSC exacerbated lung 
pathology in cGvHD mice. 
Although the liver is a major target for GvHD, very little pathology was observed 
in cGvHD mice by day 28 (Figure 4.6 A&B). cGvHD mice displayed lymphocyte 
infiltration around periportal areas (Figure 4.6 A).  The administration of human MSC 
reduced lymphocyte infiltration in the livers of cGvHD mice (Figure 4.6 A).   
cGvHD mice displayed impaired germinal centre formation and overall presence 
of lymphocytes within the spleen (Figure 4.6 A).  The administration of human MSC 
therapy did not restore germinal centre formation or significantly reduce spleen pathology 
(Figure 4.6 A).  This may suggest impaired B cell engraftment after transplantation or a 
complication associated with chronic GvHD (Figure 4.6 A). These results suggest that 
xenogeneic transplant of human MSC may offer some protection against damage to the 
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spleen in models of cGvHD, but that these may become more pronounced during latter 
stages of disease progression. 
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Figure 4.5. Human MSC reduced weight loss and pathology in chronic GvHD mice. Graphical 
representation of (A) survival, (B) percentage weight change and (C) pathological score of syngeneic 
transplant mice (black line) and MSC treated syngeneic transplant mice (red line).  5 x 106 bone marrow 
cells and whole spleen cells (limited to 1 x 106 CD4+ cells) from B10.D2 mice were administered to 
irradiated BALB/c mice.  1 x 106 human MSC were given as cell therapy on days 1 and 3.   Transplanted 
mice were monitored every 7 days for the duration of the experiment.  Chronic GvHD mice are represented 
by the black line and chronic GvHD mice which received human MSC therapy are represented by red line. 
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Figure 4.6. Human MSC significantly lowered the pathological score of small intestine but increased 
lymphocyte infiltration to the lungs of chronic GvHD mice. 5 x 106 bone marrow cells and whole spleen 
cells (limited to 1 x 106 CD4+ cells) from B10.D2 mice were administered to irradiated BALB/c mice.  1 x 
106 human MSC were given as cell therapy on days 1 and 3.   Mice were sacrificed on day 28 and small 
intestine, lung, liver and spleen harvested and tissue sections were analysed by (A) H&E staining and (B) 
a defined scoring system.  (A) Tissue samples were processed and stained with H&E and analysed for 
lymphocyte infiltration (L), villi destruction (V), thickening of epithelial airways (T) or germinal centre 
formation (GC).  Pathological score determined by 2 independent researchers. Tissues samples were stained 
using H&E and images captured at 100X and 400X.  (B) Graphical representation of combined pathological 
score for syngeneic control mice (white bars) and human MSC treated syngeneic mice (black bars). n=3 
per group.  Statistical analysis was carried out using a paired student T test. * < 0.05. 
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4.5 HUMAN MSC INCREASED SURVIVAL AND REDUCED PATHOLOGY IN MODELS OF 
ACUTE GVHD 
Acute GvHD (aGvHD) is a life threatening complication following allogeneic 
HSCT which can occur in 30-50% of patients who receive sibling matched transplants.  
The model of aGvHD utilised in this experiment was established using a major MHC 
mismatched transplant. BALB/c mice were sub-lethally irradiated (7 Gy) and 
transplanted with 5x106 bone marrow cells and whole splenocytes limited to 1x106 CD4+ 
cells isolated from C57BL/6 mice. Human MSC were administered to mice at days 1 and 
3 post transplantation (Figure 4.1).  As before, mice were monitored on a weekly basis 
and the development of aGvHD was defined as previously described (Table 4.1).  Mice 
which received a combined pathological score of 6 from 8 or displayed weight loss in 
excess of 25% were considered to have severe aGvHD and sacrificed humanely. 
The administration of human MSC significantly increased the survival of mice 
with aGvHD with 80% of mice surviving for the duration of this study while all non-
treated mice succumbed to GvHD by day 57 (Figure 4.7 A).  Human MSC therapy also 
resulted in reduced weight loss (Figure 4.7 B) and a lower clinical score compared to non-
treated mice (Figure 4.7 C).   
As before, the level of pathology in target organs was analysed through H&E 
staining of tissue sections from the small intestine, lung, liver and spleen. Human MSC 
therapy significantly reduced aGvHD associated pathology within the small intestine of 
aGvHD mice (Figure 4.8 A&B).  Although the large accumulations of lymphocytes 
observed in cGvHD models were not present in the acute GvHD mice, significant 
destruction of the villi was clear throughout the organ (Figure 4.8 A). Healthy villi 
structure in MSC treated mice indicated the protective effect of human MSC in the small 
intestine (Figure 4.8 A).   
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Lower levels of lymphocyte infiltration were observed in the lungs of aGvHD 
mice (Figure 4.8 A) compared to chronic GvHD mice (Figure 4.6 A).  However, there 
was much greater damage to lung architecture in aGvHD mice (Figure 4.8 A).  In contrast 
to both syngeneic transplant and cGvHD mice, the administration of human MSC to mice 
did not significantly enhance lung pathology during aGvHD (Figure 4.8 A&B).  Lower 
levels of lymphocyte infiltration may be caused by poor immune reconstitution in aGvHD 
mice and therefore an impaired immune response against human MSC. 
Similar to pathology observed in the lung, human MSC had no significant effect 
on liver pathology during aGvHD (Figure 4.8 A&B).  Significant lymphocyte infiltration 
around hepatic veins was observed in aGvHD mice, although to the same extent in 
cGvHD mice (Figure 4.6 A).  Human MSC therapy did not lower pathological scores or 
significantly reduce lymphocyte infiltration in the liver during aGvHD (Figure 4.8 A&B).  
Spleens taken from aGvHD mice completely lacked germinal centre formation 28 
days post transplantation (Figure 4.8 A).  This lack of germinal centre formation may be 
a result of a failure of B cells to engraft post transplantation.  The expression of murine 
CD19 was also significantly reduced in the spleens of aGvHD mice (Figure 4.9).  Overall 
human MSC therapy had no effect on pathological score, germinal centre formation or 
the expression of CD19 in the spleens of aGvHD mice (Figure 4.8 A; Figure 4.9).  
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Figure 4.7. Human MSC significantly increased survival and reduced weight loss and clinical score 
in acute GvHD mice.  Graphical representation of (A) survival, (B) percentage weight change and (C) 
pathological score of syngeneic transplant mice (black line) and MSC treated syngeneic transplant mice 
(red line).  5 x 106 bone marrow cells and whole spleen cells (limited to 1 x 106 CD4+ cells) from C57BL/6 
mice were administered to irradiated BALB/c mice.  1 x 106 human MSC were given as cell therapy on 
days 1 and 3.   Transplanted mice were monitored every 7 days for the duration of the experiment.  Non-
treated mice (black line) and mice which received human MSC (red line). n=6.  Statistical analysis was 
carried out using the un-paired student T test. * < 0.05. 
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Figure 4.8. Human MSC significantly improved pathology in the small intestine of acute GvHD mice.  
5 x 106 bone marrow cells and whole spleen cells (limited to 1 x 106 CD4+ cells) from C57BL/6 mice were 
administered to irradiated BALB/c mice.  1 x 106 human MSC were given as cell therapy on days 1 and 3.   
Mice were sacrificed on day 28 and small intestine, lung, liver and spleen harvested and tissue sections 
were analysed by (A) H&E staining and (B) a defined scoring system.  (A) Tissue samples were processed 
and stained with H&E and analysed for lymphocyte infiltration (L), villi destruction (V), thickening of 
epithelial airways (T) or germinal centre formation (GC).  Pathological score determined by 2 independent 
researchers. Tissues samples were stained using H&E and images captured at 100X and 400X.  (B) 
Graphical representation of combined pathological score for syngeneic control mice (white bars) and 
human MSC treated syngeneic mice (black bars). n=3 per group.  Statistical analysis was carried out using 
a paired student T test. * < 0.05. 
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Figure 4.9. Human MSC did not protect B cell engraftment in the spleen.  Graphical representation of 
murine CD19 mRNA expression in the spleens of syngeneic controls, non-treated acute GvHD mice and 
GvHD mice which received MSC therapy as measured by real time PCR at 28 days post transplantation.  
n=3 per group.  Statistical analysis was carried out using the students paired t test.  ** < 0.01. 
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4.6 HUMAN MSC DID NOT INHIBIT CD4+ OR CD8+ T CELL ENGRAFTMENT AFTER 
TRANSPLANTATION  
 After HSCT, it is essential that donor hematopoietic cells successfully engraft 
within the patient to provide a functional immune system and to eliminate any remaining 
tumour cells.  This therefore requires that any potential new therapies against GvHD do 
not impair engraftment.  To determine the effect of human MSC on the engraftment of 
murine CD4+ and CD8+ T cell populations, spleens were harvested from syngeneic mice, 
cGvHD mice and aGvHD mice at 28 and 63 days post transplantation.  Lymphocyte 
populations were isolated from each spleen and analysed for the expression of CD4+ and 
CD8+ populations.  The major MHC mismatch between the C57BL/6 donor cells and the 
BALB/c recipient mouse used in the acute model of GvHD also made it possible to 
distinguish T cells of donor origin (H2b+) from recipient T cells (H2d+) using flow 
cytometry. 
Human MSC therapy had no effect on the total number of CD4+ or CD8+ T cells 
recovered from the spleen of syngeneic control mice 28 days post transplantation (Figure 
4.10 A).  However, significantly more CD4+ T cells were recovered from the spleens of 
syngeneic control mice after human MSC therapy 63 days post transplantation (Figure 
4.10 B).  
 The administration of human MSC to cGvHD mice resulted in approximately 
50% more CD4+ T cells being recovered from the spleens 28 days after transplantation 
(Figure 4.10 C), however there was no significant difference.  This increase in CD4+ T 
cells in human MSC treated mice was also evident 63 days post transplantation (Figure 
4.10 D).  Although there was a slight increase in CD8+ T cells in cGvHD mice that 
received human MSC at both day 28 and 63, the results obtained were not significant 
(Figure 4.10 C&D).   
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  The spleen is a primary target of acute GvHD and significant reductions in size 
as well as the development of extensive necrotic regions were observed in acute GvHD 
mice.  This damage to splenic architecture was subsequently accompanied by a significant 
reduction in the numbers of viable lymphocytes recovered from the spleen.  Similar to 
results observed in cGvHD models, human MSC therapy resulted in an increased 
engraftment of CD4+ T cell populations when compared to non-treated mice at both 28 
and 63 days after transplantation (Figure 4.10 E&F).  A greater number of CD8+ T cells 
were also recovered from the spleens of mice which received human MSC therapy (Figure 
4.10 E&F).  All CD4+ and CD8+ T cells recovered from the spleens of both human MSC 
treated and non-treated aGvHD mice were positive for the MHC class I haplotype Kb and 
were therefore of C57BL/6 origin (Figure 4.11).  These data suggest the administration 
of human MSC to murine models of chronic or acute GvHD does not impair the 
engraftment of transplanted cells. 
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Figure 4.10. Human MSC therapy increased engraftment of CD4+ and CD8+ T cells post 
transplantation. Graphical representation of total CD4+ and CD8+ T cell numbers recovered from spleens 
of syngeneic control mice (A & B, chronic GvHD models (C & D) and acute GvHD models (E & F) which 
did not receive treatment (white bars) or received human MSC therapy (black bars) as measured by flow 
cytometry on days 28 (A, C & E) and 63 (B, D & F).  n=3 per group.  Statistical analysis was carried out 
using the students paired T test. * < 0.05, ** < 0.01. 
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Figure 4.11. Reconstituted lymphocytes in acute GvHD are donor derived.  Representative image 
comparing the expression of MHC class I haplotypes Kd and Kb on live CD4+ lymphocytes recovered from 
the spleens of (A) syngeneic transplant mice and (B) acute GvHD mice as measured by flow cytometry 28 
days after transplantation.  n=3 per group. 
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4.7 SUMMARY 
 The main aims of this chapter were to (1) determine whether human (xenogeneic) 
MSC therapies can be assessed in murine models of acute or chronic GvHD, (2) to 
investigate the capacity for human MSC to promote survival in GvHD mice and (3) to 
examine the effect of human MSC on pathology, weight loss and engraftment.  
Transplantation of xenogeneic MSC into syngeneic control mice had no adverse effect 
on survival, weight gain or pathology (Figure 4.2); however human MSC significantly 
increased lymphocyte infiltration and thickening of the airway epithelial wall within the 
lungs of these mice (Figure 4.3).  Syngeneic control mice which received human MSC 
also contained significantly more CD4+ T cells in BAL fluid recovered from the lungs 
than non-treated mice after 28 days (Figure 4.4).  Human MSC therapy had no effect on 
splenic T cell populations 28 days after transplantation but did however result in 
significantly more splenic CD4+ T cells at day 63 (Figure 4.4).  The administration of 
human MSC to cGvHD mice resulted in a slightly lower clinical score and reduced weight 
loss than non-treated mice 63 days post transplantation (Figure 4.5 A-C).  Human MSC 
therapy reduced lymphocyte infiltration and overall pathological score in the small 
intestine of cGvHD mice (Figure 4.6 A&B).  The administration of human MSC to 
cGvHD mice resulted in increased lymphocyte infiltration to the lungs, particularly 
around bronchi, and more profound airway epithelium thickening compared to non-
treated mice (Figure 4.6 A).  Human MSC therapy reduced the level of infiltrating 
lymphocytes around periportal areas in the livers of cGvHD mice (Figure 4.6 A).   
Human MSC significantly increased survival and reduced pathological score and 
weight loss during aGvHD (Figure 4.7).  Moreover, human MSC therapy significantly 
reduced pathology in the small intestine and provided protection from villous destruction 
when compared to non-treated mice (Figure 4.8 A&B).  In contrast to results presented 
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for syngeneic control mice and cGvHD mice, the administration of human MSC did not 
exacerbate lung pathology in aGvHD mice (Figure 4.8 A&B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
151 
 
 
 
 
 
 
 
CHAPTER 5 
 
HUMAN MSC SIGNIFICANTLY PROLONG SURVIVAL IN A 
HUMANISED MOUSE MODEL OF AGVHD 
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5.1 INTRODUCTION 
In the previous chapter, a number of limitations in the murine GvHD animal 
models were identified.  This study highlighted the importance of developing novel 
animal models of aGvHD to further extend the understanding of aGvHD and to elucidate 
how human MSC might control the disease progression.  The series of experiments 
conducted in chapter 4 demonstrated that human (xenogeneic) MSC therapies can be 
assessed in murine models of aGvHD, and provided a platform from which to investigate 
how human MSC modulate aGvHD.   However, the major limitations, which included an 
immune response against the human MSC and the fact that the effector cells are murine 
rather than human, led to the development of a more clinically relevant model of aGvHD. 
 The development of humanised mice has yielded exciting new methods of 
studying human haematopoiesis and immunity in vivo and over the last number of years 
the development of humanised mouse models of disease has grown substantially (Shultz 
et al. 2012).  Previous work within our research group has focussed on developing a 
robust and reproducible humanised mouse model of aGvHD by administering human 
PBMC to the NOD-SCID IL-2 receptor gamma null (NOD-SCID IL-2rγnull)(NSG) 
mouse, first developed by Pearson et al. (Pearson et al. 2008).  The NSG model of aGvHD 
offers a more clinically relevant model of disease than those developed in chapter 4 as 
the disease is triggered and sustained by human immune cells.  The development of this 
humanised mouse model of aGvHD allowed the identification that human MSC 
prolonged survival and reduced pathology of aGvHD mice through the inhibition of cell 
proliferation in vivo (Tobin et al. 2013).   
PBMC isolated from freshly drawn blood were used to establish the NSG model 
of a GvHD; however, the use of PBMC from freshly extracted blood is extremely limiting 
in the amount of cells which can be isolated and therefore impacting the scale of the 
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experiments possible.  Therefore, this chapter aimed to establish a consistent and 
reproducible humanised mouse model of aGvHD from PBMC isolated from buffy-packs.  
Isolating PBMC from buffy-packs provides significantly more PBMC and facilitates 
larger scale in vivo experiments to probe further into how MSC prolong the survival of 
aGvHD mice.  This chapter will then use the aGvHD model as a platform to test 
therapeutic interventions.  Specifically the efficacy of Fasciola hepatica tegumental 
antigen as a novel therapy against aGvHD will be investigated. 
 The objectives of this chapter were broken down as follows: 
(1) Develop a robust and reproducible humanised mouse model of acute GvHD 
using PBMC isolated from buffy-packs. 
(2) Identify potential mechanisms behind MSC protection against aGvHD. 
(3) Determine whether the administration of γMSC therapy was more efficient 
than resting MSC therapy on day 7. 
(4) Investigate whether multiple dose MSC therapy is more efficacious than 
single dose therapy.  
(5) Utilise the humanised mouse model of aGvHD as a platform to test a novel 
immunomodulatory therapy (Fasciola hepatica). 
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5.2 OPTIMISATION OF THE HUMANISED MOUSE MODEL OF AGVHD USING BUFFY PACK 
DERIVED LYMPHOCYTES 
 Previous work from our research group had developed a humanised mouse model 
of GvHD using PBMC isolated from freshly drawn blood (Tobin et al. 2013) from the 
protocol originally described by Pearson et al. (2008).  The main limiting factor with 
these studies was the number of PBMC which could be recovered from freshly isolated 
blood.  Therefore this study sought to advance this model to allow larger scale in vivo 
experiments.  It was hypothesised that PBMC isolated from buffy-packs would be capable 
of provoking aGvHD in irradiated NSG mice.  Using the studies by Pearson et al. and 
Tobin et al. as guidelines, a humanised mouse model of aGvHD was developed.  This 
model is described in chapter 2.10.4.  Briefly, after conditioning by low dose whole body 
irradiation (2.4 Gy), human PBMC were injected via the tail vein and the progression of 
GvHD was monitored.  In accordance with the local ethical committee the development 
of GvHD was defined as total body weight loss of >20% of original starting weight with 
a series of clinical manifestations including posture, reduction in activity, fur condition 
and diarrhoea.  These parameters were scored as described in Table 4.1, where any mouse 
which fell below 80% of their starting body weight or accumulated a clinical score of 6 
or more was sacrificed humanely.   
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5.2.1 DETERMINATION OF OPTIMAL PBMC DOSE TO INDUCE AGVHD 
Pearson et al. suggest a total dose of 2 x 107 PBMC was sufficient for consistent 
development of aGvHD in a humanised mouse model (Pearson et al. 2008).  However, 
the previous work conducted by our research group had found that the administration of 
2 x 107 PBMC resulted in inconsistent aGvHD development and instead suggested a dose 
of 6.3 x 105 PBMC gram-1 from freshly drawn blood.  PBMC isolated from freshly drawn 
blood are more responsive than those isolated from buffy packs and therefore it was 
hypothesised that a higher dose would be required.  At the time of initial experiments in 
this model, the information on dose adjusted to mouse body weight was not available and 
so a total dose of 3 x 107 human PBMC was chosen to establish aGvHD in irradiated NSG 
mice.   
To investigate whether 3 x 107 PBMC would trigger aGvHD, NSG mice were 
sub-lethally irradiated (2.4 Gy) and transplanted with either 3 x 107 human PBMC or PBS 
via tail vein injections. The survival and percentage weight loss were monitored 
throughout the experiment.  The reproducibility of administering 3 x 107 PBMC was 
determined by examining the development of aGvHD using 4 different PBMC donors. 
Transplanted mice were monitored regularly and the development of aGvHD determined 
as described above (Table 4.1).  As expected, all irradiated mice which received PBS 
survived until the conclusion of the experiment (Figure 5.1 A).  PBS mice remained 
healthy and gained weight throughout the duration of the experiment (Figure 5.1 B).  The 
administration of 3 x 107 PBMC to irradiated NSG mice successfully established aGvHD 
in all mice.  However, administering 3 x 107 PBMC to irradiated NSG mice resulted in 
rapid and aggressive aGvHD symptoms.  Notably all the mice which received PBMC lost 
over 20% body weight by day 11 (Figure 5.1 B).  The aggressive nature of aGvHD 
induced by administering 3 x 107 PBMC was not suitable for future studies examining 
the effect of MSC therapy, suggesting that a lower PBMC dose was required. 
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While the work of Pearson et al. suggested a standard PBMC dose of 2 x 107 
PBMC per mouse, the model of aGvHD previously established in our research group was 
designed as an individual dose of 6.3 x 105 PBMC gram-1.  Therefore a similar approach 
was taken while optimising the dose of buffy pack PBMC and it was hypothesised that 
the administration of 8 x 105 PBMC gram-1 would consistently initiate aGvHD in 
irradiated NSG mice.  NSG mice were irradiated as before and were then injected with 8 
x 105 PBMC gram-1.  The consistency of GvHD development was determined using 
PBMC isolated from 4 different donors.  One group of irradiated mice received PBS to 
act as a control.  The mice were monitored and aGvHD determined as before.  Initial 
optimisation studies mice which had suffered over 20% weight loss or accumulated a total 
score greater than 6 (Table 4.1) were sacrificed humanely.  However, it was agreed with 
the NUIM ethics committee that in subsequent studies mice which had suffered over 15% 
weight loss over successive days or accumulated a score of 6 or more would be sacrificed. 
Control mice which received PBS in place of PBMC had a survival rate of 100% 
at the conclusion of the experiment (Figure 5.2 A).  The sub-lethal radiation dose 
administered as pre-conditioning regiment results in slight weight loss in all experimental 
groups (Figure 5.2 B); however PBS control mice remain asymptomatic and returned to 
their starting weight by day 28 (Figure 5.2 B).  Mice which received PBMC from 3 of the 
donors developed GvHD during the desired period.  aGvHD was established in these mice 
from day 10, as illustrated by the significant weight loss after this day, and all of the mice 
had succumbed to aGvHD by day 16 (Figure 5.2 A).  However, the establishment of 
aGvHD in mice which received PBMC from donor 007 was not as robust.  Weight loss 
was delayed in these mice and 50% survived until day 28 (Figure 5.2). These results 
suggest that the administration of 8 x 105 PBMC, isolated from buffy-packs, was capable 
of initiating aGvHD but the variation between human donors indicated that some PBMC 
donors or preparations might not be suitable. 
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Figure 5.1. 3 x 107 PBMC results in aggressive aGvHD.  Graphical representation of (A) survival and 
(B) percentage weight change of irradiated NSG mice which have received 3 x 107 human PBMC from 
donors 001 (blue), 002 (red), 003 (yellow), 004 (green) or PBS control mice (white). Transplanted mice 
were monitored every 2 days until day 9 and then every day for the duration of the experiment.  n = 6 mice 
per group.  Statistical analysis was carried out using the un-paired student t-test. 
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Figure 5.2. Administration of 8 x 105 PBMC gram-1 results in a reproducible model of aGvHD.  
Graphical representation of (A) survival and (B) percentage weight change of irradiated NSG mice which 
have received 8 x 105 human PBMC gram-1 from donors 005 (blue), 006 (red), 007 (yellow), 008 (green) 
or PBS control mice (white). Transplanted mice were monitored every 2 days until day 9 and then every 
day for the duration of the experiment.  n = 6 mice per group. Statistical analysis on survival curve was 
carried out using a Mantel-Cox test. * < 0.05. 
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5.2.2 OPTIMISING AGVHD MODEL FOR CRYOPRESERVED PBMC 
As highlighted from figure 5.2, the variability in PBMC responsiveness between 
donors can significantly impair the efficacy of this model.  Therefore it was hypothesised 
that a bank of responsive PBMC populations could be amassed and stored in liquid 
nitrogen.  PBMC were isolated from buffy packs as before and cryopreserved as described 
in chapter 2.3.4.  In order to create a bank of reactive PBMC, it was first necessary to 
determine whether PBMC recovered from cryopreservation were capable of consistently 
inducing aGvHD.  It was thought that PBMC recovered from liquid nitrogen storage 
would be less effective than freshly isolated PBMC and therefore higher doses were 
investigated.  NSG mice were irradiated as before and then received a total dose of 3 x 
107 thawed PBMC, 9.3 x 105 PBMC gram-1 or 1 x 106 PBMC gram-1.  Control mice were 
also established by administrating PBS to irradiated NSG mice.  Mice were monitored 
and aGvHD determined as previously described.  As before, mice which had suffered 
over 20% weight loss or accumulated a total score greater than 6 (Table 4.1) were 
sacrificed humanely. 
 Unlike the previous experiments, one of the PBS control mice began to lose 
weight and had to be sacrificed after 8 days of the study.  However, none of the remaining 
PBS mice displayed any aGvHD symptoms and all recovered to their starting weight by 
day 12.  When each irradiated mouse was given a total dose of 3 x 107 PBMC, aGvHD 
was established using both thawed PBMC donors; however the development of aGvHD 
was not consistent for the two donors. aGvHD mice which received PBMC from donor 
002 began to display pathological signs of GvHD early and all of these mice were 
sacrificed by day 11 (Figure 5.3 A).  Mice which received PBMC from donor 004 showed 
more delayed weight loss and the onset of aGvHD was more similar to the desired model 
of aGvHD (Figure 5.3).  These results suggested that tailoring the dose of thawed PBMC 
to each individual mouse may result in a more consistent model of aGvHD. 
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 The ability of 9.3 x 105 thawed PBMC gram-1 to establish aGvHD in irradiated 
NSG mice was subsequently investigated.  As seen with figure 5.3, variability between 
PBMC donors 002 and 004 resulted in differences in the development of aGvHD.  Mice 
which received PBMC from donor 002, demonstrated steady weight loss and aGvHD 
development between days 10 and 16; with 84% of mice being sacrificed by day 16 
(Figure 5.4 A).  However, mice which were given PBMC from donor 004 developed 
aGvHD later but did however display steady weight loss and all mice which received 
PBMC from donor 004 had to be sacrificed by day 28 (Figure 5.4 B).  These results 
suggested that administrating 9.3 x 105 thawed PBMC gram-1 was better than a total dose 
of 3 x 107 PBMC but might still be lower than optimal. 
 To determine the reliability of establishing aGvHD with 1 x 106 gram-1 thawed 
PBMC, PBMC were isolated from buffy-packs obtained from 4 different healthy donors. 
All PBS control mice survived until the conclusion of the experiment and steadily gained 
weight throughout the 28 days.  Similar to the results presented in figure 5.2, 3 of the 4 
PBMC donors generated aGvHD.  Mice which received PBMC from donors 001, 002 or 
004 all began to gradually lose weight between days 9 and 15 with all of the mice 
developing aGvHD and being sacrificed by day 18 (Figure 5.5 A).  The variability 
associated with human donors was again witnessed in mice which received PBMC from 
donor 003.  Administering 1 x 106 gram-1 thawed PBMC from donor 003 resulted in an 
overly aggressive form of aGvHD where mice rapidly lost weight and all mice from this 
group had to be sacrificed by day 11 (Figure 5.5).  These results indicate that it is possible 
to establish a robust and reproducible model of aGvHD from a frozen bank of responsive 
PBMC with a dose of 1 x 106 gram-1 PBMC. 
 
 
161 
 
 
 
Figure 5.3. Administration of 3 x 107 thawed PBMC resulted in inconsistent aGvHD development.  
Graphical representation of (A) survival and (B) percentage weight change of irradiated NSG mice which 
have received 3 x 107 thawed human PBMC from donors 002 (blue) or 004 (red).  PBS control mice are 
represented by white boxes. Transplanted mice were monitored every 2 days until day 9 and then every day 
for the duration of the experiment.  n = 6 mice per group.  Statistical analysis was performed using student 
t-test where *** < 0.001 between blue and red boxes. 
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Figure 5.4. aGvHD was less severe following administration of 9.3 x 105 thawed PBMC gram-1.  
Graphical representation of (A) survival and (B) percentage weight change of irradiated NSG mice which 
have received 9 x 105 thawed human PBMC gram-1 from donors 002 (blue) or 004 (red).  PBS control mice 
are represented by white boxes. Transplanted mice were monitored every 2 days until day 9 and then every 
day for the duration of the experiment.  n = 6 mice per group.   
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Figure 5.5. Administration of 1 x 106 thawed PBMC gram-1 results in a reproducible model of 
aGvHD.  Graphical representation of (A) survival and (B) percentage weight change of irradiated NSG 
mice which have received 1 x 106 human PBMC gram-1 from donors 001 (blue), 002 (red), 003 (yellow) or 
004 (green).  PBS control mice are represented by white boxes. Transplanted mice were monitored every 2 
days until day 9 and then every day for the duration of the experiment.  n = 6 mice per group.  
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5.2.3 OPTIMISATION OF BUSULFAN AS A CONDITIONING AGENT FOR AGVHD MODEL 
Other research groups which have utilised the NSG mouse for models of aGvHD, 
have administered human PBMC without the use of a pre-conditioning regimen.  These 
models of GvHD require the administration of 6 x 107 PBMC and can take up to 30 days 
before the mice developed GvHD (Hippen et al. 2012).  The development of sub-lethal 
whole body irradiation (2.4 Gy) as a pre-conditioning regimen in this study significantly 
reduces the amount of PBMC required as well as shortening the duration of the 
experiment.  However, future collaborative projects required a chemical pre-conditioning 
regimen and therefore the potential use of the chemotherapeutic agent Busulfan as a pre-
conditioning agent was investigated.  Busulfan was administered by I.P. injection (25 
mg/kg) in two doses, on day -2 and day -1.  A separate group of mice were irradiated on 
day 0 as before.  Mice which received Busulfan or irradiation then received 8 x 105 PBMC 
gram-1 via tail vein injection.  Control groups of mice pre-conditioned with Busulfan or 
irradiation were also given sterile PBS. The mice were monitored and aGvHD determined 
as before where mice which had suffered over 20% weight loss or accumulated a total 
score greater than 6 (Table 4.1) were sacrificed humanely. 
 There was one irradiated PBS control mouse which had to be sacrificed in the first 
few days of the study.  This was due to the mouse not moving around the cage or 
responding to stimuli and did not seem related to aGvHD but most likely to the 
manipulation of the tail during the administration of agents.  Pre-conditioning of NSG 
mice with Busulfan prior to PBMC administration resulted in a very similar survival curve 
to mice which were pre-conditioned with irradiation (Figure 5.6 A).  However, mice 
which were pre-conditioned with Busulfan appeared to be ill for a number of days after 
receiving Busulfan.  This was illustrated by the significantly higher weight loss in 
Busulfan treated mice on day 1 compared to irradiated mice (Figure 5.6 B).  However, 
Busulfan treated mice recovered their weight loss and were very similar to irradiated mice 
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between days 3 and 9.  Mice which received irradiation appeared to develop GvHD 
slightly earlier and had significantly higher weight loss on days 10 and 11 (Figure 5.6 B).  
Despite this, there was no difference in survival between mice which received Busulfan 
and mice which were irradiated suggesting that the chemical pre-conditioning of NSG 
mice with Busulfan could provide a viable alternative to irradiation.  Hereafter the dose 
of PBMC from buffy packs derived from a single donor of 8 x 105 PBMC gram-1 was 
used as the most reliable protocol for further study. 
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Figure 5.6. Pre-conditioning with Busulfan is comparable to irradiation in the humanised mouse 
model of aGvHD.  Graphical representation of (A) survival and (B) percentage weight change of irradiated 
NSG mice which have received 8 x 105 human PBMC gram-1 from after 25 mg/kg Busulfan on day -2 and 
day -1 (blue boxes) or irradiation on day 0 (red circles).  PBS control mice which received 25 mg/kg 
Busulfan on day -2 and day -1 are represented by white boxes while PBS mice which received irradiation 
on day 0 are represented by yellow circles. Transplanted mice were monitored every 2 days until day 9 and 
then every day for the duration of the experiment.  Graph represents 2 PBMC donors with n = 6 mice per 
donor.  Statistical analysis was carried out using the un-paired student t-test where * < 0.05, ** < 0.01 and 
*** < 0.001.
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5.3 HUMAN MSC SIGNIFICANTLY INCREASED SURVIVAL AND REDUCED WEIGHT LOSS 
OF AGVHD MICE 
Following optimisation of the model, this study sought to determine whether 
human MSC suppressed acute GvHD in this model.  PBMC were isolated from buffy-
packs and administered to irradiated (2.4 Gy) NSG mice via tail vein injection (8x105 
PBMC gram-1).  Control groups were also established by administrating sterile PBS to 
irradiated NSG mice.  All mice were monitored on a regular basis and the development 
of GvHD was defined as previously described (Table 4.1).  Mice which received a 
combined pathological score higher than 6 or displayed weight loss in excess of 15% 
were considered to have severe GvHD and sacrificed humanely (in accordance with local 
ethics committee recommendations at NUI Maynooth). 
After PBMC administration, the survival and weight loss of each mouse was 
monitored every 2 days until day 9 and then every day for the duration of the experiment 
(Figure 5.7).  As expected, the administration of PBS to irradiated NSG mice had no 
effect on survival and did not result in any weight loss of PBS mice (Figure 5.8 A).  NSG 
mice which received PBMC developed acute GvHD with only 10% surviving until day 
15 and none surviving past day 19 (Figure 5.8 A).  The administration of MSC therapy to 
PBMC mice on day 7 significantly prolonged the survival of aGvHD mice with 50% of 
mice surviving past day 15 and 26% of MSC treated mice surviving the duration of the 
experiment (Figure 5.8 A). aGvHD mice which received MSC therapy also displayed 
significantly less weight loss between days 14 and 20 (Figure 5.8 B).  After day 20 
however, the difference in weight loss was no longer significant and all MSC treated mice 
demonstrated signs of developing aGvHD by day 22 (Figure 5.8 B).   
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Figure 5.7. Development of a humanised mouse model of aGvHD.  NOD-SCID IL-2rγnull (NSG) mice 
were exposed to a sub-lethal dose of gamma irradiation (2.4 Gy).  8 x 105 PBMC gram-1 or sterile PBS was 
then administered intravenously (300 µl) to each mouse via the tail vein.  Mesenchymal stromal cells (6.4 
x 104 gram-1) were administered intravenously on day 7.  The development of aGvHD was monitored every 
second day until day 9 and then everyday thereafter by recording weight loss, fur texture, posture, activity 
and diarrhoea. 
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Figure 5.8. MSC significantly prolong survival and reduce weight loss in aGvHD mice. (A) survival 
curve, and  (B) percentage weight change of aGvHD mice (blue line) and MSC treated aGvHD mice (red 
line).  PBS control mice are represented by the yellow line.  8 x 105 human PBMC gram-1 were administered 
to irradiated NSG mice (2.4 Gy).  6.4 x 104 human MSC gram-1 were given as cell therapy on day 7.   
Transplanted mice were monitored every 2 days until day 9 and then every day for the duration of the 
experiment. n=29 for PBMC mice, n=23 for PBMC + MSC mice and n=10 for PBS mice.  Statistical 
analysis was carried out using a Mantel-Cox test for the survival curve and un-paired student t-test for 
weight change where * < 0.05 and *** < 0.001. 
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5.4 ADMINISTRATION OF HUMAN MSC DID NOT REDUCE THE ENGRAFTMENT OF PBMC 
The administration of MSC to acute GvHD mice resulted in significantly 
prolonged survival, reduced weight loss and lower pathological scores.  However, GvHD 
mice which received MSC eventually developed typical acute GvHD symptoms from 16 
days post transplantation and most of these mice developed GvHD by the end of the study.  
The engraftment of transplanted HSC is essential for the recovery of HSCT patients after 
transplantation and novel cell therapies designed to control aGvHD should not impair this 
process.  To examine whether the increased survival observed in MSC treated aGvHD 
mice (Figure 5.8) was associated with impaired PBMC engraftment, irradiated NSG mice 
were given PBMC (8 x 105 gram-1) and treated with MSC 7 days later.  On day 12, mice 
were sacrificed and the engraftment of human CD45+ lymphocytes in the spleen was 
determined by flow cytometry (Figure 5.9).  The engraftment of human CD45+ 
lymphocytes was unaffected by MSC therapy (Figure 5.10 A).  Neither the percentages 
nor total numbers of human CD45+ lymphocytes recovered from the spleens of aGvHD 
mice were reduced in mice which had received MSC therapy. 
Although antigen presenting cells (APC) have previously been reported to be 
essential in the development of GvHD, recent studies have indicated that T cells are the 
main drivers of GvHD pathology (Li et al. 2012).  Therefore the effect of MSC on the 
engraftment of CD4+, CD8+ and CD4+CD8+ cells was investigated.  Live cells were gated 
for human CD45 and the expression of human CD4+, CD8+ or CD4+CD8+ was 
determined.  There was no difference in the percentage of human CD4+, CD8+ or 
CD4+CD8+ populations in the spleens of aGvHD mice after MSC treatment (Figure 5.10 
B).  Interestingly, the total number of human CD45+CD4+ cells was significantly higher 
when aGvHD mice received MSC compared to mice that received PBMC alone (Figure 
5.10 B).  Total numbers of human CD8+ and CD4+CD8+ cell populations were unaffected 
by MSC therapy. 
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Figure 5.9: Representative example of gating strategies used to define human CD4+ and CD8+ T cells 
from the tissues of GvHD mice. (A) Illustrates the gated lymphocyte population from SSC against FSC 
plot,  (B) represents the gating position for human CD45+ (APC) expression within the CD4+ lymphocyte 
population and (C) illustrates the gating position for CD4 (FITC) and CD8 (PE) expression within the 
CD45+ population. All gating positions were determined using matching isotype controls. 
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Figure 5.10. MSC did not impair the engraftment of human lymphocytes in the spleens of aGvHD 
mice.  NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 per gram-1) via tail 
vein injection were analysed on day 12 by flow cytometry.  (A) Analysis of the percentage of human CD45+ 
lymphocytes recovered from the spleen of aGvHD mice using 2 different PBMC donors with 2 different 
MSC donors (n=6 for each). (B) The total number of human CD45+ lymphocytes recovered from the spleens 
of aGvHD mice using 2 different PBMC donors with 2 different MSC donors (n=6 for each). (C) The 
percentage of human CD4+, CD8+ or CD4+CD8+ cells recovered from the spleens of aGvHD mice using 2 
different PBMC donors with 2 different MSC donors (n=6 for each).  (D) The total cell number of human 
CD4+, CD8+ or CD4+CD8+ cells recovered from the spleens of aGvHD mice using 2 different PBMC donors 
with 2 different MSC donors (n=6 for each).  Non-treated aGvHD mice are represented by white bars and 
aGvHD mice which received MSC therapy are represented by black bars. The total number of human 
lymphocytes was assessed using counting beads during flow cytometry. Statistical significance was 
determined using student t-test where * < 0.05. 
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5.5. HUMAN MSC THERAPY DID NOT PREVENT THE ENGRAFTMENT OF PBMC IN THE 
LIVER OR LUNGS OF AGVHD MICE 
 GvHD is characterised by the infiltration of effector lymphocytes and subsequent 
destruction of specific target organs including the liver and the lungs.  Therefore, the 
ability of MSC to prevent the migration of effector T cells to these organs was identified 
as a possible mechanism by which they prolonged survival of aGvHD mice (Figure 5.8).  
To examine this hypothesis, it was necessary to develop a method of recovering 
comparatively pure human lymphocyte populations from the tissues of aGvHD mice.  As 
described in detail in Chapter 2, the liver and lungs of aGvHD mice were harvested under 
sterile conditions and mechanically digested.  Human lymphocytes were isolated using 
density gradient centrifugation and examined for the expression of human CD45, CD4 
and CD8 by flow cytometry using the gating strategy illustrated in figure 5.9. 
The administration of MSC therapy had no significant effect on the percentages 
or total number of human CD45+, CD4+, CD8+ or CD4+CD8+ cells recovered from the 
liver of aGvHD mice, 12 days after PBMC transplantation (Figure 5.11 A & B). The 
engraftment of human lymphocytes in the lungs of aGvHD mice was also unaffected by 
the administration of MSC therapy.  There was a slight increase in the total number of 
human CD45+ and CD4+ lymphocytes recovered from the lungs of aGvHD mice (Figure 
5.11 C & D).   However, these increases were not significant.  These results suggest that 
MSC therapy does not impair the engraftment of human lymphocytes in the lungs or livers 
of aGvHD mice. 
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Figure 5.11. MSC did not inhibit the engraftment of human lymphocytes in the liver or lungs of 
aGvHD mice. NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 per gram-
1) via tail vein injection were analysed on day 12 by flow cytometry.  (A) Analysis of the percentage of 
human CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the liver of aGvHD mice using 
2 different PBMC donors with 2 different MSC donors (n=6 for each). (B) The total number of human 
CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the liver of aGvHD mice using 2 
different PBMC donors with 2 different MSC donors (n=6 for each).  (C) Analysis of the percentage of 
human CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the lungs of aGvHD mice using 
2 different PBMC donors with 2 different MSC donors (n=6 for each). (D) The total number of human 
CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the lungs of aGvHD mice using 2 
different PBMC donors with 2 different MSC donors (n=6 for each).  Non-treated aGvHD mice are 
represented by white bars and aGvHD mice which received MSC therapy are represented by black bars. 
The total number of human lymphocytes were assessed using counting beads during flow cytometry. 
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5.6. MSC DID NOT PREVENT T CELL POLARISATION TO EFFECTOR OR MEMORY T CELL 
PHENOTYPES 
 The phenotypic characterisation of naïve, central (Tcm) and effector memory 
(Tem) T cell populations from post-BMT patients can provide valuable information and 
help to define the immunological basis of GvHD (Ali et al. 2012).  The characterisation 
of these T cell sub-populations is essential in understanding the nature of the immune 
response associated with xenogeneic models of GvHD and may help to further understand 
the immune response in GvHD patients.  It was hypothesised that the prolonged survival 
of aGvHD mice which received MSC therapy may be caused by impaired polarisation to 
effector T cell populations. Anti-human CD45RO, CD27 and CD62L antibodies were 
combined with either anti-human CD4 or CD8 antibodies to characterise naïve (CD45RO-
CD27+), central memory (CD45RO+CD27+CD62L+) or effector memory 
(CD45RO+CD27+CD62L-) T cell populations within CD4+ populations in the spleen, 
liver and lung.  Representative example of gating strategies used to define T cell subsets 
from murine tissues are shown in figure 5.12. 
 The administration of MSC, 7 days after PBMC injection, had no effect on the 
presence of effector or memory T cells within the spleens (Figure 5.13 A & B), livers 
(Figure 5.13 C & D) or lungs (Figure 5.13 E & F) of aGvHD mice.  The percentages and 
total numbers of naïve, Tcm and Tem human CD4+ cells were unaffected by the 
administration of MSC therapy in each of the organs tested.  These results suggest that 
the increased survival observed in MSC treated aGvHD mice was not mediated by 
preventing the development of CD4+ Tem or the ability of these cells to migrate to target 
organs. 
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Figure 5.12: Representative example of gating strategies used to define human Tem and Tcm subsets 
from the tissues of aGvHD mice. (a) illustrates the gating position for human CD4+ (PercP) expression,  
(b) represents the gating position for human CD45RO+ (APC) expression within the CD4+ population and 
(c) illustrates the gating position for CD27 (FITC) and CD62L (PE) expression within the CD4+CD45RO+ 
population. All gating positions were determined using matching isotype controls. 
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Figure 5.13. MSC do not reduce the percentage or number of activated (CD45RO+), naïve (CD45RO-
), Tem (CD45RO+CD27+) and Tcm (CD45RO+CD27+CD62L+) human CD4+ T cells in acute GvHD 
mice.  NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 per gram-1) via tail 
vein injection were analysed on day 12 by flow cytometry.  Graphical representation of the percentage of 
activated, naïve, Tem and Tcm CD4+ cells recovered from the spleen (A), livers (C) and lungs (E) of non-
treated aGvHD mice (white bar) or aGvHD mice which received MSC therapy (black bar).  Accumulated 
data illustrating the total number of activated, naïve, Tem and Tcm CD4+ cells recovered from the spleen 
(B), livers (D) and lungs (F) of non-treated aGvHD mice or aGvHD mice which received MSC therapy.  
n=6 per group (2 PBMC donors with 2 MSC donors).  The total number of human CD45+ lymphocytes 
was assessed using counting beads via flow cytometry. 
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5.7. MSC THERAPY DID NOT REDUCE LEVELS OF PRO-INFLAMMATORY CYTOKINES IL-
2, IFN-γ OR IL-1 IN AGVHD MICE 
 Acute GvHD is a systemic disorder driven by the recognition of patient HLA by 
the transplanted graft.  One of the key drivers of pathology is the production of pro-
inflammatory cytokines such as IL-1β, IFN-γ and IL-2.  Therefore, it was hypothesised 
that the reduced mortality observed in aGvHD mice which received human MSC (Figure 
5.8) may be a result of impaired human IL-2, IFN-γ or IL-1β production by human T cells 
after MSC therapy.  The levels of circulating human IFN-γ, IL-2 and IL-1β were analysed 
from serum samples obtained through facial bleeds taken from aGvHD mice 12 days after 
transplantation and analysed by bead array cytokine assay or ELISA.  The ability of 
human CD4+ and CD8+ T cells to produce IFN-γ or IL-2 was also determined using intra-
cellular cytokine staining and analysed by flow cytometry. 
Contrary to the hypothesis, the administration of human MSC to aGvHD mice had 
no effect on the serum levels of human IL-1β on day 12, as measured by ELISA (Figure 
5.14).  MSC therapy, administered 7 days after PBMC administration, did not reduce the 
levels of circulating human IL-1β when compared to aGvHD mice which received no cell 
therapy (Figure 5.14). 
Surprisingly, aGvHD mice which received human MSC therapy on day 7 had 
enhanced serum levels of human IFN-γ compared to aGvHD mice which did not receive 
MSC (Figure 5.15 A).  In fact the total number of IFN-γ producing CD4+ cells in the 
spleen of aGvHD mice was slightly increased after MSC therapy (Figure 5.15 B); 
however the total number of CD8+ T cells producing IFN-γ was significantly lowered 
after MSC administration (Figure 5.15 C).  
The level of circulating IL-2 was also unaffected by the administration of human 
MSC therapy when compared to non-treated aGvHD (Figure 5.16 A).  MSC therapy 
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resulted in a slight increase in the total number of human IL-2 producing CD4+ and CD8+ 
T cells recovered from the spleens of aGvHD mice (Figure 5.16 B & C).  However, these 
increases were not significant.   
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Figure 5.14. Human MSC therapy had no effect on levels of human IL-1β in the serum of aGvHD 
mice.  NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 gram-1) via tail 
vein injection.  On day 12, post transplantation, facial bleeds were performed on PBS control mice (not 
detected), aGvHD mice (white bar) and aGvHD mice which received MSC therapy (black bar) and the 
presence of human IL-1β was determined using ELISA. n=20 per group (4 PBMC donors).  Statistical 
significance was analysed using Student t test. 
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Figure 5.15. Human MSC therapy did not reduce the levels of IFN-γ in the serum of aGvHD mice.  
NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 gram-1) via tail vein 
injection.  On day 12, post transplantation, facial bleeds were performed on PBS control mice (not detected), 
aGvHD mice (white bar) and aGvHD mice which received MSC therapy (black bar). (A) The total level of 
circulating human IFN-γ was analysed in the serum of aGvHD mice using ELISA. n=20 per group (4 PBMC 
donors).  The total number of human IFN-γ producing CD4+ (B) and CD8+ (C) T cells was determined from 
the spleens of aGvHD by intra-cellular flow cytometry. n=4 for (B) and (C). Statistical significance was 
analysed using student t-test where * < 0.05. 
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Figure 5.16. Human MSC therapy did not reduce the levels of IL-2 in the serum of aGvHD mice.  
NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 gram-1) via tail vein 
injection.  On day 12, post transplantation, facial bleeds were performed on PBS control mice (not detected), 
aGvHD mice (white bar) and aGvHD mice which received MSC therapy (black bar). (A) The total level of 
circulating human IL-2 was analysed in the serum of aGvHD mice using ELISA. n=20 per group (4 PBMC 
donors).  The total number of human IL-2 producing CD4+ (B) and CD8+ (C) T cells was determined from 
the spleens of aGvHD by intra-cellular flow cytometry. n=4 for (B) and (C). Statistical significance was 
analysed using student t-test. 
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5.8. MSC SIGNIFICANTLY REDUCED TNF-α PRODUCING T CELLS 
 The role of TNF-α as one of the main drivers of pathogenesis in aGvHD has been 
well characterised (Ferrara et al. 2009).  The ability of human MSC to prevent the 
development of human TNF-α producing CD4+ and CD8+ T cells during aGvHD was 
analysed in the spleens of aGvHD mice using intra-cellular flow cytometry.  The effect 
of MSC therapy on the ability of human TNF-α producing T cells to engraft in the liver 
or lungs of aGvHD mice was also investigated. 
 Human CD4+ and CD8+ T cells were recovered from the spleens of both MSC 
treated and non-treated aGvHD mice 12 days after PBMC administration.  The potential 
for TNF-α production was investigated in these cells via intra-cellular flow cytometry.  
As hypothesised, MSC therapy significantly reduced the total number of human TNF-α 
producing CD4+ and CD8+ T cells in the spleens of aGvHD mice (Figure 5.17 B).  In 
addition to this, the ability of human TNF-α producing T cells within the liver and lungs 
of aGvHD mice was also investigated.  As hypothesised, human TNF-α producing CD4+ 
and CD8+ T cells were observed in both the liver and lungs of aGvHD mice.  Interestingly, 
the administration of human MSC therapy significantly reduced the total number of TNF-
α producing CD4+ and CD8+ T cells in the lungs, but not the liver of aGvHD mice (Figure 
5.18).  These results suggest that MSC therapy protection against mortality in aGvHD 
mice may involve the reduction of TNF-α production. 
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Figure 5.17. MSC significantly reduced the total number of human TNF-α producing CD4+ and CD8+ 
T cells in the spleens of aGvHD mice.  NSG mice were sub-lethally irradiated (2.4 Gy) and given PBMC 
(8x105 gram-1) via tail vein injection were analysed on day 12 by intra-cellular flow cytometry.  Graphical 
representation of the percentage of human TNF-α, producing CD4+ T and CD8+ T cells recovered from the 
spleen (A). Accumulated data for total cell number of human TNF-α producing CD4+ T and CD8+ T cells 
recovered from the spleen (B).  n=6 per group (2 PBMC donor with 2 MSC donors). White bars represent 
non-treated aGvHD mice while black bars represent aGvHD mice which have received MSC therapy.  The 
total number of human lymphocytes was assessed using counting beads during flow cytometry. Statistical 
significance was determined using student t-test where * < 0.05. 
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Figure 5.18. MSC reduced the total number of TNF-α producing CD4+ and CD8+ T cells in the livers 
and lungs of aGvHD mice. NSG mice were sub-lethally irradiated (2.4 Gy) and given PBMC (8x105 gram-
1) via tail vein injection were analysed on day 12 by intra-cellular flow cytometry.  Graphical representation 
of the percentage of human TNF-α, producing CD4+ T and CD8+ T cells recovered from the liver (A) and 
the lungs (C) of aGvHD mice. Accumulated data for total cell number of human TNF-α producing CD4+ T 
and CD8+ T cells recovered from the liver (B) and lungs (D) of aGvHD mice.  n=6 per group (2 PBMC 
donor with 2 MSC donors).  White bars represent non-treated aGvHD mice while black bars represent 
aGvHD mice which have received MSC therapy. The total number of human lymphocytes was assessed 
using counting beads during flow cytometry. Statistical significance was determined using student t-test 
where * < 0.05. 
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5.9. MSC THERAPY SIGNIFICANTLY INCREASED REGULATORY T CELLS DURING 
AGVHD 
 Regulatory T cells (Treg) are potent regulators of the immune system and their 
potential to control aGvHD is one of the main methods of treatment currently being 
investigated.  Previous work from our research group had published that Treg cells did 
not engraft in the NSG model of aGvHD (Tobin et al. 2013).  However, the work carried 
out in the present study utilised a more sensitive method of recovering human 
lymphocytes from murine tissue.  This resulted in a purer cell population with less non-
specific background which allowed the detection of human Treg cells in the spleens, 
livers and lungs of aGvHD mice.  Therefore the ability for human MSC therapy to 
modulate Treg cells during aGvHD was investigated under the hypothesis that MSC 
increase the survival of aGvHD in part due to the induction, expansion or maintenance of 
Treg cells. 
 MSC treated and non-treated aGvHD mice were sacrificed on day 12 and the 
spleens, lungs and livers harvested under sterile conditions.  Human Treg cells were 
defined as human CD4+CD25+FoxP3+ and determined by intra-cellular flow cytometry.  
Very small populations of Treg cells were recovered from the spleens of GvHD mice 
which had not received MSC therapy; however the administration of human MSC on day 
7 resulted in a significant increase in the total number of Treg cells recovered from the 
spleen of aGvHD mice (Figure 5.19 B).  Interestingly, the total number of human Treg 
cells was also significantly increased in the lungs and livers of aGvHD mice which 
received human MSC therapy (Figure 5.19 D & F).  These results suggest that MSC 
therapy results in increased Treg cells during aGvHD and that these Treg cells are capable 
of engrafting within areas of inflammation associated with GvHD. 
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Figure 5.19. MSC therapy significantly increased the number of Treg cells during aGvHD. NSG mice 
were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 gram-1) via tail vein injection were analysed 
on day 12 by intra-cellular flow cytometry.  Graphical representation of the Treg cells recovered from the 
spleen (A), liver (C) and lung (E) from non-treated aGvHD mice (white bar) or aGvHD mice which received 
MSC therapy (black bar) mice.  Accumulated data for total cell number of Treg cells recovered from the 
spleen (B), liver (D) and lung (F).  n=6 per group (2 PBMC donor with 2 MSC donors). The total number 
of human lymphocytes was assessed using counting beads during flow cytometry. Statistical significance 
was determined using student t-test where * < 0.05, ** <0.005. 
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5.10. MSC PRESERVE REGULATORY T CELLS RATHER THAN INDUCE OR ENHANCE THEM 
IN VITRO 
 Treg cells are potent mediators of the immune response and the significant 
increase in the number of Treg cells observed after MSC therapy offers a potential 
mechanism by which MSC therapy prolongs survival in aGvHD mice.  However, the 
mechanism behind how MSC generate Treg cells remains a contentious issue. A number 
of in vitro experiments were designed to try to shed some light on how MSC increase 
Treg cells in vivo.  Some research groups have published data suggesting that MSC can 
directly induce the polarisation of naïve CD4+ T cells into Treg cells.  Other research 
groups, including our own, have published data which suggests that MSC do not induce 
but expand resident Treg populations.  However, a third method by which MSC generate 
Treg cells may be by promoting the survival of resident Treg populations.  To determine 
whether MSC induced or expanded Treg populations, PBMC were isolated from buffy-
packs and sorted into CD4+CD25+ or CD4+CD25- populations using a BD FACS Aria 
cell sorter under the premise that resident Treg cells should be contained in the 
CD4+CD25+ T cell population.  Both populations of cells were then cultured with or 
without MSC for 72 hours and the presence of Treg cells was then analysed by flow 
cytometry.  Treg cells were defined as CD4+CD25+FoxP3+ cells. 
 The number of CD4+CD25+FoxP3+ cells recovered from the CD4+CD25- 
population after 72 hours was very low and culturing CD4+CD25- cells in the presence of 
MSC did not increase the number of CD4+CD25+FoxP3+ cells (Figure 5.20).  This result 
suggests that MSC were not capable of inducing Treg populations from CD4+CD25- cell 
populations.  After 72 hours, the number of CD4+CD25+FoxP3+ cells recovered from the 
CD4+CD25+ population was much higher.  In addition, culturing CD4+CD25+ cells in the 
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presence of MSC enhanced the total number of CD4+CD25+FoxP3+ cells (Figure 5.20).  
These results suggested that MSC were not capable of inducing Treg populations but this 
approach in isolation could not distinguish whether MSC were enhancing or preserving 
the residual Treg population.  Therefore, the proliferation marker KI-67 was used to 
determine whether Treg cells were actively expanding when cultured in the presence of 
MSC (Figure 5.21).  For this experiment, CD4+ T cells were isolated from whole PBMC 
using MACS beads (Miltenyi Biotec).  Isolated CD4+ T cells were then cultured with or 
without MSC for 72 hours.  Treg cells were defined as CD4+CD25+FoxP3+ cells and the 
proliferation marker KI-67 was used to distinguish expanding cells from resting cells.  As 
expected isolated CD4+ T cells cultured without stimulus did not express the proliferation 
marker KI-67 after 72 hours (Figure 5.22 B).  When CD4+ T cells were cultured in the 
presence of MSC there was indeed a significant increase in the total number of Treg cells 
compared to CD4+ T cells cultured alone (Figure 5.22 A); however Treg cells cultured in 
the presence of MSC did not express the proliferation marker KI-67 (Figure 5.22 C & D).  
Taken together, these results suggest that MSC did not induce or expand Treg populations 
and that the increase in number of Treg cells was due to MSC preserving the original Treg 
population. 
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Figure 5.20. MSC did not induce Treg cells from CD4+CD25- populations.  PBMC were isolated from 
buffy packs and sorted into CD4+CD25- or CD4+CD25+ populations using FACS Aria cell sorter.  
CD4+CD25- or CD4+CD25+ cells were cultured in the presence or absence of MSC (3 PBMC: 1 MSC) for 
72 hours.  The total number of Treg cells was determined using flow cytometry. n=4 PBMC donors with 2 
MSC donors. White bars represent T cell populations cultured alone while black bars represent T cell 
populations cultured in the presence of human MSC.  The total number of human lymphocytes was assessed 
using counting beads during flow cytometry. 
 
 
 
 
191 
 
 
 
Figure 5.21. Representative image of KI-67 antibody optimisation. PBMC were isolated from buffy 
packs and CD4+ T cells were purified using MACS beads.  CD4+ T cells were cultured in the presence or 
absence of T cell activating beads and the expression of KI-67 was determined using flow cytometry. 
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Figure 5.22. MSC co-culture did not result in the expansion of Treg cells.  PBMC were isolated from 
buffy packs and CD4+ T cells were purified using MACS beads.  CD4+ T cells were cultured in the presence 
or absence of MSC (3 PBMC: 1 MSC) for 72 hours.  (A) The total number of Treg cells recovered from 
co-culture was determined using flow cytometry.  Treg cells were characterised as CD4+CD25+FoxP3+ 
and the expression of KI-67 was determined on CD4+ T cells alone (B) and CD4+ T cells co-cultured with 
two different MSC donors (C) and (D).  n=4 per group (2 PBMC donor with 2 MSC donors). The total 
number of human lymphocytes was assessed using counting beads during flow cytometry. Statistical 
significance was determined using student t-test where * < 0.05. 
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5.11. MSC INCREASED INKT CELL POPULATIONS DURING AGVHD 
 Invariant natural killer T (iNKT) cells are a very rare auto-reactive CD1d 
restricted T cell sub-population characterised by the expression of an invariant T cell 
receptor alpha chain (Vα24-Jα18) (Montoya et al. 2007).  The ability of iNKT cells to 
modulate their micro-environment and interact with a wide range of immune cells has 
resulted in their association with a number of diseases including aGvHD (Schneidawind 
et al. 2014).  Recent analysis of patient data has suggested that the post-transplant 
recovery of iNKT cells correlates with a lower risk of aGvHD development (Rubio et al. 
2012).  Therefore it was hypothesised that the administration of human MSC therapy 
resulted in increased engraftment of iNKT cells during aGvHD.  To examine this 
hypothesis, aGvHD mice were sacrificed on day 12 and the spleens, livers and lungs were 
harvested under sterile conditions.  Human lymphocytes were isolated as described in 
section 2 and iNKT cells were characterised as human CD3+Vα24-Jα18+ by flow 
cytometry.   
 The administration of human MSC therapy resulted in a significantly higher 
percentage of human CD3+Vα24-Jα18+ lymphocytes in the spleens of aGvHD mice.  
There was no difference in the percentage of human CD3+Vα24-Jα18+ recovered from the 
livers of aGvHD after MSC therapy; however the percentage of human CD3+Vα24-Jα18+ 
cells was significantly increased in the spleens of aGvHD mice which received MSC 
therapy (Figure 5.23 A).  There was also a slight, but not significant, increase in the 
percentage of human CD3+Vα24-Jα18+ cells recovered from the lungs of aGvHD mice 
which received MSC therapy (Figure 5.23 C).  These results suggest that human MSC 
therapy may have a beneficial effect on the post-transplant engraftment of donor iNKT 
cells in the spleen. 
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Figure 5.23. MSC therapy resulted in increased iNKT populations during aGvHD.  NSG mice which 
were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 per gram-1) via tail vein injection were 
analysed on day 12 by flow cytometry.  iNKT cells were characterised as CD3+Vα24-Jα18+ using flow 
cytometry.  Graphical representation of the percentage of iNKT cells recovered from the spleen (A), livers 
(B) and lungs (C) of non-treated aGvHD mice (white bar) or aGvHD mice which received MSC therapy 
(black bar).  n=4 per group (2 PBMC donors with 1 MSC donors).  The total number of human lymphocytes 
was assessed using counting beads via flow cytometry.  Statistical significance was determined using 
student t-test where ** < 0.01. 
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5.12. THE ADMINISTRATION OF IFN-γ STIMULATED MSC ON DAY 7 DID NOT FURTHER 
IMPROVE SURVIVAL OF AGVHD MICE COMPARED TO THE ADMINISTRATION OF 
RESTING MSC. 
 As mentioned before, previous research from our laboratory has demonstrated that 
the administration of IFN-γ stimulated MSC (γMSC) on day 0 resulted in increased 
survival and reduced pathology of aGvHD mice while the administration of resting MSC 
on day 0 did not protect against aGvHD.  Therefore this study investigated whether 
administering γMSC on day 7 would demonstrate increased efficacy compared to resting 
MSC.  
NSG mice were irradiated and PBMC were administered as before.  MSC or 
γMSC therapies were then administered 7 days later and the survival and weight loss of 
mice was monitored (Figure 5.24).  NSG mice which received human MSC demonstrated 
significantly higher survival and lower weight loss compared to non-treated mice.  Mice 
which received γMSC therapy also demonstrated significantly higher survival and lower 
weight loss than non-treated mice (Figure 5.25). However, the use of γMSC therapy did 
not significantly prolong survival or prevent weight loss compared to resting MSC 
therapy (Figure 5.25). 
As previously demonstrated, the administration of human MSC therapy on day 7 
did not reduce T cell engraftment within GvHD mice.  However, γMSC are more potent 
regulators of T cell proliferation and therefore the effect of γMSC, on day 7, on T cell 
engraftment in target organs was also investigated.  The administration of resting MSC 
therapy on day 7 did not inhibit T cell engraftment as measured by the total number of 
CD4+ and CD8+ cells recovered from the spleens of GvHD mice (Figure 5.26 A).  γMSC 
therapy on day 7 also did not inhibit the engraftment of CD4+ or CD8+ T cells in the 
spleens of GvHD mice (Figure 5.26 A).  The ability of γMSC to prevent the migration of 
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CD4+ or CD8+ T cells to the lungs and livers of GvHD mice was not affected by the 
administration of resting MSC.  The ability of γMSC to prevent the engraftment of CD4+ 
or CD8+ T cells within the livers and lungs of GvHD mice was subsequently investigated.  
The numbers of CD4+, CD8+ or CD4+CD8+ cells recovered from the livers of GvHD mice 
were not significantly reduced by the administration of either resting MSC or γMSC on 
day 7 (Figure 5.26 B).  In contrast to the hypothesis, the administration of MSC and γMSC 
had increased the amount of cells infiltrating the lungs of aGvHD mice (Figure 5.26 C).  
The ability of γMSC to reduce the TNF-α production by human CD4+ and CD8+ 
T cells during aGvHD was analysed by intra-cellular flow cytometry.  GvHD mice were 
sacrificed on day 12 and spleens, livers and lungs were harvested under sterile conditions.  
Human cells were recovered from the tissues and the number of human TNF-α producing 
CD4+ and CD8+ T cells were determined by flow cytometry.  The administration of 
resting MSC resulted in a significant decrease in the number of human TNF-α producing 
CD4+ and CD8+ T cells found in the spleen, liver and lungs of GvHD mice (Figure 5.27).  
While the administration of γMSC also resulted in significant reductions in human TNF-
α producing cells in comparison to non-treated GvHD mice, the numbers of human TNF-
α producing cells were not lower than observed when resting MSC therapy was used 
(Figure 5.27). 
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Figure 5.24. Development of a humanised mouse model of aGvHD to compare MSC and γMSC 
therapies.  NOD-SCID IL-2rγnull (NSG) mice were exposed to a sub-lethal dose of gamma irradiation (2.4 
Gy).  8 x 105 PBMC gram-1 or sterile PBS was then administered intravenously (300 µl) to each mouse via 
the tail vein.  MSC or γMSC (6.4 x 104 gram-1) were administered intravenously on day 7.  The development 
of aGvHD was monitored every second day until day 9 and then everyday thereafter by recording weight 
loss, fur texture, posture, activity and diarrhoea. 
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Figure 5.25. Both γMSC and resting MSC significantly prolonged survival and lowered weight loss 
in aGvHD mice. (A) Survival curve and (B) percentage weight change of aGvHD mice (red square), MSC 
treated aGvHD mice (blue triangle) and γMSC (green triangle).  PBS control mice are represented by the 
white circles.  8 x 105 human PBMC gram-1 were administered to irradiated NSG mice (2.4 Gy).  6.4 x 104 
human gram-1 MSC or γMSC were given as cell therapy on day 7.   Transplanted mice were monitored 
every 2 days until day 9 and then every day for the duration of the experiment. n=6 mice per group.  
Statistical analysis was carried out using the un-paired student t-test. 
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Figure 5.26. γMSC therapy did not impair the engraftment of human lymphocytes in aGvHD mice.  
NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC (8 x 105 per gram-1) via tail vein 
injection were analysed on day 12 by flow cytometry.  (A) The total number of human CD45+, CD4+, CD8+ 
and CD4+CD8+ lymphocytes recovered from the spleen of aGvHD mice. (B) The total number of human 
CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the livers of aGvHD mice. (C) The total 
number of human CD45+, CD4+, CD8+ and CD4+CD8+ lymphocytes recovered from the livers of aGvHD 
mice. n=6 for each.  Non-treated aGvHD mice are represented by black bars, aGvHD mice which received 
MSC therapy are represented by white bars and aGvHD mice which received γMSC therapy are represented 
by striped bars. The total number of human lymphocytes was assessed using counting beads during flow 
cytometry. Statistical significance was determined using paired student t-test. 
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Figure 5.27. MSC and γMSC therapies reduced the total number of TNF-α producing CD4+ and 
CD8+ T cells in the spleens, livers and lungs of aGvHD mice. NSG mice were sub-lethally irradiated (2.4 
Gy) and given PBMC (8x105 gram-1) via tail vein injection were analysed on day 12 by intra-cellular flow 
cytometry.  Graphical representation of accumulated data for total cell number of human TNF-α producing 
CD4+ T and CD8+ T cells recovered from the spleen (A), liver (B) and lungs (C) of aGvHD mice.  n=6 per 
group (2 PBMC donor with 2 MSC donors).  White bars represent non-treated aGvHD mice, black bars 
represent aGvHD mice which have received MSC therapy and striped bars represent aGvHD mice which 
have received γMSC therapy. The total number of human lymphocytes was assessed using counting beads 
during flow cytometry. Statistical significance was determined using student t-test where * < 0.05.  
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5.13. ADMINISTRATION OF TWO MSC THERAPEUTIC DOSES DID NOT FURTHER 
ENHANCE SURVIVAL OR PREVENT WEIGHT LOSS COMPARED TO SINGLE DOSE MSC 
TREATMENT 
 As demonstrated throughout this chapter, the administration of human MSC 
therapy significantly prolonged survival and reduced weight loss in a humanised mouse 
model of aGvHD.  However, MSC therapy does not prevent aGvHD development and by 
the end of each study almost all of the mice which received MSC had succumbed to or at 
least exhibited symptoms associated with aGvHD.  Therefore, the next step was to 
investigate whether the administration of multiple doses of MSC therapy would further 
prolong survival and prevent aGvHD progression.  To achieve this, NSG mice were 
irradiated (2.4 Gy) and injected with human PBMC (8 x 105 gram-1) or PBS via tail vein 
injection.  As before, one group of mice received a single dose of human MSC (6.4 x 104 
gram-1) on day 7.  Another group of mice received two doses of human MSC (6.4 x 104 
gram-1) on days 7 and 9.  Transplanted mice were closely monitored as before and the 
survival and weight loss of each mouse was recorded (Figure 5.28). 
 The administration of 8 x 105 gram-1 human PBMC resulted in consistent aGvHD 
development in non-treated mice.  aGvHD mice which received no cell therapy began to 
exhibit gradual but significant weight loss from day 10 and all non-treated aGvHD mice 
were sacrificed by day 17.  The administration of human MSC therapy on day 7 resulted 
in significantly prolonged survival and reduced weight loss in aGvHD mice (Figure 5.29 
A).  aGvHD mice which received two doses of human MSC (day 7 and day 9) also 
demonstrated significantly prolonged survival and reduced weight loss compared to 
aGvHD mice which did not receive cell therapy (Figure 5.29 A).  However, the survival 
of aGvHD mice which received two doses of MSC therapy was not enhanced compared 
to aGvHD mice which received a single dose of MSC.  Surprisingly, weight loss was 
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slightly increased after the administration of the second MSC dose compared to mice 
which received MSC on day 7 only (Figure 5.29 B). 
The effect of administering two doses of human MSC on the TNF-α production 
was also analysed by intra-cellular flow cytometry after 12 days.   GvHD mice were 
sacrificed on day 12 and spleens, livers and lungs were harvested under sterile conditions.  
Human cells were recovered from the tissues and the number of human TNF-α producing 
CD4+ and CD8+ T cells were determined by flow cytometry.  The administration of a 
single MSC dose on day 7 resulted in the reduction of number of human TNF-α producing 
CD4+ and CD8+ T cells found in the liver and lungs of GvHD mice; however there was 
no reduction of human TNF-α producing CD4+ and CD8+ T cells detected in the spleen 
(Figure 5.31 A).  Interestingly, the administration of 2 doses of MSC therapy, day 7 and 
day 9, seemed to further reduce the number of human TNF-α producing CD4+ and CD8+ 
T cells in the lungs and liver compared to aGvHD mice which received a single dose of 
MSC, although these reductions were not determined to be significant (Figure 5.31 B & 
C).  These results suggest that while the administration of two separate doses of MSC 
resulted in a slight reduction in TNF-α producing cells, there was no difference in the 
survival or weight loss when compared to single dose MSC therapy.  At present a 
beneficial effect for multiple doses cannot be ruled out, but examination of TNF-α as a 
marker might be a useful diagnostic for optimising a timing of further doses. 
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Figure 5.28. Development of a humanised mouse model of aGvHD to investigate double doses of MSC 
therapy.  NOD-SCID IL-2rγnull (NSG) mice were exposed to a sub-lethal dose of gamma irradiation (2.4 
Gy).  8 x 105 PBMC gram-1 or sterile PBS was then administered intravenously (300 µl) to each mouse via 
the tail vein.  Mesenchymal stromal cells (6.4 x 104 gram-1) were administered intravenously as either a 
single dose on day 7 or as a multiple dose therapy on days 7 and 9.  The development of aGvHD was 
monitored every second day until day 9 and then everyday thereafter by recording weight loss, fur texture, 
posture, activity and diarrhoea. 
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Figure 5.29. Single dose was comparable to double dose MSC therapy in aGvHD mice. (A) Survival 
curve and (B) percentage weight change of aGvHD mice (red square), single dose MSC treated aGvHD 
mice (blue triangle) and multiple dose MSC (green triangle).  PBS control mice are represented by the white 
circles.  8 x 105 human PBMC gram-1 were administered to irradiated NSG mice (2.4 Gy).  6.4 x 104 human 
gram-1 MSC were given as cell therapy on day 7 and day 9.  Transplanted mice were monitored every 2 
days until day 9 and then every day for the duration of the experiment. n=6 mice per group.  Statistical 
analysis was carried out using the un-paired student t-test where *** < 0.001 between red square and blue 
triangle, and also between the red square and green triangle. 
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Figure 5.30. Both single and double dose MSC therapy reduced the total number of TNF-α producing 
CD4+ and CD8+ T cells in the spleens, livers and lungs of aGvHD mice. NSG mice were sub-lethally 
irradiated (2.4 Gy) and given PBMC (8x105 gram-1) via tail vein injection were analysed on day 12 by intra-
cellular flow cytometry.  Graphical representation of the human TNF-α producing T cells recovered from 
the spleen (A), liver (C) and lung (E) from aGvHD mice. Accumulated data for total cell number human 
TNF-α producing CD4+ T and CD8+ T cells recovered from the spleen (B), liver (D) and lungs (F) of 
aGvHD mice.  n=6 per group (2 PBMC donor with 2 MSC donors).  White bars represent non-treated 
aGvHD mice, black bars represent aGvHD mice which have received MSC therapy and striped bars 
represent aGvHD mice which have received 2 doses of MSC therapy. The total number of human 
lymphocytes was assessed using counting beads during flow cytometry. Statistical significance was 
determined using student t-test where * < 0.05.  
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5.14. Summary I 
 The main objectives of this section were to (1) to develop a robust and 
reproducible humanised mouse model of acute GvHD using PBMC isolated from buffy-
packs, (2) investigate how MSC effect human PBMC in vivo, (3) compare the efficacy of 
γMSC to resting MSC after day 7 administration and (4) to determine whether 
administering double doses of MSC increased protection from aGvHD compared to 
single dose.  The Nod Scid IL-2rγnull model of aGvHD initially designed by Pearson et 
al. (2008); using this as a guideline an optimised and consistent model of aGvHD was 
developed for use with PBMC isolated from buffy packs.  This chapter also presents an 
optimised model of aGvHD for use with buffy pack PBMC which were thawed from a 
frozen stock and demonstrates the possibility of using the chemotherapeutic agent 
Busulfan as a conditioning agent in situations where irradiation is not possible. 
 Using this optimised and consistent model of aGvHD, the administration of 
human MSC therapy on day 7 was shown to significantly prolong the survival and reduce 
weight loss during aGvHD.  MSC therapy did not inhibit the engraftment of human 
lymphocytes within the spleens, lungs or livers of aGvHD mice.  The addition of human 
MSC therapy did not prevent the polarisation of PBMC to effector or central memory T 
cells.  The production of human IL-1β, IL-2 or IFN-γ were not reduced in aGvHD mice 
which received human MSC therapy.  However, administration of human MSC on day 7 
resulted in the significant reduction in human TNF-α producing CD4+ and CD8+ T cells 
in aGvHD mice.  This chapter also demonstrates that human MSC therapy significantly 
increases the number of Treg cells in the liver and lungs of aGvHD 12 days after PBMC 
administration.   
 The next step was to investigate whether the administration of γMSC on day 7 
were more beneficial than resting MSC.  While the administration of γMSC on day 7 
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resulted in prolonged survival and reduced weight loss when compared to non-treated 
aGvHD mice, there was no significant difference compared to resting MSC.  Similarly, 
aGvHD mice which received two doses of MSC, day 7 and day 9, did not display 
enhanced survival or reduced weight loss when compared to aGvHD mice which received 
a single dose of MSC.  Taken together these results demonstrate a beneficial effect of 
MSC therapy against aGvHD in a humanised mouse model.  The beneficial effect of MSC 
therapy may be a result of reduced TNF-α production and an increase in Treg populations. 
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5.15. FASCIOLA HEPATICA 
Fasciola hepatica is a parasitic flatworm which can cause chronic liver infection 
(fascioliasis) in mammals (Collins et al. 2004) with over 2 million reported cases in 
humans worldwide (McManus & Dalton 2006).  F. hepatica have the ability to modulate 
the immune response of its host organism and can subsequently avoid clearance.  Recent 
studies into how F. hepatica modulate their host’s immune system have focussed around 
antigens embedded on the tegumental coat which is shed every 2-3 hours.  F. hepatica 
tegumental antigen (Fh-Teg)  has been shown to suppress LPS induced expression of DC 
maturation markers CD80, CD86 and CD40, as well as the production of pro-
inflammatory cytokines IFN-γ and IL-12p70 by DC in mouse models of septic shock 
(Hamilton et al. 2009; Dowling et al. 2010).  Fh-Teg did not detrimentally affect the 
survival of DC after LPS stimulation (Hamilton et al. 2009).  Fh-Teg have also been 
shown to inhibit murine mast cells ability to drive Th1 immune responses by inhibiting 
the release of TNF-α, IL-6, IFN-γ and IL-10 (Vukman et al. 2013).  These studies have 
focused on the ability of Fh-Teg to modulate murine immune cells and to date there is no 
data available as to whether Fh-Teg can suppress human immune cells in a similar 
manner.  Therefore this study was designed to investigate whether Fh-Teg could suppress 
human T cell function in humanised mouse model of GvHD. 
The main aims of this section were to examine (1) whether Fh-Teg treatment of 
PBMC could promote survival in GvHD mice, (2) to investigate the effect of Fh-Teg on 
the engraftment of PBMC within NSG mice and (3) to determine the effect of Fh-Teg on 
human T cell function in vivo as measured by the expression of memory T cell markers 
and the ability of T cells to produce pro-inflammatory cytokines in response to 
xenogeneic stimulation.   
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5.16. FH-TEG INCREASED SURVIVAL AND LOWERED PATHOLOGICAL SCORE IN AGVHD 
MICE 
The ability of Fh-Teg to suppress the immune system has previously been 
described in mice; however the effect of Fh-Teg on human immune cells has not yet been 
characterised.  In order to examine whether Fh-Teg were capable of supressing human 
immune cells, Fh-Teg stimulated PBMC were administered to the humanised mouse 
model of GvHD.  The ability for xenogeneic recognition and subsequent GvHD induction 
of Fh-Teg stimulated PBMC compared to PBMC was used as an indicator of an immune 
suppressive effect.  PBMC were isolated from buffy packs and either rested (PBMC) or 
stimulated with Fh-Teg (Fh-Teg PBMC) (10µg/ml) overnight.  The following day PBMC 
and Fh-Teg PBMC were counted and administered to irradiated (2.4 Gy) NSG mice via 
tail vein injection (1x106 PBMC per gram).  As before the mice were monitored on a 
regular basis and the development of GvHD was defined as previously described (Table 
4.1).  Mice which received a combined pathological score of 6 from 8 or displayed weight 
loss in excess of 15% were considered to have severe GvHD and sacrificed humanely. 
After PBMC administration, the survival, weight loss and GvHD pathological 
score of each mouse was monitored every 2 days until day 9 and then every day for the 
duration of the experiment (Figure 5.31).  PBMC mice developed acute GvHD as 
expected as PBMC mice did not survive past day 14; however the survival of Fh-Teg 
PBMC mice was significantly longer with 50% of mice surviving past day 15 (Figure 
5.31 A). The accumulative pathological score of Fh-Teg PBMC mice was significantly 
lower than PBMC mice from day 10 until the end of the experiment (Figure 5.31 B). 
Weight loss in Fh-Teg PBMC mice was significantly lower until day 14; after which it 
was similar to PBMC mice (Figure 5.31 C).  After day 15 however, the pathological score 
and weight loss of Fh-Teg PBMC mice increased and all Fh-Teg PBMC mice either 
succumbed to or showed signs of developing GvHD by day 22 (Figure 5.31).   
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Figure 5.31. Fh-Teg PBMC significantly prolonged survival and reduced pathological score in 
aGvHD mice.  PBS control mice are represented by diagonally lined bars, mice which received PBMC are 
represented by white bars and mice which received Fh-Teg PBMC are represented by black bars. Statistical 
significance was determined using a Martel-Cox test for (A) and student t-test for (B) where * < 0.05, ** < 
0.005 and *** < 0.001. n=5 for PBS, n=18 for PBMC, n=21 for Fh-Teg PBMC. 
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5.17. FH-TEG SIGNIFICANTLY IMPAIRED PBMC ENGRAFTMENT  
The data presented in section 5.18 suggest a mechanism by which pre-stimulation 
of PBMC with Fh-Teg overnight can delay the onset of acute GvHD (Figure 5.31).  In 
order to confirm that overnight stimulation with Fh-Teg did not result in apoptosis of the 
PBMC, EB/AO staining was used to examine cell viability.  The percentage of live PBMC 
following Fh-Teg stimulation was not significantly different compared to PBMC which 
were not stimulated with Fh-Teg (Figure 5.32).  Despite these results, all Fh-Teg PBMC 
mice began to develop typical acute GvHD symptoms from 15 days post transplantation 
and most of these mice developed GvHD by the end of the study.  Therefore it was 
hypothesised that pre-treating PBMC with Fh-Teg impaired the ability of the PBMC to 
engraft within the mouse.  To examine this hypothesis, irradiated NSG mice were given 
PBMC or Fh-Teg PBMC (1 x 106 per gram) and monitored as before.  On day 12, the 
mice were sacrificed and the engraftment of human CD45+ lymphocytes in the spleen was 
determined by flow cytometry.  There was a significant reduction in the percentage of 
human CD45+ lymphocytes recovered from the spleens of Fh-Teg PBMC mice when the 
results from all 4 PBMC donors were combined (Figure 5.33 I).  The total number of 
human CD45+ lymphocytes was also significantly reduced in the spleens of Fh-Teg 
PBMC mice (Figure 5.33 J).  
Although APCs have previously been reported to be essential in the development 
of GvHD, recent studies have indicated that T cells are the main drivers of GvHD 
pathology (Li et al. 2012).  Therefore it was hypothesised that the reduction in mortality 
and pathological score observed in Fh-Teg PBMC mice (Figure 5.31) could be a result of 
impaired engraftment of human T cells in vivo.  Therefore live cells were gated for human 
CD45 and their expression of human CD4+, CD8+ or CD4+CD8+ populations was 
determined.  While there was no difference in the percentage of CD45+ cells which were 
CD4+, CD8+ or CD4+CD8+ between PBMC and Fh-PBMC mice, the total number of 
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CD4+, CD8+ and CD4+CD8+ T cell populations was significantly reduced in Fh-Teg 
PBMC mice (Figure 5.34 A&B). 
 
 
 
Figure 5.32. Overnight stimulation with Fh-Teg did not affect PBMC viability. Prior to administration 
to NSG mice, PBMC were cultured overnight in the presence or absence of Fh-Teg (10 µg/ml). Ethidium 
Bromide/ Acrylamide Orange staining was used to determine the viability of PBMC following Fh-Teg 
stimulation (n=4 PBMC donors). PBMC are represented by white bars and Fh-Teg PBMC mice are 
represented by black bars. 
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Figure 5.33. Fh-Teg PBMC significantly reduced the percentage and total number of human CD45+ 
lymphocytes in the spleens of acute aGvHD mice. NSG mice which were sub-lethally irradiated (2.4 Gy) 
and given PBMC or Fh-Teg PBMC (1x106 per gram) via tail vein injection were analysed on day 12 by 
flow cytometry.  (A)-(D) Analysis of the percentage of human CD45+ lymphocytes recovered from the 
spleen of GvHD mice using 4 different PBMC donors (n=3 for each). (E)-(F) The total number of human 
CD45+ lymphocytes recovered from the spleens of GvHD mice using 4 different PBMC donors (n=3 for 
each). (I) The accumulated data analysing the percentage of human CD45+ lymphocytes from all 4 PBMC 
donors (n=12) and (J) the accumulated data of the total number of human CD45+ lymphocytes from all 4 
PBMC donors (n=12).  PBMC are represented by white bars and Fh-Teg PBMC mice are represented by 
black bars. The total number of human CD45+ lymphocytes was assessed using counting beads during flow 
cytometry. Statistical significance was determined using student t-test where * < 0.05. 
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Figure 5.34. Fh-Teg significantly reduced the total number of human CD4+, CD8+ and CD4+CD8+ 
lymphocytes in the spleens of aGvHD mice. Graphical representation of percentage and total number of 
human CD4+, CD8+ and CD4+CD8+ cell populations as measured by flow cytometry. NSG mice were sub-
lethally irradiated (2.4 Gy) and given PBMC or Fh-Teg PBMC (1x106 per gram) via tail vein injection.  (A) 
The accumulated data analysis of the percentage of human CD4+, CD8+ or CD4+CD8+ cells recovered 
from the spleens of PBMC (white bar) and Fh-Teg PBMC (black bar) mice. (B) The total cell number of 
human CD4+, CD8+ or CD4+CD8+ cells recovered from the spleens of PBMC and Fh-Teg PBMC mice.  
The total number of human CD4+ and CD8+ lymphocytes were determined using counting beads during 
flow cytometry. n=12 per group (4 PBMC donors).  Statistical significance was determined using student 
t-test where * < 0.05. 
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5.18. FH-TEG SIGNIFICANTLY REDUCES THE INFILTRATION OF HUMAN LYMPHOCYTES 
TO THE LIVER AND LUNG OF GVHD MICE 
 GvHD is characterised by the tissue specific destruction of target organs by 
infiltrating lymphocytes.  Therefore it was hypothesised that the reduction in GvHD 
pathological score and mortality when PBMC were pre-treated with Fh-Teg (Figure 5.31) 
was caused by impaired migration of human lymphocytes to the organs of humanised 
mice.  To examine this hypothesis, PBMC and Fh-Teg PBMC treated groups were 
sacrificed on day 12 and liver and lungs were harvested.  Both organs were mechanically 
digested and PBMC recovered by density gradient centrifugation.  Isolated cells were 
then examined for the expression of human CD45 by flow cytometry. There was a small 
but significant reduction in the percentage of human CD45+ cells recovered from the liver 
(Figure 5.35 A) and in the lung (Figure 5.35 C) of Fh-Teg PBMC mice.  The actual 
number of CD45+ cells recovered from the liver (Figure 5.35 B) and the lungs (Figure 
5.35 D) of Fh-Teg PBMC mice was significantly reduced.  Human CD45+ lymphocytes 
recovered from the liver and the lung of GvHD mice were also analysed for human CD4+, 
CD8+ and CD4+CD8+ populations.  The percentage of human CD4+ and CD4+CD8+ cell 
populations were significantly reduced in the liver of Fh-Teg PBMC mice but no 
significant change in the percentage of human CD8+ cells was detected (Figure 5.36 A).  
Similar to results observed in the spleen, significantly less human CD4+, CD8+ or 
CD4+CD8+ cells were recovered from the livers of Fh-Teg PBMC mice during GvHD 
(Figure 5.36 B).  The expression of human CD4+, CD8+ or CD4+CD8+ was also 
determined in the lung of PBMC and Fh-Teg PBMC mice.  Fh-Teg PBMC mice had a 
significantly lower percentage of CD4+, CD8+ and CD4+CD8+ cells than mice which had 
received PBMC (Figure 5.36 C).  Similar to results observed in the liver (Figure 5.36 B), 
there was a significant reduction in the total number of human CD4+, CD8+ or CD4+CD8+ 
T cells recovered from the lungs of Fh-Teg PBMC mice (Figure 5.36 D). 
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Figure 5.35. Fh-Teg significantly reduced the percentage and total number of CD45+ lymphocytes in 
liver and lungs of GvHD mice. NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC 
or Fh-Teg PBMC (1x106 per gram) via tail vein injection were analysed on day 12 by flow cytometry.  
Analysis of the percentage of human CD45+ lymphocytes recovered from (A) the liver and (C) the lungs of 
PBMC (white bar) and Fh-Teg PBMC (black bar) mice.  Accumulated data analysing the total number of 
human CD45+ lymphocytes recovered from (B) the liver and (D) the lungs of acute GvHD mice.  n=12 per 
group (4 PBMC donors).  The total number of human CD45+ lymphocytes was assessed using counting 
beads during flow cytometry Statistical significance was determined using student t-test where * < 0.05, 
*** < 0.001. 
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Figure 5.36. Fh-Teg significantly reduced the percentage and total number of human CD4+, CD8+ 
and CD4+CD8+ cells in GvHD mice. Graphical representation of percentage and total number of human 
CD4+, CD8+ and CD4+CD8+ cell populations recovered from the livers and lungs of GvHD mice and 
measured on day 12 by flow cytometry. NSG mice were sub-lethally irradiated (2.4 Gy) and given PBMC 
or Fh-Teg PBMC (1x106 per gram) via tail vein injection.  Analysis of the percentage of human CD4+, 
CD8+ and CD4+CD8+ lymphocytes recovered from (A) the liver and (C) the lungs of PBMC (white bar) 
and Fh-Teg PBMC (black bar) mice.  Accumulated data analysing the total number of human CD4+, CD8+ 
and CD4+CD8+ lymphocytes recovered from (B) the liver and (D) the lungs of acute GvHD mice.  n=12 
per group (4 PBMC donors). The total number of human CD4+ and CD8+ lymphocytes were determined 
using counting beads during flow cytometry.  Statistical significance was determined using student t-test 
where * < 0.05, ** < 0.005. 
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5.19. FH-TEG SIGNIFICANTLY REDUCES THE NUMBER OF HUMAN CENTRAL AND 
EFFECTOR MEMORY LYMPHOCYTES IN THE SPLEEN, LIVER AND LUNG OF GVHD MICE 
 The phenotypic characterisation of naïve, central (Tcm) and effector memory 
(Tem) T cell populations from post-BMT patients can provide valuable information and 
help to define the immunological basis of GvHD (Ali et al. 2012).  The characterisation 
of these T cell sub-populations is essential in understanding the nature of the immune 
response associated with xenogeneic models of GvHD and may help to further understand 
the immune response in GvHD patients.  It was hypothesised that the reduced mortality 
and pathology observed using Fh-Teg PBMC (Figure 5.31) may be caused by impaired 
polarisation to effector T cell populations after stimulation with Fh-Teg. Anti-human 
CD45RO, CD27 and CD62L antibodies were combined with either anti-human CD4 or 
CD8 antibodies to characterise naïve (CD45RO-CD27+), central memory 
(CD45RO+CD27+CD62L+) or effector memory (CD45RO+CD27+CD62L-) T cell 
populations within CD4+ or CD8+ populations in the spleen, liver and lung.  The 
characterisation of T cell sub-populations from the spleens of GvHD mice demonstrated 
that pre-treating PBMC with Fh-Teg did not significantly affect the percentage of human 
naïve, Tem or Tcm populations within either the CD4+ (Figure 5.37 A) or CD8+ 
populations (Figure 5.38 A).  One PBMC donor expressed a significantly higher 
proportion of Tcm within both the CD4+ and CD8+ populations; however, this increase 
in Tcm was not replicated across the other PBMC donors and the accumulated data from 
all 4 PBMC donors showed no difference in naïve, Tem or Tcm populations between 
PBMC and Fh-Teg PBMC mice.  Similar to the results presented above, there was a 
significant reduction in the total number of CD4+ (Figure 5.37 B) and CD8+ (Figure 5.38 
B) naïve, Tem and Tcm populations recovered from the spleen from mice which had 
received Fh-Teg PBMC.  
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 The ability of Tcm and Tem cells to home to and infiltrate the liver and lungs of 
GvHD mice was also analysed.  T cell sub-populations recovered from the livers of GvHD 
mice showed that Fh-Teg PBMC had no effect on the percentages of naïve, Tem or Tcm 
cells within either the CD4+ (Figure 5.37 C) or CD8+ (Figure 5.38 C) gates.  As for the 
spleen, significantly less cells were recovered from each T cell sub-population. Fh-Teg 
PBMC mice had significantly reduced amounts of naïve, Tem and Tcm cells within both 
CD4+ (Figure 5.38 D) and CD8+ (Figure 5.39 D) cells.  
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Figure 5.37. Fh-Teg significantly reduced the number of activated (CD45RO+), naïve (CD45RO-), 
Tem (CD45RO+CD27+) and Tcm (CD45RO+CD27+CD62L+) human CD4+ T cells in aGvHD mice. 
NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-Teg PBMC (1x106 per gram) 
via tail vein injection were analysed after 12 days.  Graphical representation of the percentage of activated, 
naïve, Tem and Tcm CD4+ cells recovered from the spleen (A), livers (C) and lungs (E) of PBMC (white 
bar) or Fh-Teg PBMC (black bar) mice.  Accumulated data illustrating the total number of activated, naïve, 
Tem and Tcm CD4+ cells recovered from the spleen (B), livers (D) and lungs (F) of PBMC or Fh-Teg 
PBMC mice.  n=12 per group (4 PBMC donors).  The total number of human lymphocytes was assessed 
using counting beads during flow cytometry. Statistical significance was determined using student t-test 
where * < 0.05, ** < 0.005, *** < 0.001. 
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Figure 5.38. Fh-Teg significantly reduced the number of activated (CD45RO+), naïve (CD45RO-), 
Tem (CD45RO+CD27+) and Tcm (CD45RO+CD27+CD62L+) human CD8+ T cells in aGvHD mice. 
NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-Teg PBMC (1x106 per gram) 
via tail vein injection were analysed after 12 days.  Graphical representation of the percentage of activated, 
naïve, Tem and Tcm CD8+ cells recovered from the spleen (A), livers (C) and lungs (E) of PBMC (white 
bar) or Fh-Teg PBMC (black bar) mice.  Accumulated data illustrating the total number of activated, naïve, 
Tem and Tcm CD8+ cells recovered from the spleen (B), livers (D) and lungs (F) of PBMC or Fh-Teg 
PBMC mice.  n=12 per group (4 PBMC donors).  The total number of human lymphocytes was assessed 
using counting beads during flow cytometry.  Statistical significance was determined using student t-test 
where * < 0.05, ** < 0.005. 
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5.20. FH-TEG SIGNIFICANTLY REDUCES THE ENGRAFTMENT OF PRO-  INFLAMMATORY 
CYTOKINE PRODUCING HUMAN T CELLS 
One of the key characteristics of aGvHD is the production of pro-inflammatory 
cytokines such as TNF-α, IFN-γ and IL-2 (Ferrara et al. 2009).  Therefore, it was 
hypothesised that stimulation of PBMC with Fh-Teg before administration may impair 
the ability of PBMC to produce these cytokines in vivo and subsequently result in the 
reduced mortality and GvHD pathological score observed in figure 5.31.   
The level of circulating human TNF-α was analysed in serum obtained through 
facial bleeds taken from PBMC and Fh-Teg PBMC mice 10 days after transplantation 
and analysed by ELISA.  There was a significant reduction in the amount of human TNF-
α detected from mice which received Fh-Teg PBMC during acute GvHD (Figure 5.39).  
Control mice, which were transplanted with PBS rather than PBMC, had no detectable 
levels of human TNF-α. 
In order to determine the underlying factor behind the reduction of human TNF-
α in the serum of Fh-Teg PBMC mice, intra-cellular flow cytometry was performed on 
human T cells recovered from PBMC and Fh-PBMC mice for the production of TNF-α, 
IFN-γ and IL-2.  Human CD4+ and CD8+ lymphocytes were isolated from the spleens, 
livers and lungs of PBMC and Fh-Teg PBMC and analysed for the expression of human 
TNF-α, IFN-γ and IL-2.  Analysis of human CD4+ lymphocytes from the spleen 
demonstrated that pre-stimulation of PBMC with Fh-Teg before administration had no 
effect on the percentages of CD4+ lymphocytes producing human TNF-α, IFNγ or IL-2 
(Figure 5.40 A); however a significant reduction in the total number of human TNF-α, 
IFN-γ and IL-2 producing CD4+ lymphocytes recovered from the spleens of mice was 
observed in Fh-Teg PBMC mice (Figure 5.40 B).  Apart from one PBMC donor, which 
had a significantly higher percentage of IFN-γ producing CD8+ cells, there were no 
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detectable differences in the percentages of human TNF-α, IFN-γ or IL-2 producing CD8+ 
lymphocytes recovered from the spleen (5.41 A).  The total number of human CD8+ 
lymphocytes which were producing TNF-α, IFN-γ and IL-2 was also significantly lower 
in Fh-Teg PBMC mice (Figure 5.41 B). 
As mentioned above the systemic pathology associated with aGvHD is driven by 
the ability of donor T cells to migrate to target organs such as the liver and the lungs.  
Another key factor to consider is whether these infiltrating T cells are producing pro-
inflammatory cytokines.  Therefore the ability of infiltrating CD4+ and CD8+ T 
lymphocytes to produce human TNF-α, IFN-γ and IL-2 was analysed on lymphocytes 
recovered from the liver and the lungs of GvHD mice.  Pre-treating PBMC with Fh-Teg 
had no significant effect on the percentage of human TNF-α, IFN-γ or IL-2 producing 
CD4+ T cells which had infiltrated the liver (Figure 5.40 C).  Similar to the spleen 
however, the total number of human TNF-α, IFN-γ or IL-2 producing CD4+ T cells 
recovered from the liver was significantly reduced in Fh-Teg PBMC mice (Figure 5.40 
D).  The percentages of human TNF-α, IFN-γ or IL-2 producing CD8+ T cells in the liver 
was also unaffected by pre-stimulating the PBMC with Fh-Teg (Figure 5.41 C).  The total 
number of infiltrating CD8+ T cells capable of producing TNF-α, IFN-γ or IL-2 was 
significantly reduced in the livers of Fh-Teg PBMC mice (Figure 5.41 D).  The pre-
treatment of PBMC with Fh-Teg had no effect on the percentages of human TNF-α, IFN-
γ or IL-2 producing CD4+ T cells which had infiltrated the lung (Figure 5.40 E).  The total 
number of human TNF-α, IFN-γ or IL-2 producing CD4+ T cells recovered from the lung 
was significantly reduced in Fh-Teg PBMC mice (Figure 5.40 F). The percentages of 
human TNF-α, IFN-γ or IL-2 producing CD8+ T cells recovered from the lung was also 
unaffected by pre-stimulating the PBMC with Fh-Teg (Figure 5.41 E).  The total number 
of infiltrating CD8+ T cells capable of producing TNF-α, IFN-γ or IL-2 was significantly 
reduced in the lungs of Fh-Teg PBMC mice (Figure 5.41 F). 
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Figure 5.39. Fh-Teg stimulation significantly reduced levels of human TNF-α in the serum of aGvHD 
mice. NSG mice which were sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-Teg PBMC (1x106 
per gram) via tail vein injection.  On day 10, post transplantation, facial bleeds were performed on PBS 
control mice (not detected), PBMC mice (white bar) and Fh-Teg PBMC mice (black bar) and the presence 
of human TNF-α was determined using ELISA. n=20 per group (4 PBMC donors).  Statistical significance 
was determined using student t-test where * < 0.05. 
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Figure 5.40. Fh-Teg significantly reduced the number of human TNF-α, IFN-γ and IL-2 producing 
CD4+ T cells in aGvHD mice.  NSG mice were sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-
Teg PBMC (1x106 per gram) via tail vein injection were analysed on day 12 by intra-cellular flow 
cytometry.  Graphical representation of the TNF-α, IFN-γ and IL-2 producing CD4+ T cells recovered from 
the spleen (A), liver (C) and lung (E) from PBMC (white bar) or Fh-Teg PBMC (black bar) mice.  
Accumulated data for total cell number of cytokine producing CD4+ T cells recovered from the spleen (B), 
liver (D) and lung (F).  n=12 per group (4 PBMC donor). The total number of human CD4+ lymphocytes 
was assessed using counting beads during flow cytometry. Statistical significance was determined using 
student t-test where * < 0.05, ** <0.005 and *** < 0.001. 
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Figure 5.41. Fh-Teg significantly reduced the number of human TNF-α, IFN-γ and IL-2 producing 
CD8+ T cells in aGvHD mice.  NSG mice were sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-
Teg PBMC (1x106 per gram) via tail vein injection were analysed on day 12 by intra-cellular flow 
cytometry.  Graphical representation of the TNF-α, IFN-γ and IL-2 producing CD8+ T cells recovered from 
the spleen (A), liver (C) and lung (E) from PBMC (white bar) or Fh-Teg PBMC (black bar) mice.  
Accumulated data for total cell number of cytokine producing CD8+ T cells recovered from the spleen (B), 
liver (D) and lung (F).  n=12 per group (4 PBMC donor). The total number of human CD8+ lymphocytes 
was assessed using counting beads during flow cytometry. Statistical significance was determined using 
student t-test where * < 0.05, ** <0.005. 
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5.21. FH-TEG SIGNIFICANTLY REDUCES PATHOLOGY IN AGVHD MICE  
The target organs involved in acute GvHD pathology include the liver, spleen 
gut and lung. As seen in Figure 5.31, PBMC which had been pre-treated with Fh-Teg 
resulted in significantly lower pathological scores. Therefore, histological analysis was 
carried out on GvHD target organs to compare the effect of PBMC to Fh-Teg PBMC on 
GvHD pathology.   
Irradiation and PBS administration did not adversely affect the lung architecture 
of control mice or induce pathology as measured by lymphocyte inflammation around 
peribronchial areas (L) or airway epithelium thickening (T) (Figure 5.42).  PBMC mice 
had large accumulations of lymphocytes around peribronchial areas and demonstrated 
distinct epithelium thickening around the airways in the lungs (Figure 5.42).  In 
accordance with the flow cytomtetry data presented above, Fh-Teg PBMC mice 
demonstrated reduced lymphocyte infiltration in the lung.  Despite the reduction in 
lymphocyte infiltration there was no observable difference in airway epithelium 
thickening when compared to PBMC mice (Figure 5.42).  
PBS control mice demonstrated no adverse effect on liver pathology, as measured 
by lymphocyte infiltration (L) and damage to the structural integrity of the liver (D).  
Although the liver is a major target for GvHD, very little pathology was observed in 
PBMC or Fh-Teg PBMC mice on day 12.  However PBMC mice did display large 
amounts of lymphocyte infiltration around periportal areas of the liver (Figure 5.42).  The 
administration of Fh-Teg PBMC resulted in a significant decrease in the level of 
infiltrating lymphocytes in the liver, particularly at periportal ducts (Figure 5.42).  GvHD 
pathology of the small intestine was determined by lymphocyte infiltration (L) and villous 
destruction (V).  The administration of PBS to irradiated mice did not result in any 
pathology within the gut (Figure 5.42).  PBMC mice demonstrated a significant increase 
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in gut pathology.  There was a significant increase in the frequency of villous destruction 
which was accompanied by the infiltration of human lymphocytes (Figure 5.42).  There 
was no significant difference in pathology observed in the gut of Fh-Teg PBMC (Figure 
5.42).  There was a similar level of destruction to villi and also with a similar level of 
lymphocyte infiltration as was observed in PBMC mice (Figure 5.42).  Irradiated control 
mice treated with PBS had very little structural architecture of the spleen (Figure 5.42).  
While the red pulp (RP) and white pulp (WP) of the spleen was clearly visible there were 
no resident lymphocytes.  The administration of PBMC resulted in lymphocyte 
infiltration to the spleen and human lymphocytes can be clearly seen in the red pulp of 
the spleen (Figure 5.42).  As seen with the spleen and the liver, there was a visible 
reduction in the amount of lymphocytes present in the spleens of Fh-Teg mice (Figure 
5.42).  Lymphocytes present in the spleens of Fh-Teg mice were found only in the red 
pulp. 
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Figure 5.42. Fh-Teg PBMC resulted in reduced pathology and lowered lymphocyte infiltration in the lung, liver and spleens of aGvHD mice.  NSG mice which were 
sub-lethally irradiated (2.4 Gy) and given PBMC or Fh-Teg PBMC (1x106 per gram) via tail vein injection, on day 12. Tissue samples were paraffin embedded and stained 
with H&E and representative images analysed for lymphocyte infiltration (L), villi destruction (V), thickening of epithelial airways (T) or red pulp (RP) and white pulp (WP) 
in the spleen and representative images are displayed for each group. n=12 per group (4 PBMC donors). Tissues samples were stained using H&E and images captured at 100X 
and 400X. 
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5.22. SUMMARY II 
 The main aims of this section were to examine (1) whether Fh-Teg treatment of 
PBMC could promote survival in GvHD mice, (2) to investigate the effect of Fh-Teg on 
the engraftment of PBMC within NSG mice and (3) to determine the effect of Fh-Teg on 
T cell function in vivo as measured by the expression of memory T cell markers and the 
ability of T cells to produce pro-inflammatory cytokines in response to xenogeneic 
stimulation.  The pre-treatment of PBMC with Fh-Teg significantly reduced mortality 
and GvHD pathological score in xenogeneic mouse model (Figure 5.31).  The 
administration of Fh-Teg PBMC also resulted in the detection of significantly lower 
levels of human TNF-α in the serum of GvHD mice after 10 days (Figure 5.39).  
Moreover, the engraftment of human CD45+ lymphocytes within NSG mice was 
significantly impaired after PBMC were treated with Fh-Teg (Figure 5.32).  As previously 
described, the number of PBMC which engraft within irradiated NSG mice correlates 
with the development of GvHD in this model.  Therefore the increase in survival and 
reduced pathological score observed in Fh-Teg PBMC mice was a result of the impaired 
engraftment of human T cells and subsequently delayed the development of GvHD 
(Figure 5.31).  The detection of significantly lower levels of human TNF-α in the serum 
of Fh-Teg PBMC mice can also be explained by the presence of fewer cytokine producing 
T cells in the mouse rather than the ability of Fh-Teg to prevent TNF-α production per se 
(Figure 5.39).  This data demonstrates the usefulness of the model as a platform to test 
novel immunomodulatory agents. 
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CHAPTER 6 
 
DISCUSSION 
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6.1 MSC support B cell survival through cell contact dependent up-regulation of 
VEGF 
In 1991, Arnold Caplan predicted a major role for MSC therapy in regenerative 
medicine, particularly in terms of the replacement or regeneration of damaged tissue 
(Caplan 1991).  However, over the past decade, the focus of MSC therapies has shifted 
away from the regeneration of damaged tissues and towards the development of a cell 
therapy capable of modulating inflammation and immune mediated disease. The idea that 
trophic factors produced by MSC could be used to modulate the immune system was 
proposed (Haynesworth et al. 1996) before initial studies examining the administration 
of autologous MSC therapy proved feasible and safe (Koç et al. 2000).  However it was 
not until the ability of MSC to modulate inflammation and immune cell function in an 
allogeneic setting was determined (Bartholomew et al. 2002; Aggarwal & Pittenger 2005) 
that the field of MSC therapy garnered the attention of the scientific community.  The 
ability to bypass allogeneic immune recognition facilitates the clinical transfusion of 
allogeneic MSC therapy without rejection, facilitating the development of a standardised, 
regulatable “off the shelf” cell therapy against inflammatory and immune mediated 
diseases.   
Clinical trials have demonstrated the beneficial potential of MSC as a novel cell 
therapy, particularly against GvHD, Crohn’s disease and myocardial infarction 
(Duijvestein et al., 2010; Hare et al., 2009; Prasad et al., 2011).  Despite these recent 
advances, there are outstanding questions which need to be addressed before the full 
potential of MSC therapy can be realised.  The main unresolved issues include the optimal 
conditions for large scale manufacturing of MSC, the persistence and bio-distribution of 
MSC in vivo and the widespread clinical use of MSC therapy without a complete 
understanding of their mechanisms of action.  To address these outstanding issues and 
develop an optimised MSC therapy for routine clinical use, it is essential to take a step 
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back from clinical administration and develop novel models of disease designed to 
characterise how MSC therapy perform mechanistically in clinically relevant systems. 
The ability of MSC to suppress the adaptive immune system is a key feature in 
the development of MSC therapy, however the progress in elucidating the mechanisms 
by which MSC modulate T cells and B cells has not progressed at the same rate.  The 
mechanism by which MSC attract and suppress activated T cells has been thoroughly 
characterised and is mediated through a combination of chemokines (Ren et al. 2008), 
cell contact signals and immunosuppressive soluble factors (Di Nicola 2002).  The 
expression of CXCR3 on MSC attracts T cells (Ren et al. 2008) before binding via the 
expression of ICAM-1 and VCAM-1 (Ren et al. 2010).  The immunosuppressive soluble 
factors secreted by MSC are known to include HGF, TGF-β (Di Nicola 2002), IDO 
(Meisel et al. 2004), PGE2 (Németh et al. 2009), IL-10 (Yang et al. 2009), IL-6 (Najar et 
al. 2009), semaphorin-3A, Galectin-1 (Lepelletier et al. 2010), Galectin-9 (Gieseke et al. 
2013), adenosine (Sattler et al. 2011) and TSG-6 (Lee et al. 2009; Oh et al. 2010; Prockop 
& Oh 2012).  In addition to directly suppressing effector T cells, MSC are also capable 
of promoting the generation of Treg cells (Maccario et al. 2005; Di Ianni et al. 2008) as 
well as inducing T cell apoptosis (Akiyama et al. 2012).  The characterisation of how 
MSC modulate T cell function in vitro has led to hypothesis driven experiments (in animal 
models of T cell mediated disease) to examine the immuno-suppressive ability of MSC 
in vivo.  These studies successfully demonstrated impaired T cell responses (González et 
al. 2009b; Chiesa et al. 2011; Tobin et al. 2013) and expansion of Treg cell populations 
(Boumaza et al. 2009; Madec et al. 2009) in models of GvHD, colitis and diabetes. 
However, under certain conditions, MSC have the potential to support T cell proliferation 
and sustain disease through IL-7 production (Nemoto et al. 2013), highlighting the 
necessity to fully understand how MSC therapy will respond following clinical 
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administration.  In stark contrast to the detailed characterisation of T cell suppression by 
MSC, the effect of MSC on B cell function remains less clear (Franquesa et al. 2012).  
B cells are major regulators of the adaptive immune system and the activation and 
rapid proliferation of peripheral B cells in response to antigen recognition is essential to 
the development of a functional immune response (Pieper et al. 2013).  Accordingly, to 
develop a complete understanding of how MSC therapy will respond following 
administration it is essential to elucidate exactly how MSC interact with and modulate B 
cell function.  Therefore chapter 3 of this thesis was dedicated to determining how MSC 
affect B cell biology in terms of activation, proliferation and survival and to elucidating 
the mechanisms involved. 
Studies on the effect of MSC on B cell biology in vitro have reported conflicting 
results (Corcione et al. 2006; Tabera et al. 2008; Rasmusson et al. 2007; Traggiai et al. 
2008; Franquesa et al. 2012).  The majority of the major in vitro published data suggest 
that MSC inhibit the proliferation and antibody production of adult B cells (Corcione et 
al. 2006; Comoli et al. 2008; Tabera et al. 2008); contrary to this however, a number of 
published studies suggest that MSC support proliferation and antibody production 
(Rasmusson et al. 2007; Traggiai et al. 2008).  The reasons for such conflicting results is 
likely due to variability among experimental protocols used between different 
laboratories resulting in very varied B cell populations.  In the aforementioned studies, 
starting B cell populations vary between whole PBMC (Comoli et al. 2008; Traggiai et 
al. 2008) and purified B cells (Corcione et al. 2006; Rasmusson et al. 2007; Tabera et al. 
2008).  The ratio of MSC to B cells also varies from 1:1 to 1:20 and a single defined B 
cell activating protocol was not implemented throughout these studies.  In support of this 
theory, a recent publication has demonstrated that MSC have the potential to either inhibit 
or support B cell proliferation depending on the presence of T cells in the co-culture 
(Rosado et al. 2014).  In addition to the variability of experimental protocol, a significant 
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inhibitory factor to determining how MSC modulate B cells is that the mechanism by 
which MSC support or suppress B cell biology has not yet been established.  In the 
previous studies, Rasmusson et al. and Traggiai et al. demonstrate the requirement for 
cell contact to support B cell antibody production (Rasmusson et al. 2007; Traggiai et al. 
2008) while the work published by both Corcionne et al. and Comoli et al. demonstrate 
that inhibition of B cell proliferation and antibody production was mediated through 
soluble factors (Corcione et al. 2006; Comoli et al. 2008).  Given that T cell contact 
signals are required for B cell help, and that activated T cells bind to MSC it is possible 
that confounding factors have influenced these data and their interpretation. 
The initial experiments of this project were designed to identify the effect of MSC 
on a purified population of human CD19+ B cells. In chapter 3, we demonstrated that 
MSC enhanced the activation and proliferation of purified CD19+ B cell populations 
through a contact dependent mechanism.  This parallels previous observations reported 
by Traggiai et al. (Traggiai et al. 2008), but importantly identifies that enhanced B cell 
activation was not influenced by allogeneic recognition of MSC; B cells cultured in the 
presence of MSC without cytokine activation did not significantly increase CD69, CD80, 
CD86 or CD25 expression.  As described in section 1.3, the clonal expansion of activated 
B cells is essential for the development of antibody producing effector B cells and 
generally occurs within secondary lymphoid tissues.  It is now clear that transplanted 
MSC have the capacity to migrate to lymph nodes (Schwarz et al., 2014).  Thus the 
administration of MSC in concurrence with B cell activation may lead to enhanced 
expansion of B cells; which in the case of B cell driven or idiopathic disease may be 
detrimental to the patient.  This premise is consistent with experimental data; the 
administration of allogeneic MSC in a murine model of lupus resulted in exacerbated 
disease (Youd et al. 2010) and is a good example of the potential adverse effects 
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associated with MSC therapy if promoted without adequate experimental understanding 
of the functional mechanisms.   
Antibody production by activated B cells is one of the hallmarks of B cell 
mediated disease; however the ability of MSC to support or inhibit antibody production 
is also a contentious issue.  The studies conducted by Traggiai et al. observed increased 
IgG and IgM when B cells from lupus patients were cultured in the presence of MSC, 
while Rasmusson et al. reported increased IgG production by healthy B cells following 
culture with MSC (Traggiai et al. 2008; Rasmusson et al. 2007).  In contrast to these 
studies, our data showed that MSC had no effect on the IgG or IgM production by purified 
CD19+ B cells.  These differential findings might be caused by variances in experimental 
setup as the ratio of B cell to MSC, activating molecules and the purity of B cell 
populations all differ between our studies.  Some of these studies used ratios of 1:1 or 1:2, 
however, these ratios are extremely unlikely to occur in vivo.  In an attempt to create a 
more physiologically relevant system, our study utilised a B cell:MSC co-culture ratio of 
5:1.  Although total levels of IgG and IgM are commonly analysed by ELISA, it may also 
be possible that the ELISA kit used in our experiments became completely saturated 
making it impossible to determine any differences between samples.  Another possibility 
is that the cytokine cocktail used to activate B cells in this experiment may have been 
sufficient to maximise B cell production of IgG and IgM.  IL-21 is a known to induce 
plasma cell differentiation and IgG production (Ettinger et al. 2005) and is notably absent 
from the studies which reported increased IgG (Rasmusson et al. 2007; Traggiai et al. 
2008).  Therefore, the activation cocktail used to stimulate B cells in this study may have 
maximised IgG and IgM production, making it impossible to detect any increases in the 
presence of MSC.  
 In vivo, MSC function as stromal cells and are essential for maintaining the 
haematopoietic stem cell niche within the bone marrow (Mendez-Ferrer et al., 2010; 
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Tokoyoda et al., 2010).  In adults, B cell development occurs within this MSC supported 
environment (Uccelli et al. 2006) and we hypothesised that in vitro B cell:MSC co-
cultures mimic the HSC niche where MSC support the survival of B cells. Indeed, B cell 
viability was significantly increased in the presence of MSC and this was mediated 
through a cell contact dependent mechanism (Section 3.6).  This result supports previous 
work by Tabera et al. (2008), but further demonstrates MSC influence on purified B cell 
populations and highlights the requirement for cell contact.  In contrast to this study 
however, Tabera et al. demonstrated inhibition of B cell proliferation during MSC co-
culture (Tabera et al., 2008).  The difference in results between these two studies likely 
lies in the activation status if the B cells.  In our study B cells were activated with CD40L 
and CpG in the presence of B cell supportive cytokines IL2, IL-10 and IL-21, while the 
study of Tabera et al. used anti-Ig and IL-4 in conjunction with CD40L and CpG during 
B cell activation.  The B cell supportive cytokines IL-2, IL-10 and IL-21 were included 
in our study in an attempt to create a similar micro-environment to that encountered by B 
cells during an activating immune response (Ettinger et al. 2005) and may be more 
supportive of B cell viability than anti-Ig and IL-4.  Increased B cell survival when 
exposed to MSC may well offer an explanation to the increased activation and 
proliferation, as more viable population of B cells would be more responsive to the 
activation cytokines.  Thus the B cell:MSC interaction is likely to be further modulated 
by T cells in vivo; but the major effect of MSC on activated B cells is supportive of 
expansion when mature T cells are absent.  This finding has consequences for cell therapy 
in terms of disease targets and especially the route and timing of administration.  
While a requirement for cell contact has previously been identified for MSC 
support of B cell proliferation (Rasmusson et al. 2007; Traggiai et al. 2008) no further 
advances in defining how MSC modulate B cell biology have been reported.  Identifying 
the mechanisms behind MSC modulation of T cell function has provided a platform from 
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which to design effective MSC therapies.  Therefore, it was hypothesised that identifying 
the mechanism involved in MSC support of B cell survival would further our 
understanding of how MSC interact with B cells and provide valuable information 
regarding the development of future in vivo studies.  With cell contact dependency already 
established, a detailed review of the literature identified a number of potential cell surface 
proteins which may have a role in signalling between MSC and B cells.  The first standout 
target identified was B cell activating factor (BAFF). Under normal physiological 
conditions, BAFF signalling is a potent inducer of B cell expansion and survival 
(Schneider et al., 1999).  In addition to this, the expression of BAFF on the surface of 
adipocyte derived MSC has been described (Wang et al., 2011).  Therefore, the possibility 
that BAFF signalling was mediating MSC support on B cell survival and proliferation 
was investigated.  Although low levels of constitutive BAFF expression were detected on 
our bone marrow derived MSC, this expression was significantly up-regulated following 
stimulation with pro-inflammatory cytokines IFN-γ or TNF-α suggesting that in the 
presence of the correct signals our MSC could express high levels of BAFF.  However, 
neutralising BAFF signalling in our system did not prevent MSC from enhancing B cell 
proliferation, indicating that MSC support of B cell in vitro expansion was not dependent 
on BAFF. 
An alternative cell contact dependent signalling pathway known to have a role 
in B cell survival is notch.  Notch signalling is a highly conserved immune regulatory 
pathway with established roles in immune cell development, proliferation, differentiation 
and survival (Fiuza and Arias, 2007).  The development of peripheral B cells is dependent 
on notch signalling (Thomas et al., 2007) and the importance of the notch signalling 
pathway in immune modulation by MSC has been established.  The ability for MSC to 
inhibit DC maturation and antigen presentation (Chen et al., 2007) as well as the induction 
of regulatory T cells (Del Papa et al., 2013) are mediated through notch signalling.  The 
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role of notch signalling during interactions between MSC and both innate and adaptive 
immune cells and the dependence on notch for B cell development highlighted notch as 
a potential candidate for the contact signal mediating MSC support of B cell survival.  In 
addition, MSC have previously been shown to support the survival of B acute lymphocyte 
leukemia (B-all) cells through signalling through notch 3/4 (Nwabo Kamdje et al. 2011).  
However, blocking studies, described in section 3.8, demonstrated that notch signalling 
was not essential for MSC support of B cell survival in our study. 
 To elucidate the cell contact dependent mechanism behind MSC modulation of B 
cell biology it was necessary to explore more indirect pathways.  MSC are known to 
modulate immune cells through the secretion of a wide range of immune-modulatory 
soluble factors (Barry et al. 2005).  Hence, it was hypothesised that cell contact between 
MSC and B cells was triggering the production of a soluble anti-apoptotic signal by the 
MSC which in turn was promoting B cell survival.  As before, a comprehensive review 
of existing literature was used to identify potential candidates and identified VEGF as an 
interesting target.  VEGF has been described as one of the most important factors 
controlling angiogenesis (Leung et al. 1989; Keck et al. 1989) but an important role for 
VEGF in anti-apoptotic signalling has also been established (Abid et al., 2004; Xia et al., 
2009).  In fact, the addition of recombinant VEGF to TNF-α induced apoptotic epithelial 
cells in vitro was sufficient to induce survival in 80 - 90% of cells (Spyridopoulos et al., 
1997).  Interestingly, VEGF production by MSC has also been identified as a major 
contributor to MSC support of angiogenesis (Beckermann et al. 2008).  Therefore it was 
hypothesised that B cell contact stimulated VEGF production by the MSC and that 
increased levels of VEGF induced anti-apoptotic signalling in the B cell in our system.  
In agreement with published data, resting MSC constitutively produced VEGF (Section 
3.9).  Interestingly, a significant up-regulation in VEGF was detected following MSC 
contact with B cells.  The level of VEGF production by MSC was also very similar to the 
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previously published concentrations of recombinant VEGF capable of protecting 
endothelial cells from apoptosis (Spyridopoulos et al., 1997).  The physiological 
relevance of this VEGF up-regulation was investigated using a blocking antibody.  
Significant differences between the levels of B cell survival with or without the VEGF 
inhibitor were noted.  MSC support of B cell survival was completely abrogated when 
VEGF signalling was blocked.  The anti-apoptotic signalling pathway associated with 
VEGF signalling is mediated through the phosphorylation of AKT and results in a 
reduction in caspase 3 cleavage (Abid et al., 2004; Xia et al., 2009; Zhou et al., 2000).  
MSC support of B cell survival mirrored this increase in phosphorylated AKT (pAKT) 
and dramatically reduced levels of cleaved caspase 3; these levels were completely 
restored by the addition of the VEGF inhibitor.  At this stage we had a strong indication 
of a mechanism driving MSC support of B cell survival; however the cell contact signal 
required to initiate the process had yet to be identified.  
 Following the same approach as before, we studied the literature in search of cell 
contact signals associated with cell survival and VEGF production.  CXCR4-CXCL12 
binding has previously been reported to result in the up-regulation of VEGF production 
(Liang et al., 2007) and in addition to this the constitutive expression of CXCR4 by B 
cells and the expression of its ligand CXCL12 by the MSC (Nakao et al. 2010) identified 
CXCR4-CXCL12 as an attractive candidate for the contact signal required for MSC 
production of VEGF.  However, inhibiting CXCR4 binding in our system had no effect 
on the ability of MSC to promote B cell survival, suggesting that CXCR4 is not essential 
for MSC support of B cell viability. 
An interesting alternative to CXCR4-CXCL12 signalling involved stimulation of 
the EGFR, a member of the tyrosine kinase family of receptors which play an important 
role in cell survival and proliferation (Wells, 1999).  The expression of the EGFR on 
human bone marrow derived MSC has previously been reported and its activation results 
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in significant up-regulation of pro-angiogenic factors including VEGF (De Luca et al. 
2011).  The EGFR is stimulated by a range of ligands, many of which are expressed by 
peripheral B cells, and so a specific neutralising antibody targeting EGFR on the MSC 
was used in our system.  The EGFR was determined to be essential for MSC viability and 
therefore the highest dose of inhibitor which did not kill the MSC was used.  The addition 
of the EGFR inhibitor to MSC and B cell co-cultures did not prevent MSC support of B 
cell survival.  However, the concentration of EGFR used may not have been sufficient to 
completely neutralise signalling (this could not be demonstrated) and therefore 
stimulation through the EGFR cannot be ruled out as the contact signal between MSC 
and B cells. 
 Chapter 3 was designed to determine how MSC affect the activation, proliferation 
and survival of peripheral CD19+ B cells and to elucidate the mechanisms by which MSC 
modulate B cell biology.  Although the critical cell contact signal between MSC and B 
cells remains to be elucidated, the data presented here represents a step forward in 
understanding the mechanism by which MSC support the activation, proliferation and 
survival of purified CD19+ B cells.  This study reveals that cell contact between purified 
B cells and MSC induces a significant up-regulation of VEGF production by the MSC.  
VEGF induces the up-regulation of pAKT and inhibits caspase 3 mediated CD19+ B cell 
apoptosis (Figure 6.1).   
 The lack of a unique surface profile for MSC has limited the identification of MSC 
function in vivo; however, the information which has been gathered to date suggests that 
in vivo MSC support the HSC niche within the bone marrow (Méndez-Ferrer et al. 2010; 
Anthony & Link 2014).  In addition to this long lived memory B and T cells reside in the 
bone marrow, and more specifically in the presence of  IL-7 producing CXCL12+ stromal 
cells (Tokoyoda et al. 2009).  MSC production of the pro-survival factor IL-7 has been 
previously characterised (Chen et al. 2006) along with the surface expression of CXCL12 
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(Nakao et al. 2010).  Despite the potent suppression of T cell activation and proliferation, 
MSC have also been shown to support T cell survival in vitro (Benvenuto et al. 2007).  
Therefore it is reasonable to suggest that support of B cell survival described in this study 
may be a reflection of the natural stromal properties of MSC. 
An emerging hypothesis from the field of B cell immune regulation is that the 
generation of an immunosuppressive subpopulation of B cells termed regulatory B cells 
contributes to immune regulation (Fillatreau et al. 2002).  Regulatory B cells represent a 
very rare population, they lack a unique surface marker profile, are characterised by 
expression of CD1dhighCD5+ and IL-10 production (Wang et al. 2014). A recent 
publication has suggested that MSC are capable of generating regulatory B cells in vitro 
(Franquesa et al. 2014).  In terms of our study it would be interesting to examine if the 
support of B cell survival and proliferation observed here contributes to the generation or 
expansion of a regulatory B cell population.  
In order to further the development of MSC towards clinical application it is 
essential to clarify exactly how MSC interact with all cells of the immune response and 
design more tailored approaches to MSC treatment.  This study has furthered our 
understanding of how MSC interact directly with peripheral B cell populations in vitro 
and has provided key information for future studies into the relationship between MSC 
and B cells.  The limitation associated with all in vitro experiments is that in vitro 
experiments are manufactured systems designed to mimic a naturally occurring 
environment and this can lead to inconsistencies in results following progression to 
animal models.  Therefore while this study represents a major step forward in identifying 
how MSC interact with B cells, it is essential to remember that from here we can merely 
hypothesise what might happen in vivo. 
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Pre-clinical studies examining the potential of MSC therapy to treat B cell 
mediated autoimmune diseases have provided conflicting results.  The majority of studies 
examining MSC therapy in SLE and MS have demonstrated beneficial effects (Zhou et 
al. 2008; Gu et al. 2010; Zappia et al. 2005; Rafei et al. 2009); however studies carried 
out by Glenn et al. and Youd et al. have reported increased pathology after MSC therapy 
in models of EAE and SLE respectively (Glenn et al. 2014; Youd et al. 2010).  Youd et 
al. reported significantly increased pathology mediated by increased proliferation of 
autoimmune B cells during murine models of SLE (Youd et al. 2010).  The increased B 
cell survival and enhanced proliferation observed in this thesis supports the increased B 
cell proliferation described by Youd et al., however we did not observe the increased 
antibody production reported in their study. Whether MSC therapy is beneficial or 
harmful during B cell mediated disease may be dependent on the stage of disease at the 
time of administration.  Our data suggest that administering MSC during a stage of B cell 
activation and extensive proliferation would support this process and potentially 
exacerbate disease. Alternatively, administering MSC therapy during a different phase of 
disease progression may have beneficial effects, however without substantial in vivo 
evidence we can only speculate on what may happen.  Despite conflicting results and the 
absence of clear mechanistic data on how MSC modulate B cell function, phase I clinical 
trials examining the effect of MSC therapy on B cell mediated diseases RA (Wang et al. 
2013) and SLE (Sun et al. 2010; Sun et al. 2009; D. Wang et al. 2014) have already been 
completed and have progressed to phase II.  While these phase I trials were primarily 
designed to investigate the feasibility and safety of MSC therapy in RA or SLE, the 
authors have also suggested slight improvements in patient condition after MSC therapy 
after 18 months.  There are some potential explanations as to the variation between what 
our results predict and what has been observed in patients.  The main reason being that 
our system was designed to examine the direct effect of MSC on B cell function.  
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Following in vivo administration the MSC will encounter a complete immune system and 
an extensive range of cytokines.  The recent publication by Rosado et al. (2014) 
demonstrated that MSC were capable of either supporting or inhibiting B cell 
proliferation depending on the presence of T cells.  Although RA and SLE are primarily 
B cell mediated diseases, T cell help is still an essential component.  Therefore, MSC 
therapy may indirectly inhibit B cell function through the inhibition of T cell proliferation. 
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Figure 6.1. Model of mechanism of action in MSC promotion of B cell survival.  Graphical depiction 
of proposed mechanism of action behind MSC support of B cell survival. (1) In our system, MSC bind to 
CD19+ peripheral B cells (contact signal yet to be identified). (2) Cell contact signal induces a significant 
up-regulation of VEGF production by MSC.  (3) Soluble VEGF is bound by VEGFR on CD19+ B cells and 
induces phosphorylation of AKT. pAKT inhibits the pro-apoptotic caspase cascade significantly inhibiting 
caspase 3 cleavage and B cell apoptosis. 
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6.2 The development of novel models of GvHD to elucidate the mechanism of action 
by which MSC attenuate disease progression 
MSC therapy has rapidly progressed through phase I and II clinical trials, but has 
yet to successfully complete large scale phase III trials.  The most high profile of these 
trials has been a phase III trial completed by Osiris therapeutics (Martin et al. 2010).  A 
number of possible reasons as to the failure of MSC therapy to progress to routine clinical 
application have been put forward; however it is fast becoming apparent that the lack of 
standardised approaches and conceptual understanding of MSC action is inhibiting 
progress and application.  The advancement of MSC therapy from animal models of 
disease to clinical application has progressed rapidly with over 400 ongoing clinical trials 
investigating the efficacy of MSC therapy for a wide range of clinical application.  One 
of the problems associated with such a rapid progression to clinical trials is the application 
of this cellular therapy without fully understanding exactly how it works.  The application 
of MSC therapy on the grounds of compassionate use in patients with acute steroid 
resistant GvHD is an example. However, the failure to completely characterise how the 
MSC therapy regulates disease progression makes it almost impossible to determine 
optimal treatment dose, timing or importantly the identification of patients with 
underlying conditions where MSC therapy may not be suitable.  This thesis contends that 
attaining a complete understanding of how MSC therapy modulates the immune response 
during GvHD will enable the development of more targeted and specific hypotheses 
resulting in a more tailored and successful approach to treating GvHD.  Understanding 
the mechanism behind MSC modulation of aGvHD may allow the development of bio-
markers specific to MSC treatment of aGvHD.  With this in mind, Chapters 4 and 5 of 
this thesis were dedicated to the development of novel animal models designed to 
progress our understanding of the mechanisms of action utilised by MSC in the treatment 
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of acute and chronic GvHD and to provide more focused hypothesis driven clinical 
applications for MSC therapy.   
 In chapter 4, the capacity to assess human MSC therapies in murine (xenogeneic) 
models of acute or chronic GvHD was investigated.  A number of studies have examined 
the effect of murine MSC on the pathophysiology of acute and chronic GvHD using 
murine models of disease and these studies have been hugely beneficial in identifying 
potential mechanisms by which MSC inhibit GvHD progression (Polchert et al. 2008).  
However, the functional chemokine repertoire and mechanisms of immunosuppression 
are different between murine and human MSC (Chamberlain et al. 2008; Ren et al. 2009) 
and therefore may not provide a true reflection of how human MSC therapy respond 
during GvHD.  Therefore, it was hypothesised that the development of murine models of 
both acute and chronic GvHD in which human MSC therapy could be used to control 
disease progression might offer a more relevant comparison to how human MSC therapy 
might function in the clinic.  The use of xenogeneic MSC therapy in animal models of 
disease has been performed before (Pal et al. 2010; Guan et al. 2012), however not all 
attempts to examine human MSC in the murine setting have been successful (Lin et al. 
2012).  The main reasons behind the failure of xenogeneic MSC in murine models of 
disease is the relatively poor survival rate of human MSC in immune-competent mice 
(Grinnemo et al. 2004; Grinnemo et al. 2006).  In this study however, experimental mice 
are immune-compromised and it was considered that this would increase the survival rate 
of xenogeneic MSC therapy.   
Firstly, the effect of transplanting human MSC into syngeneic control mice was 
investigated to identify any potential adverse effects associated with administering 
xenogeneic MSC therapy.  Mice receiving transplantation of genetically identical 
syngeneic (control) immune cells did not develop GvHD and the administration of human 
MSC to syngeneic control mice did not adversely affect their survival or pathological 
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score.  To ensure the pathological score of each mouse was reproducible and attained 
without bias, two researchers were tasked with independently determining the 
pathological score of each mouse. Each researcher was provided with sufficient training 
to confidently distinguish between the different stages of each category of pathology 
(Table 4.1).  In cases where the pathological scores from each researcher differed 
significantly, the opinion of a third researcher was requested; thus resulting in a robust 
and reproducible GvHD scoring system between the experiments. Interestingly, 
administering human MSC therapy to syngeneic control mice resulted in significant 
infiltration of murine CD4+ and CD8+ cells into the lung as well as increased lung 
pathology. This infiltration of immune cells indicates a strong inflammatory response 
against the xenogeneic cell therapy.  It is well established that the intravenous 
administration of MSC results in the entrapment of cells in the lung for up to 24 hours 
(Schrepfer et al. 2007) and the administration of BALB/c immune cells to BALB/c mice 
likely resulted in a competent immune system capable of mounting an immune response 
against the human MSC.  These results suggest that the ability of human MSC to modulate 
allogeneic immune responses (Aggarwal & Pittenger 2005; Ryan et al. 2005) may not be 
conserved for xenogeneic immune cells.  There are many possible reasons as to why MSC 
may not evade xenogeneic recognition but one suggestion is that the trophic factors 
secreted by human MSC to escape allogeneic rejection are not functional against murine 
immune cells.  This may also explain the poor engraftment of human MSC reported in 
previous xenogeneic animal models (Grinnemo et al. 2004; Grinnemo et al. 2006).  
However, published evidence suggests that human MSC do not engraft for a prolonged 
period of time in vivo (Kidd et al. 2009; Lee et al. 2009) and therefore it is unlikely that 
the lymphocyte infiltration observed in the lung are part of an ongoing immune response 
against human MSC.  The immune response observed in the lung may actually represents 
an initial phase of repair and remodelling in response to damage caused following the 
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xenogeneic recognition of human MSC.  In response to lung endothelial cell damage, 
MCP-1 mediated infiltration of CD4+ T cells has been shown to contribute to pulmonary 
vascular remodelling (Cuttica et al. 2011). Another important issue is the disparity 
between doses of MSC therapy administered to patients compared to the doses currently 
used in animal models of disease.  Clinical administration of MSC to GvHD patients has 
varied significantly between studies, however in general has not exceeded  9 x 106 kg-1 
(Le Blanc et al. 2008).  Although the number of human MSC administered in our study 
was significantly lower than similar publications (Sudres et al. 2006; Li et al. 2014), 
infusing 2 separate doses of 1 x 106 MSC is significantly higher than the standard dose in 
humans.  For a 25g mouse, this dose of MSC correlates to 40 x 106 kg-1 per infusion.  It 
may also be possible that the inflammatory response and damage to the lungs following 
xenogeneic MSC therapy would be reduced after administrating a lower MSC dose.  
Hence, to increase the clinical relevance of this disease model, it may be necessary to 
lower the dose of MSC therapy administered to murine models of GvHD. 
 In comparison to aGvHD, relatively few clinical studies investigating the 
administration of MSC therapy (as a potential alternative to the immunosuppressive 
steroids currently used) for treating cGvHD have been published (Zhou et al. 2010; Weng 
et al. 2010).  In 2010, Weng et al., published the results of a small scale clinical study 
where 19 refractory cGvHD patients were treated with MSC (Weng et al. 2010).  Despite 
the relatively small treatment group and lack of placebo controlled patients, the results 
from the study were very promising.  The authors reported that 14 of the 19 cGvHD 
patients demonstrated a partial or complete response to MSC therapy with no observable 
adverse effects. Furthermore, of the 14 responding patients, 5 were able to discontinue 
their immune-suppressive steroid regimen (Weng et al. 2010).  Similar to the data 
presented from the Prochymal phase III clinical study (Osiris) in aGvHD, MSC therapy 
was more protective in selective organs rather than systemically (Martin et al. 2010; 
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Weng et al. 2010).  The responsiveness of cGvHD patients suffering from GI symptoms 
was approximately 90%, yet patients displaying symptoms in the lungs were non-
responsive to MSC treatment (Weng et al. 2010).  Despite the promising results reported 
from this clinical study, many open questions on the use of MSC therapy against cGvHD 
remain to be answered before MSC therapy can be considered routine therapy.  The 
optimal dose, timing and number of MSC administrations as well as the extent of MSC 
expansion prior to administration all remain to be determined before MSC therapy can be 
used on a larger scale.  The ability to analyse the efficacy of human MSC therapy in 
murine models of cGvHD would provide a useful tool which could begin to answer these 
questions and further the development of a clinically relevant MSC therapy.  
Unfortunately, restrictions on time available at Case Western Reserve University resulted 
in the model of cGvHD being stopped before the development of cGvHD; however the 
data recorded up to this time (Section 4.4) was promising.  cGvHD mice which had 
received human MSC displayed reduced pathology and weight loss on day 63 when the 
experiment was finished, however whether human MSC would have resulted in increased 
survival remains inconclusive. As observed with the syngeneic control mice, the 
administration of human MSC to cGvHD mice resulted in significantly increased 
lymphocyte infiltration and pathology within the lungs of cGvHD mice which received 
human MSC therapy.  As described above, this may have been a result of the xenogeneic 
recognition and immune response against the human MSC which had become trapped in 
the lungs.  Interestingly however, human MSC therapy significantly reduced villus 
destruction and lymphocyte infiltration in the small intestine of cGvHD mice.  The 
observed protection of the small intestine but increased damage to the lungs of cGvHD 
mice following human MSC therapy is in line with the observations of Weng et al. after 
MSC administration to cGvHD patients (Weng et al. 2010), suggesting comparisons 
between the model and clinical data.  While the ability of MSC to increase survival of 
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cGvHD mice could not be determined, the results presented here support the possibility 
of analysing the efficacy of human MSC therapy in murine models of cGvHD.  A fully 
optimised model of cGvHD in which to analyse human MSC therapy could be used to 
address outstanding issues regarding the optimal dose, timing and expansion of MSC 
prior to infusion.  In addition to this, it would provide a platform to elucidate the 
mechanisms involved in MSC modulation of cGvHD.  
 The potential of MSC therapy in aGvHD has been studied in greater detail than 
cGvHD in both animal models and the clinic.  Since the pioneering work of Le Blanc et 
al. demonstrated that MSC therapy was beneficial for the treatment of steroid resistant 
aGvHD in paediatric patients (Le Blanc et al. 2004), there have been a number of 
successful small scale clinical studies which have highlighted the potential of MSC 
therapy for aGvHD (Le Blanc et al. 2008).  However, despite the relative success 
observed in these clinical studies, the progression to large scale blinded trials have proved 
unsuccessful (Martin et al. 2010).  As mentioned above, a number of reasons which might 
explain the failure of the large scale trials have been put forward; however one of the 
major problems associated with MSC therapy for aGvHD is the absence of a clear 
understanding of how MSC modulate disease progression on a mechanistic level.  The 
development of novel animal models which more closely mimic the aGvHD micro-
environment is essential to the progression of our understanding and the development of 
a more targeted and effective MSC therapy.  As a result, this study was designed to 
determine whether a murine model of aGvHD could be used to examine the efficacy of 
human MSC therapy and subsequently provide a platform from which future studies 
could investigate the mechanisms behind MSC protection during aGvHD.  As expected, 
all aGvHD mice resulted in full donor chimerism, developed aGvHD and succumbed to 
the disease by day 56.  In contrast, there was a significant increase in the survival of 
aGvHD mice after human MSC administration with 80% of the mice surviving the 
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duration of the experiment.  The administration of human MSC also resulted in significant 
protection against lymphocyte infiltration and villi destruction in the small intestine.  The 
protection against gut pathology is in agreement with results presented from the 
Prochymal™ clinical trial (Martin et al. 2010). Similar to the results from the 
Prochymal™ clinical study, MSC therapy was selectively rather than systemically 
protective and the protection observed in the gut was not evident in every tissue.  In fact, 
lung pathology was significantly higher in aGvHD mice which received human MSC.  In 
line with the results presented for syngeneic control and cGvHD mice, the increased 
pathology in the lungs was probably a result of xenogeneic recognition and immune 
response to the human MSC.  These results suggest that human MSC are capable of 
controlling the development of aGvHD in mouse models and offer a potential new method 
of progressing our knowledge on how MSC therapies protect against aGvHD. 
 In contrast to the results from this study, other research groups have reported no 
beneficial role for MSC therapy in this model of aGvHD (Sudres et al. 2006; Jeon et al. 
2010).  Sudres et al. also transplanted bone marrow from C57Bl/6 mice into sub-lethally 
irradiated BALB/c mice; however in their study, Sudres et al., administered murine MSC 
therapy at the same time as the bone marrow transplant (Sudres et al. 2006).  Jeon et al. 
administered human MSC therapy to sub-lethally irradiated BALB/c mice 7 days after 
the transplantation of bone marrow from C57Bl/6 mice (Jeon et al. 2010).  Neither of 
these studies reported the increase in survival or reduction in pathology observed after 
MSC therapy in our study.  One of the key factors which may explain the disparities 
between the 3 studies is the timing of MSC administration.  Previous research from our 
group has demonstrated the critical nature of the time of MSC administration and 
especially that the administration of resting MSC at the same time as PBMC had no 
beneficial effect (Tobin et al. 2013).  This may explain why the study of Sudres et al. did 
not find an increase in survival after MSC therapy.  The study of Joen et al. delayed MSC 
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administration until 7 days after bone marrow transplantation, whereas our study 
administered 2 doses of MSC on day 1 and day 3.  The transplantation of C57Bl/6 derived 
immune cells to irradiated BALB/c mice is characterised by a severe cytokine storm 
induced by the major MHC mismatch between donor immune cells and host tissue.  The 
cytokine storm peaks at day 7 and therefore the administration of MSC therapy at this 
stage may be too late to prevent significant damage.  On the other hand, administration 
of human MSC on days 1 and 3 may limit the effects of this cytokine storm and result in 
the protection observed, in particular of the small intestine, during our study. 
 This study clearly indicates that human MSC are capable of modulating aGvHD 
within murine models of disease; however the results presented in this thesis also 
highlight the limitations associated with using xenogeneic disease models to study human 
MSC therapy.  The murine models of aGvHD were designed to examine the effect of 
human MSC; however, within these models the effector cells are murine and may respond 
differently to human MSC.  The immune response to the human MSC therapy suggests 
that mechanisms utilised by human MSC to evade allogeneic rejection were not 
functional in the xenogeneic setting.  The differential mechanisms by which human MSC 
interact with murine and human immune cells may restrict the clinical relevance of results 
obtained from xenogeneic models of GvHD.  Another limitation of the aGvHD model is 
the time frame associated with disease progression.  The aGvHD model required 63 days 
to confidently determine that human MSC therapy was successful in prolonging survival 
and reducing disease pathology.  Prolonged in vivo studies require a lot of time and money 
and therefore we decided to shift our focus to the development of a humanised mouse 
model of aGvHD in which to investigate potential mechanisms of immune modulation 
by MSC therapy.  
 While the immunomodulatory ability of MSC highlights their potential as a useful 
cell therapy, there are a number of inhibitory factors surrounding the development of 
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MSC therapy.  Firstly, generating sufficient numbers of MSC to treat aGvHD or cGvHD 
patients without compromising the immune-modulatory ability of these cells remains an 
issue.  The number of MSC delivered to aGvHD patients has varied from 0.4 to 9 x 106 
cells kg-1 per infusion (Le Blanc et al. 2008).  The generation of these quantities of MSC 
from a single donor requires extensive ex vivo expansion, which is known to negatively 
affect the immune-suppressive capacity of these cells.  The donor to donor variability in 
MSC growth kinetics, gene expression and immunomodulatory ability is another major 
inhibiting factor to the development of a standardised MSC therapy (Siddappa et al. 2007; 
Jansen et al. 2010; Menard et al. 2013).  The range of contributing factors to donor 
variability already identified, including age (Choudhery et al. 2014), gender (Siegel et al. 
2013), and underlying medical conditions (Nie et al. 2010) suggest that the development 
of stringent expansion protocols may not be sufficient to create a standardised cell therapy 
for clinical administration. The establishment of a standardised immune suppression 
potency assay would ensure the infusion of functional and comparable doses of MSC 
therapy (Menard et al. 2013). The proliferation kinetics, differentiation ability and 
immunosuppressive capacity of freshly isolated MSC could be screened against this 
profile before clinical administration.   
The development of humanised mouse models to study aGvHD has provided the 
most clinically relevant system by which to study the pathophysiology of disease.  The 
humanised mouse model of aGvHD facilitates the engraftment of adult human immune 
cells within the mouse.  These transplanted immune cells become active and proliferate 
in response to the xenogeneic recognition of murine MHC molecules, providing a system 
which mimics the basis of aGvHD development.  The humanised mouse model of aGvHD 
also exhibits a number of experimental advantages over the mouse-mouse model of 
aGvHD used in the previous section.  Importantly the pathogenesis in these models is 
mediated by human immune cells and therefore provides a system to investigate the 
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ability of a human cell therapy to control disease.  In addition, disease progression is faster 
in humanised models of aGvHD significantly reducing the time and cost associated with 
large scale in vivo experiments.  Therefore this thesis focused on the optimisation of a 
humanised model of aGvHD for the determination of how MSC modulate aGvHD. 
 There are a number of humanised mouse models available to study aGvHD 
(Shultz et al. 2012), however the NSG model is at the cutting edge (Ali et al. 2012). In a 
direct comparison with another frequently used humanised mouse model of aGvHD, the 
BALB/c-Rag2nullIL-2Rγnull (BRG) humanised mouse, the NSG mouse displayed faster 
expansion of human CD45+ lymphocytes and higher engraftment of human CD3+ T cells 
within the peripheral blood, spleens, lymph nodes and bone marrow compared to BRG 
mice (Ali et al. 2012).  The increased human lymphocyte engraftment and function in 
vivo allows for the faster development and progression of aGvHD. This system facilitates 
the study of human cell therapy in an aGvHD model driven by human T cells and thus 
represents a more clinically relevant system.  
 Using the NSG mouse model, this thesis set out to build on and enhance previous 
work from our research group which sought to elucidate the mechanisms by which MSC 
control aGvHD.  Tobin et al. developed an aGvHD NSG mouse model using human 
lymphocytes obtained from freshly drawn blood and based on a protocol published by 
Pearson et al. (Tobin et al. 2013; Pearson et al. 2008).  The original protocol developed 
by Pearson et al. suggested that the administration of 2 x 107 PBMC, isolated from buffy 
packs, to irradiated NSG mice resulted in consistent aGvHD development (Pearson et al. 
2008).  However, previous attempt to replicate this protocol within the Mahon lab were 
unsuccessful and resulted in inconsistent aGvHD development between mice of the same 
group; hence the focus was switched to developing the humanised model from freshly 
isolated blood where the dose of PBMC was normalised to the weight of each mouse 
(Tobin et al. 2013).  While this approach facilitated consistent aGvHD development, the 
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relatively low numbers of PBMC which can be isolated from laboratory scale sampling 
of fresh blood significantly restricted the number of mice which could be used in each 
experiment.  The progression of this model to PBMC isolated from buffy packs, while 
still retaining robust and reproducible aGvHD development, would facilitate the 
performance of large scale in vivo experiments; subsequently enhancing the investigation 
of how MSC attenuate aGvHD development.  In order to determine the optimal PBMC 
dose required to consistently induce aGvHD, two separate approaches were taken.  The 
first approach was designed to overcome the inconsistent aGvHD development 
previously observed within the Mahon lab by administering a higher dose of PBMC.  
However, this higher dose of PBMC resulted in the development of an extremely 
aggressive aGvHD.  The sudden onset of aGvHD made it impossible to study the effect 
of MSC therapy on disease progression.  The second approach investigated whether 
administering a dose of PBMC tailored to each particular mouse would result in a more 
consistent disease model.  The PBMC dose for each NSG mouse was calculated based on 
the weight of each mouse, extending the work of Tobin et al. (Tobin et al. 2013).  In 3 of 
the 4 PBMC donors tested, the results were very promising.  All of the mice within these 
groups displayed a gradual weight loss pattern while still developing aGvHD.  However, 
the development of aGvHD was not consistent in mice which received the PBMC from 
the fourth donor.  Inconsistent development of aGvHD within an experimental group is 
likely to be associated with the quality or level of responsiveness of the PBMC acquired 
from a particular donor. A link between the physical health of individuals and the 
functional ability of their immune cells has been reported (Amar et al. 2007; O’Shea et 
al. 2010).  Therefore it is possible that despite the ‘healthy donors’ used in this study 
being clear of disease or infection, obesity, sub-clinical infection or other environmental 
factors can reduce the responsiveness of PBMC.  Less responsive PBMC would not 
respond to the xenogeneic recognition of mouse MHC at the same rate and/or scale as 
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healthier cells; which may result in a reduced severity, delayed onset or complete absence 
of disease and may explain the observed results.  Despite the disparity associated with 
one donor, the robust and reproducible nature of the other 3 donors was adequate to 
determine that 8 x 105 PBMC gram-1 per mouse was the optimal dose required to induce 
aGvHD in irradiated NSG mice using PBMC obtained from buffy packs. 
 Failure of PBMC from a particular donor to engraft and induce aGvHD is 
extremely costly in terms of time and reagents but also presents an ethical issue in terms 
of use of the NSG mice.  To overcome this issue, it was hypothesised that PBMC thawed 
from liquid nitrogen storage could also be used to induce aGvHD in NSG mice.  This 
would allow batches of PBMC to be tested for efficacy in small pilot studies and only 
PBMC batches which reliably cause aGvHD would be used for large scale studies.  To 
test this, PBMC were isolated from buffy packs as before and stored in liquid nitrogen.  
To account for a reduction in responsiveness and proliferative capacity which may have 
been lost by PBMC during liquid nitrogen storage (freezing and thawing process), 
irradiated NSG mice were given a higher dose of PBMC than optimised for freshly 
isolated PBMC.  Similar to the results observed above, this dose was too high and the 
onset and progression of aGvHD was too sudden.  Next, we decided not only to reduce 
the overall PBMC dose but also to take a similar approach as above by calculating the 
dose of PBMC for each mouse based on weight.  The reduced dose of PBMC resulted in 
a more gradual disease progression and weight loss than observed with the higher dose; 
however the timing of disease onset was later than desired.  Therefore, the dose of PBMC 
was increased slightly and was subsequently administered to irradiated NSG mice.  The 
administration of 1 x 106 PBMC gram-1 to irradiated NSG mice resulted in a robust and 
reproducible model of aGvHD in 3 of the 4 donors tested.  In the fourth PBMC donor 
analysed, the disease progression was too aggressive.  Interestingly the aggressive disease 
progression observed with this donor was also observed when these PBMC were used 
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directly after isolation and further emphasises that PBMC obtained from one donor can 
respond differently to others.  This sequence of experiments demonstrate the possibility 
of inducing aGvHD in NSG mice using thawed PBMC.  This has led to ongoing 
experiments in the English lab to identify “useable” PBMC donors, creating a bank of 
PBMC cells which can consistently produce aGvHD.  The presence of this bank of PBMC 
would address the experimental and ethical issues associated with PBMC donor 
variability surrounding this model, and may allow future characterisation of donors to 
discover what makes a PBMC donor “useable”. 
The current pre-conditioning regimen of sub-lethal irradiation is a robust and 
reproducible technique; however, many labs do not have access to an irradiator and future 
collaborative projects will need to be carried out in centres without irradiation facilities. 
Therefore the ability to induce aGvHD after chemical immune-depletion was investigated 
using the chemotherapeutic agent Busulfan.  The use of Busulfan as part of a pre-
conditioning regiment in the clinic has become common practice (Kanakry et al. 2014; 
Patel et al. 2014; Raida et al. 2014) and therefore was selected for use in the NSG system.  
The development of aGvHD in NSG mice was compared between groups of mice which 
received Busulfan or irradiation in side by side experiments.  Busulfan was administered 
in 2 doses at a concentration of 25 mg/kg, 48 and 24 hours before PBMC administration.  
Overall the onset of aGvHD was similar between mice which were irradiated and mice 
which received Busulfan.  The survival curves were very similar between the 2 sets of 
mice.  However, mice which received Busulfan displayed significant weight loss for 3 
days after administration.  This dramatic loss in body weight was not observed after 
irradiation and suggests that Busulfan is a much harsher method of immunodepletion.  
Despite this, Busulfan treated mice recovered their weight loss and appeared very similar 
to irradiated mice before the onset of disease.  Interestingly however, the survival rate of 
PBS control mice which received Busulfan was affected at later stages in the experiment 
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compared to irradiated PBS mice.  Although one of the irradiated PBS mice died early 
during the study, this mouse did not exhibit aGvHD symptoms and instead may have died 
in similar circumstances to those highlighted earlier.  These results demonstrate that it is 
possible to substitute sub-lethal irradiation for the chemotherapeutic agent Busulfan as 
the pre-conditioning regimen without sacrificing the reproducibility of the NSG model.  
The use of Busulfan is much more severe than irradiation and the mice require daily 
monitoring until at least day 5.  Other research within the English lab is currently being 
carried out to determine the lowest possible dose of Busulfan capable of facilitating the 
same level of PBMC engraftment observed in this study. The lowest effective dose of 
Busulfan will then be used throughout future collaborative research projects. 
 The model of aGvHD optimised in this thesis describes a clinically relevant 
system in which to investigate how MSC therapy responds to the aGvHD micro-
environment and subsequently modulates the inflammatory immune response associated 
with aGvHD.  The first step in doing so was to confirm that MSC therapy was effective 
in protecting against aGvHD in this particular model.  To this end, the study demonstrates 
the capacity for MSC to prolong survival in this optimised model of aGvHD when 
administered on day 7 (Section 5.3).  Following this, we tested a number of hypothesis 
exploring the mechanisms utilised by MSC in prolonging survival in aGvHD including 
the engraftment kinetics, memory phenotypes, cytokine profiles and Treg cell expansion 
of aGvHD mice.    
The engraftment of the transplanted cells after HSCT is essential to the 
development of a functional immune system and also holds anti-tumour properties; 
therefore potential cell therapies which inhibit the engraftment of transplanted cells are 
not suitable candidates for the treatment of aGvHD.  aGvHD is a systemic disease 
characterised by the migration of donor T cells to target organs including the skin, liver, 
lungs and small intestine resulting in extensive tissue damage (Duffner et al. 2003; Fu et 
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al. 2014).  MSC are known to inhibit T cell proliferation and function in vitro and in vivo 
(Di Nicola 2002; Meisel et al. 2004; Németh et al. 2009; González et al. 2009a; Tobin et 
al. 2013) and therefore may attenuate the ability of T cells to engraft in aGvHD target 
organs. It has been established that the use of MSC therapy does not inhibit the 
engraftment of transplanted cells in aGvHD patients (Lee et al. 2002; Le Blanc et al. 
2008); however it was necessary to determine the effects of MSC therapy on engraftment 
in the NSG model.  In our system, aGvHD onset occurs between days 10 and 14; therefore 
the effect of MSC therapy on PBMC engraftment at day 12 was investigated.  In 
correlation with the data provided from clinical studies (Lee et al. 2002; Le Blanc et al. 
2008), the total number of human CD45+ lymphocytes engrafted in the spleens of aGvHD 
mice was unaffected by MSC therapy.  In fact the engraftment of human CD4+ T cells 
was significantly higher in aGvHD mice which received MSC therapy, suggesting that 
MSC therapy in the NSG mouse is in line with clinical data (Le Blanc et al. 2008).  The 
administration of human MSC therapy did not reduce the total number of human CD45+ 
lymphocytes recovered from the livers or lungs of aGvHD mice, suggesting that human 
MSC therapy does not affect the ability of PBMC to engraft in target organs during 
aGvHD pathogenesis.  
Following exposure to lymphopenic conditions, naïve T cells develop a memory 
phenotype (Ali et al. 2012).  Memory T cells are primarily classed as effector memory T 
cells (Tem) or central memory T cells (Tcm) (King et al. 2008).  Tem cells represent the 
effector arm of memory T cell populations and are characterised by the migration to 
inflamed tissue (Sallusto et al. 1999; Weninger et al. 2001; Sallusto et al. 2004).  Tcm 
cells are primarily located in the secondary lymphoid organs (Sallusto et al. 1999; 
Weninger et al. 2001; Sallusto et al. 2004) and are responsible for the long term memory 
against foreign antigens (Zaph et al. 2004).  Tcm are capable of responding to repeated 
antigenic stimulation by undergoing self-renewal and generating Tem (Zheng et al. 
265 
 
2009).  Compared to Tcm, Tem cells are characterised by rapid proliferation and 
production of perforin and IFN-γ while Tcm maintain a greater proliferative capacity.   It 
is becoming apparent that central memory T cells mediate aGvHD development (Zheng 
et al. 2009).  While the MHC mismatched transplantation of effector memory T cells to 
irradiated mice was not sufficient to sustain a GvHD response, it is believed that a role 
for effector memory T cells exists during aGvHD (Zhang et al. 2012).  Given that the 
number of engrafted PBMC was not reduced by MSC, this study examined the effect of 
MSC on the expression of naïve and memory phenotypes in the engrafted PBMC.  The 
administration of MSC therapy did not reduce the percentage or total number of CD4+ 
Tcm or Tem cells recovered from the organs of aGvHD mice.  The tissue specific 
distribution of Tem and Tcm cells is comparable to the results obtained from previous 
studies (Ali et al. 2012).  Spleen samples were rich with Tcm populations whereas 
samples obtained from lungs and livers of aGvHD mice displayed more Tem cells.  These 
results suggest that enhanced survival in the aGvHD model is not associated with MSC 
impairment of Tcm or Tem cell development or engraftment in target organs.   
 Pro-inflammatory cytokine production is one of the driving forces behind the 
development of aGvHD.  The presence of the pro-inflammatory cytokines IFN-γ, IL-1, 
IL-2 and TNF-α are essential for the progression of the disease (Ferrara et al. 2009). IL-
1β is an important member of the initial cytokine storm which is essential during phase 1 
of aGvHD pathogenesis (Ferrara et al. 2009).  IL-1β is also product of the NLRP3 
inflammasome which is currently being investigated as a potential mediator of 
inflammation during aGvHD (Jankovic et al. 2013).  We utilised our model of aGvHD to 
examine the effect of MSC on the production of these cytokines by human PBMC.  The 
effect of MSC treatment on the production of IL-1β is not very well documented and was 
investigated under the hypothesis that MSC therapy reduces the levels of circulating 
human IL-1β which may impair aGvHD progression.  However, the level of human IL-
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1β detected in the serum of aGvHD mice production day 12 was unaffected by MSC 
therapy.  In fact MSC therapy had no significant effect on the serum levels of any of the 
human cytokines examined (IL-1β, IL-2 or IFN-γ) after 12 days in aGvHD NSG mice. 
Notably, the role for IL-1β has been established as an integral mediator of phase 1 aGvHD 
pathology and therefore is important very early in disease.  Therefore, the administration 
of MSC therapy on day 7 may be too late to have an effect on IL-1β production.   
Although, measuring cytokine levels in serum provides an overall view of 
circulating cytokine concentrations, this assay does not provide any detail of cytokines 
being produced at the cellular level.  It may be the case that although no changes are 
evident in total serum cytokine level, there may be important differences in the type or 
number of cells producing cytokines. In line with the total serum levels of IL-2 and IFN- 
γ, the total number of human T cells producing these cytokines was not reduced following 
MSC therapy.  The failure of MSC to reduce IL-2 production was not surprising 
considering there was no reduction in PBMC engraftment, however the slight increase in 
levels of human IFN-γ in the serum of aGvHD following MSC therapy was not expected.  
MSC inhibition of T cell proliferation in vitro also corresponds to reduced IFN-γ (Patel 
et al. 2010; Zinöcker & Vaage 2012) and infusion of MSC therapy to murine models of 
colitis reduced production of Th1 cytokines including IFN-γ (González et al. 2009a).  The 
increased levels of IFN-γ are difficult to explain and whilst it might be an additional 
allogeneic (effector T cell vs MSC) effect, it certainly reflects the complexity of the 
model. 
The production of TNF-α is a hallmark of aGvHD and the ability of MSC to 
prevent the production of human TNF-α during NSG models of aGvHD may be one 
method by which survival is increased.  We have previously reported the reduction in 
total TNF-α in the serum of aGvHD mice (Tobin et al. 2013), but whether this reduction 
was caused by T cells or another cell type remained unanswered.  This study showed that 
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MSC administration significantly reduced the total number of human TNF-α producing 
T cells in the spleen and lungs of aGvHD mice.  The failure of MSC therapy to reduce 
the number of TNF-α producing CD4+ or CD8+ T cells in the livers of aGvHD mice was 
unexpected but this result is in line with the organ specific rather than systemic effect of 
MSC therapy during aGvHD.  This result supports our previous observation than MSC 
therapy reduced the total levels of TNF-α in the serum of aGvHD mice and may offer a 
potential mechanism by which MSC support survival.  Targeting the production of TNF-
α as a treatment for aGvHD has already provided encouraging results.  A study carried 
out by King et al. demonstrated that blocking of TNF-α production using Etanercept 
resulted in prolonged survival of NSG aGvHD mice (King et al. 2009).  The correlation 
between elevated serum levels of TNF-α and aGvHD development has also been reported 
in humans (Holler et al. 1990; Kitko et al. 2008) which has led to suggestions that serum 
levels of TNF-α could be used as a bio-marker of aGvHD (Paczesny et al. 2009). 
 Studies dedicated to the discovery of novel cell therapies capable of regulating 
aGvHD development have identified the potential for Treg cells (Taylor et al. 2002; 
Hoffmann et al. 2002; Edinger et al. 2003).  The reduced engraftment or depletion of 
Treg cells results in increased aGvHD progression and severity (Taylor et al. 2002).  In 
addition, the infusion of donor derived Treg cells at the time of allogeneic BMT increased 
survival and reduced pathology in murine models of aGvHD through an IL-10 dependent 
mechanism (Hoffmann et al. 2002; Edinger et al. 2003).  The correlation between reduced 
Treg cell engraftment and aGvHD development has also been identified in the peripheral 
blood of HSCT patients (Magenau et al. 2010).  Interestingly, we observed significantly 
increased engraftment of Treg cells in the spleens, livers and lungs of aGvHD mice which 
received MSC therapy.  These results are in line with previous in vivo studies which also 
report the increase in Treg cells in aGvHD mice after MSC transfusion (Joo et al., 2010; 
Hao et al., 2011).  However, this result is in contrast to previous reports from our 
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laboratory which did not find any increase in Treg cells within murine tissues (Tobin et 
al., 2013).  The differences are likely caused by the improved recovery of lymphocytes 
using a more optimised protocol.  The previous experiments mechanically digested the 
organs and then stained samples for flow cytometry.  In this study, the mechanically 
digested organs were then purified using density gradient centrifugation.  This allowed 
the recovery of a purer lymphocyte population which resulted in less artefacts or non-
specific staining during the analysis. Although the total number of Treg cells is modest, 
the potent nature of the cell means that the presence of these Treg cells may be playing a 
role in the regulation of aGvHD pathogenesis.  It would be interesting to ablate the Treg 
cells from PBMC before administration or during the model to determine whether or not 
the increased Treg cells were protective.  Another interesting target for future studies on 
the relationship between MSC therapy and Treg cells during aGvHD is the expression 
levels of the anti-inflammatory cytokine IL-35. While a role for MSC in the induction of 
IL-35 production has not yet been characterised in vitro or in vivo, a recently published 
study has demonstrated that increased IL-35 production by Treg cells is capable of 
controlling aGvHD while preserving GvL effects (Liu et al. 2014).  The authors also 
demonstrate a significant correlation between the expression of IL-35 and reduced 
aGvHD progression in aGvHD patients (Liu et al. 2014).  Therefore it would be 
interesting to investigate whether the increased Treg cells detected after MSC therapy 
also resulted in increased human IL-35 production during aGvHD. 
Although the increase in Treg cells has been established as one of the primary 
mechanisms employed by MSC to regulate the immune response, it is not clear exactly 
how MSC therapy results in increased Treg cells.  One hypothesis is that MSC directly 
induce the differentiation of Treg cells from naïve CD4+ T cells (Del Papa et al., 2012; 
Luz-Crawford et al., 2013).  In this thesis we determined that MSC were unable to induce 
Treg cells from a CD4+CD25- population, however co-culturing MSC with CD4+CD25+ 
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populations resulted in increased FoxP3 expression which suggested that MSC were not 
inducing but more likely expanding Treg populations.  In order to determine whether 
MSC were enhancing Treg populations or promoting the survival of original Treg 
populations, KI-67 was used as a marker of proliferation (Section 5.10).   Absence of KI-
67 expression in the CD4+CD25+FoxP3+ Treg cells would suggest that MSC were simply 
promoting survival of existing Treg cells as opposed to enhancing their proliferation. Treg 
cells did not express KI-67 after co-culture with MSC, suggesting that MSC promote the 
survival rather than induce or enhance Treg cells in vitro.  However, while KI-67 is an 
established marker for proliferative cells it only represents one snapshot of the 
experiment.  The use of CFSE would provide a more detailed description of Treg cell 
proliferation including the number of completed division cycles.  In addition, in vitro 
analysis is a simplified system and is not always a true reflection of in vivo interactions.  
The presence of other cell types or the particular micro-environment during aGvHD 
progression may influence how MSC increase T cell numbers in vivo. 
 So far this thesis has demonstrated that the administration of human MSC on day 
7 results in increased survival, increased Treg cell numbers (in target organs) and reduced 
TNF-α production in aGvHD mice.  The next step was to investigate whether the potency 
of MSC therapy in aGvHD could be enhanced through licensing (pre-stimulation) with 
IFN- γ.  Our lab has previously shown that administering γMSC on the same day as 
PBMC significantly prolonged survival and reduced aGvHD pathology in a similar 
manner to the administration of resting MSC on day 7 (Tobin et al., 2013).  It was 
hypothesised that resting MSC therapy required activation upon delivery by human IFN-
γ produced during aGvHD development and therefore act as a treatment rather than 
preventative of aGvHD. Therefore the delivery of pre-stimulated MSC on day 7 may offer 
a more rapid, potent suppression of cytotoxic T cell activity resulting in enhanced survival 
of aGvHD mice.  However there were no differences between γMSC and MSC therapy 
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administered on day 7.  Similar to resting MSC therapy, γMSC therapy did not inhibit 
PBMC engraftment and also reduced the total number of TNF-α producing T cells in the 
spleen, liver and lungs of aGvHD mice.  Delivery of γMSC therapy on day 7 was of no 
more benefit than administering resting MSC, suggesting that the level of human IFN-γ 
present in the mouse on day 7 is sufficient to activate resting MSC.  It may be interesting 
to investigate whether the administration of γMSC at an earlier time-point (but later than 
day 0) may be more efficient in reducing TNF-α production and the subsequent 
prevention of aGvHD. 
 Although the delivery of a single dose of human MSC therapy successfully 
prolonged the survival of aGvHD mice; it does not prevent the development of aGvHD.  
This phenomenon reflects the results of MSC therapy in the clinic (Le Blanc et al. 2004).  
In this situation aGvHD patients have received and responded to a second infusion of 
MSC therapy (Le Blanc et al. 2004; Ringdén et al. 2006; Müller et al. 2008; Ball et al. 
2013).  It was hypothesised that administering a second dose of human MSC therapy prior 
to the onset of aGvHD symptoms would further prolong the survival and prevent weight 
loss than single dose MSC therapy.  The second dose of MSC therapy was delivered on 
day 9 as it represents the period when aGvHD symptoms begin to become prominent.  
The administration of 2 doses of MSC significantly prolonged the survival of aGvHD 
mice compared to non-treated mice; however the survival of aGvHD mice was not 
significantly greater than aGvHD mice which received a single dose of MSC therapy.  
Whilst there was an improvement in weight loss reduction immediately after the second 
dose of MSC therapy, this increase was not statistically significant.  The reduction in 
TNF-α production by human T cells was also similar between mice which received a 
single or double dose of MSC therapy.  These results suggest that administering 2 doses 
of MSC therapy did not enhance protection from aGvHD when compared to 
administering a single MSC therapy.  The delayed weight loss is noteworthy however and 
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it may be interesting to analyse the survival of aGvHD mice after administering a third 
dose of human MSC on day 12. Another strategy which would be worth exploring is to 
administer MSC therapies on day 4 and 7 and compare with day 7 alone.  A clinical study 
by Ball et al. suggests that patients who received their first MSC dose earlier responded 
better (Ball et al. 2013).  The earlier delivery of the extra MSC dose may further reduce 
TNF-α production or possibly increase the number of Treg cells present in aGvHD mice. 
On the other hand, the recognition of re-administered MSC therapy could lead to rapid 
clearance by the patient’s immune system before the MSC can have an effect.  
This thesis explored many aspects of MSC immune regulation both in vitro and 
in vivo.  Following MSC therapy in vivo, significantly increased numbers of Treg cells 
were present in the organs of aGvHD mice.  In addition to this, the total number of human 
TNF-α producing CD4+ and CD8+ T cells were also reduced (Figure 6.2).  Whether the 
reduction in TNF-α production is linked to the increase in Treg cells or independently 
mediated by the MSC remains to be determined, however it is hypothesised that the 
increase in Tregs and reduction of TNF-α play an important role in aGvHD survival.  
TNF-α is one of the key inflammatory signals in the progression of aGvHD in both murine 
models and in the clinical setting.  During the early stages of aGvHD, leakage of LPS 
from the gut activates donor monocytes/macrophage and DC to produce high levels of 
TNF-α (Ferrara et al. 2009) and it was hypothesised that MSC induced reduction in serum 
levels of TNF-α was achieved by interfering with this process.  While this may still be 
the case, this thesis has determined a role for MSC therapy in reducing TNF-α produced 
by human T cells within the NSG mouse.  Excessive TNF-α production can result in the 
proliferation of donor DC and T cells and result in the direct apoptosis of patient’s tissue 
cells or the activation of donor DC and cytotoxic T lymphocytes and NK cells.  TNF-α 
inflammatory responses are known to increase vascular permeability which in the case of 
aGvHD may promote the infiltration of activated donor lymphocytes to target organs 
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resulting in extensive tissue damage.  The striking protective effect of MSC in the gut of 
both murine models and humanised models of aGvHD suggest that MSC therapy may 
protect the integrity of the gut which may limit the amount of LPS leakage. These finding 
are in line with results observed in the clinical setting (Le Blanc et al. 2004) and should 
be investigated thoroughly.   
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Figure 6.2. MSC modulation of aGvHD is mediated through enhanced Treg cell numbers and 
reduced TNF-α production in aGvHD target organs. Graphical representation detailing potential areas 
of MSC inhibition during aGvHD pathophysiology.  In phase 1, although increased levels of TNF-α 
stimulate host APC, MSC administration is too late to reduce the effect of pre-conditioning regimen.  
During phase 2, activated host APC activate mature donor T cells.  Following MSC therapy, increased Treg 
cells inhibit the activation of door T cells and the secretion of immunesuppressive cytokines reduce the 
inflammatory environment. In phase 3, MSC therapy does not reduce engraftment of effector T cells in the 
lungs or liver but significantly increases Treg cells and reduces the production of TNF-α, limiting necrosis 
and apoptosis.  
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An interesting concept currently being investigated in models of Crohn’s disease 
is the role played by the microbiome in disease progression (Gevers et al. 2014).  The 
ability of MSC to alter the microbiome has not yet been reported, however suppression 
of the gut microbiome has recently been shown to prevent aGvHD development (Vossen 
et al. 2014).  Based on the consistent protection observed in the gut of aGvHD and 
Crohn’s disease patients, alterations to the gut microbiome following MSC therapy is an 
interesting concept.  Another possibility is that the increased number of Treg cells 
detected after MSC therapy promote a less inflammatory T cell population and reduces 
TNF-α production.  Circulating levels of TNF-α have long been suggested as a potential 
bio-marker of aGvHD development (Holler et al. 1990); however increased TNF-α 
production is not specific to aGvHD (Chen & Cutler 2013).  However, the reduction in 
TNF-α production following MSC therapy suggests a potential role for TNF-α as a 
possible indicator of treatment efficacy in aGvHD patients.   
 The final part of this thesis was designed to determine if our model of aGvHD 
could be used as a platform to investigate the immunomodulatory potential of non-MSC 
therapies. F. hepatica tegumental antigen (Fh-Teg) potently impairs the immune response 
of murine immune cells (Hamilton et al. 2009; Vukman et al. 2013; Adams et al. 2014) 
and ongoing collaborative research has demonstrated that Fh-Teg can also potently 
suppress human PBMC. Therefore, it was hypothesised, by our collaborators, that 
stimulating PBMC with Fh-Teg overnight before administration to irradiated NSG mice 
would reduce the inflammatory potential of these cells and prevent the development of 
aGvHD.  Indeed, the administration of Fh-Teg PBMC resulted in significantly increased 
survival, lower pathological score and reduced weight loss compared to mice which 
received PBMC alone.  These results were very promising and a larger scale in vivo 
experiment was designed to determine how Fh-Teg stimulation was reducing aGvHD.  
Similar to the MSC data, the effect of Fh-Teg stimulation on engraftment kinetics, 
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memory cell polarisation, pro-inflammatory cytokine production and pathology was 
investigated.  However, it quickly became apparent that stimulating PBMC with Fh-Teg 
significantly inhibited engraftment within the mice.  Subsequently, the number of effector 
or central memory T cells, number of pro-inflammatory cytokine producing cells and 
overall pathology were reduced.  The failure of Fh-Teg PBMC to engraft suggests that 
stimulation with Fh-Teg significantly reduced the ability of the PBMC to recognise and 
proliferate in response to xenogeneic tissue, indicating the potency of suppression by Fh-
Teg.  At this stage, it is very difficult to hypothesise the mechanism by which Fh-Teg 
suppresses the immune response; although in vitro work carried out in the collaborative 
lab has suggested Fh-Teg stimulation does not induce T cell anergy.  The key finding of 
our study is that Fh-Teg would not be a useful preconditioning regime for graft cells, as 
it impairs engraftment.  The published studies to date have established the ability of Fh-
Teg to potently inhibit DC maturation and antigen presentation ability (Hamilton et al. 
2009) and may suggest an important role for DC mediated T cell priming in the early 
stages of our model.  In murine models, Fh-Teg has been shown to skew the T cell balance 
in favour of a Th2 response (Dowling et al. 2010) and thus may reduce the cytotoxic 
ability of the T cells; however further studies are required to examine these hypotheses. 
The suppressive ability of Fh-Teg on adult immune cells is interesting and future 
experiments designed to identify which particular protein mediates immune suppression 
may have important implications in terms of immune regulation.  These data further 
validated the humanised mouse model of aGvHD as a useful platform for testing novel 
immune modulatory therapies, and rejecting those that are unlikely to succeed in the 
clinic. 
 In conclusion, this thesis represents a step forward in understanding the 
relationship between human MSC and peripheral B cells.  Chapter 3 identified a novel 
mechanism by which human MSC support the survival, proliferation and activation of 
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CD19+ peripheral B cells.  Developing a complete understanding of how MSC effect 
peripheral B cell biology will help to progress MSC therapy towards successful clinical 
application and the mechanism identified in chapter 3 significantly enhances our 
knowledge.  This thesis also represents the optimisation of a humanised mouse model of 
aGvHD.  Humanised mouse models are at the cutting edge of translational research and 
the development of this model allows in depth investigation into the pathogenesis of 
aGvHD and the mechanisms employed by MSC or other immune modulatory therapies 
to limit disease progression.  Chapter 5 identified the reduction in TNF-α production by 
human T cells and the increase in Treg cells as potential mechanisms by which MSC 
modulate aGvHD development.  This chapter also ruled out the possibility that MSC 
therapy reduced aGvHD by impairing PBMC engraftment, the polarisation to memory 
phenotypes or the production of pro-inflammatory cytokines IL-1β, IL-2 or IFN-γ.  
Overall this thesis has furthered our knowledge of human MSC biology and provided 
novel disease models to progress MSC therapy to a translational setting.  
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